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Inflammation imaging is central to the diagnosis and monitoring of the progression of a vast 
range of diseases. As is suggested by the strong upregulation in the presence of biological 
insults, the P2X7 receptor plays a fundamental role in the inflammatory cascade. In this context, 
the development of a centrally acting Positron Emission Tomography (PET) tracer is a 
promising step towards harnessing the therapeutic and diagnostic potential offered by this 
target. 
In this work, inspired by the known antagonist A-804598, a set of four novel 
18
F-labelled PET 
ligands were designed, synthesised and evaluated in in vitro and in vivo models of 
neuroinflammation. The tracers were synthesised via novel trisubstituted guanidine and copper 
alkyne-azide cyclised intermediates. Multi-step radiofluorinations were carried out with the use 
of the [
18
F]fluorobenzyl amine synthon and “click” radiochemical techniques employing 
[
18
F]fluoroethyl amine. The compounds were evaluated in vitro with radioligand binding and 
calcium influx assays. Further validation was carried out in a hypoxic ischaemic mouse tissue 
model of neuroinflammation and in lipopolysaccharide-injected rats. 
This work generated four novel PET tracers, including one able to recognise inflamed tissues in 
vivo. These developments could form an important part of a drug discovery programme and 
may lead to an improved understanding of neuroinflammatory diseases and the treatment 
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FDG: 2-Deoxy-2-fluoroglucose 
FITC: Fluorescein isothiocyanate 
FL1: Fluorescence emission  
FSC: Front scatter 
FT-IR: Fourier transform-infrared 
GAPDH: Glyceraldehyde 3-phosphate 
dehydrogenase 
GOI: Gene of interest 
Hex: Hexane 
HI: Hypoxic ischemic 
HLB: hydrophilic lipophilic bonding 
hP2X7: Human P2X7 
HPLC: High-performance liquid 
chromatography 
I/P: Intraperitoneal  
I/V: Intravenous 





ID: Injected dose 
IHC: Immunohistochemistry 
IL-4, IL-1β: Interleukin-4, interleukin-1β 
ITLC: Radioactive thin-layer 
chromatography 
J: Coupling constant 
Kd: Dissociation constant 
LC/MS: Liquid chromatography/mass 
spectrometry 
LHS: Left hand-side  
LogP: Partition coefficient 
LPS: Lipopolysaccharide 
mAU: Milli atomic units 
MeCN: Acetonitrile 
MeOD: Deuterated methanol 
MeOH: Methanol 
mP2X7: Mouse P2X7 
MRI: Magnetic resonance imaging 




NADPH: Nicotinamide adenine dinucleotide 
phosphate 
NLRP3: NACHT, LRR and PYD domains-
containing protein 3 
NMR: Nuclear Magnetic resonance 
NSB: Non-specific binding 
P2(R)X7: ATP-activated purinergic receptor 
2, subtype X, subunit 7 
pE: positron energy 
PET: Positron emission tomography 
PPTS: Pyrodonium p-toluenesulfonate 
PFA: Paraformaldehyde 
PTFE: Polytetrafluoroethylene 
QC: Quality control 
Q-TOF: Quadrupole-time of flight 
Rf: Retention factor 
RHS: Right hand-side 
RIPA: Radioimmunoprecipitation assay 
buffer 
Rn: Normalized reporter value 
ROI: Region of interest 
rP2X7: Rat P2X7 
rpm: rate per minute 
RPMI: Roswell Park Memorial Institute 
medium  
Rt: Retention time 
rt: Room temperature 
RT-PCR: Reverse transcriptase 
polymerase chain reaction 
SA: Specific activity 
SB: Self-block 
SD: Standard deviation 
SEM: Standard error of the mean 
SNPs: Single nucleotide polymorphisms 




SPECT: Single photon emission computed 
tomography 
SSC: Side scatter 
t1/2: Half life 
t
BuOH: Tert-butanol 
TBAF: Tetrabutyammonium fluoride 
TEA: Triethylamine  
TFA: Trifluoroacetic acid 
THF: Tetrahydrofuran 














Nil sine magno vita labore dedit mortalibus. 
Life grants nothing to us mortals without hard work. 






















1.2 The P2X7 receptor 
1.2.1 The discovery of P2X7’s structure 
Ever since the isolation of adenosine triphosphate (ATP) in the first half of the last century, it 
was known that this molecule was fundamental at a pharmacological and biological level.
1
  
Nonetheless, it took half a century for ATP-activated receptors to be discovered, named 
purinergic receptors and subdivided into P1 and P2 subtypes. P2 receptors were the most 
potently activated by ATP>ADP>AMP>adenosine, whereas P1 receptors followed the opposite 
trend.
2
 In the 80s, further subtypes where recognised; P2X receptors represented all ATP 
activated ligand-gated cation channels, whereas P2Y purinoceptors included all G protein-
coupled receptors. The subtypes included also P2T receptors (found to mediate aggregation on 
platelets), P2U receptors (activated by uracil), P2D receptors (mediators of adenine 
dinucleotides extracellular functions).
3, 4
. Furthermore, P2Z receptors were identified as key 
mediators of degranulation on hematopoietic cells.
5
 It was not until 1996 that this receptor was 
renamed P2X7 in recognition of its role, akin to other P2X receptors, in gating the flux of small 
cations.
6
   
 
The P2X7 receptor is now relatively well characterised. Cloning has enabled its structural 
characterisation as a 69 kDa, 595 amino acid polypeptide. P2X7 is a homotrimeric ligand-gated 
cation channel that sits on the outer cell membrane. It contains two-transmembrane (2TM) 
motifs with intracellular termini
7
 and an often N-glycosylated extracellular loop.
7
 The C-terminal 
domain is particularly long and features a tumour necrosis factor receptor-1 region, as well as a 
lipopolysaccharide (LPS) binding motif.
8
 In fact, the majority of the downstream signalling is 
thought to be carried out via this terminus.
9, 10
  In the extracellular loop, the P2X7 amino acid 
sequence includes a series of lysine and phenylalanine residues crucial for ATP binding
11
 and 







Figure 1 P2X7 amino acid sequence from N-to-C terminus
 
 
Brief activation (<10 s) of the P2X7 receptor results in a rapid, reversible membrane 









prolonged exposure to ATP or other agonists, the P2X7 receptor converts to a nonselective 
pore that is permeable to small molecules of molecular weight up to 900 Da, such as Yo-Pro 
and ethidium, both routinely used to measure the switch to pore-like behaviour of P2X7.
15
 
Interestingly, deletion of the C-terminal domain showed that it is crucial to the formation of a 
pore: of its 240 amino acids, 177 are necessary to induce pore formation.
6
 However, it is still a 
matter of debate whether ATP alone is responsible for the switch to pore-like properties. It has 
been suggested that allosteric modulators or other proteins such as the pannexin-1 pore might 
be crucially involved.
16-18
 Moreover, pannexin-1 peptide mimics have been effective at blocking 






Recently, the crystal structure of the zebrafish P2X4 receptor (zP2X4) in the open and ATP-
bound form
20, 21





Figure 2 Structural homology models of the trimeric human P2X7 receptor   
  
The key observation is the fact that three ATP molecules are able to fit the receptor and 
promote the opening of a pore transversal to the membrane via a concerted jaw-like movement 
of the three subunits, further stabilised by extracellular zinc bridges (Figure 3).
20, 24
 The 
transmembrane domains usually lie in an oblique angle to the membrane. Upon ATP activation, 
they are thought to shift to a perpendicular angle, whereby opening a gap that initially allows 
cation fluxes. Upon prolonged agonist stimulation, larger molecules are able to permeate. This 
validates the hypothesis suggested by non-denaturing protein electrophoresis that three 






Figure 3 Schematic representation of a plausible activation mechanism of P2X receptors   
  
Furthermore, a minimum of 11 receptor polymorphisms (Figure 4) are known to occur albeit with 
<5% frequency. At least 5 of them can affect the cationic fluxes and overall receptor function,
26-
30
 although it has not been entirely elucidated whether these effects are dependent on 
modifications to the receptor structure or to its conductance. Association to human disease has 
been found for several of these single nucleotide polymorphisms (SNPs)..
31, 32
 The non-
synonymous SNP rs2230912 coding for Arg
460
 instead of Gln has been linked to mood 
disorders in three large-cohort studies.
33-35
 Moreover, the A348T mutation induces increased 
ionic fluxes through P2X7 and is associated with anxiety disorders and with protection against 
symptomatic toxoplasmosis.
36
 Finally, the loss-of-function SNP rs3751143 coding for Ala
496 
over 




Figure 4 P2X7 polymorphic residues 
 
   
1.2.2 Distribution of P2X7 
A variety of techniques have been used to ascertain the distribution of the P2X7 receptor: 
electrophysiology, reverse transcription polymerase chain reaction (RT-PCR) of mRNA and in 
situ hybridised mRNA, immunostaining, immunoblotting, radioligand assays, as well as genetic 
manipulations.
39, 40
 In healthy subjects it’s been found to be a ubiquitous receptor, present 
predominantly on cells of hematopoietic origin, such as glia, granulocytes, monocytes, 
macrophages, lymphocytes, dendritic cells and platelets.
41
 Moreover, it has been found in lower 
yet conspicuous amounts on epithelial and muscle cells.
39
 Depending on the cell line and organ 
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 and proliferative stimuli,
58-62
 clearance of dead 
cells
63
 and intercellular signalling.
64-66
 
In the central nervous system (CNS), predominant P2X7 expression has been found on murine 
and human spinal cord and hippocampus. P2X7 is also abundant in the area postrema, nucleus 
tractus, brain stem, medulla, hypothalamus, cerebellum, striatum, cortex and on enteric and 
retinal neurons.
39
 In vitro autoradiography of mouse brain slices with the tritiated P2X7-selective 
antagonist [
3
H]A-804598 has shown binding throughout the brain and spinal cord, with highest 
uptake in the thalamic and hypothalamic nuclei, hippocampus, spinal trigeminal tract and 
nucleus, the cortex, cerebellum and caudate putamen.
67
 









 and other glial cells. Neuronal expression appears slightly 
less widespread; indeed some receptor detection techniques have failed to pick it up.
40
 On 
excitatory neurons, P2X7 has been observed presynaptically,
72
 as well as on neuronal terminals 
73, 74
 and the nuclear envelope of hippocampal nuclei.
75
 Troublingly, disagreement over the 
specificity of P2X7 antibodies employed to track the receptor expression has arose due to 




 This could be explained by incomplete receptor knockout in 
these transgenic models.
77
 Nevertheless, controversy over the reliability of current P2X7 
neuronal immunostaining studies remains, as a thorough comparison of all available antibodies 
has found numerous staining inconsistencies.
78
 These contradictory patterns could also be 
cautiously interpreted as being vulnerable to diverse experimental condition variations which 
impact the receptor expression itself. 
Aside from healthy cells, P2X7 has also been found to be strongly expressed on several tumour 




Despite P2X7’s diverse role, it has been shown to be outstandingly upregulated in disease both 
at a genetic as well as at a receptor level.
82
 Even if P2X7 has a significant epithelial expression, 







1.2.3 P2X7 functions 
A large body of literature exists on the function of P2X7 at a physiological level. Many factors 
point to a key role of the receptor in regulating the inflammatory cascade,
83
 as indicated by the 
following observations pertaining P2X7’s diverse functions.  
Firstly, in vitro and in vivo P2X7 blocking or genetic knock out models have shown that the 
receptor plays a central role in the release of cytokines, particularly IL-1β, from microglia and 
macrophages.
84
 In fact, the activation and externalisation of pro-IL-1β is abolished in P2X7-
deficient compared to wild-type macrophages, while the production of IL-1 and IL-1β is arrested 
only in P2X7
-/- 
LPS-injected, ATP-stimulated mice and not in wild type mice.
85, 86
 Likewise, P2X7 
blockade in wild type mice halts IL-1β release.
86
  
Secondly, P2X7 is key in recovery following treatment with a lipopolysaccharide (LPS) 
inflammatory insult.
87-90
 It is also well established that P2X7 is involved in the generation of 
reactive oxygen species (ROS) in macrophages and microglia. This is suggested in particular by 
the fact that ATP-stimulated primary rat microglia show remarkable increases in the production 
of ROS, an effect which is largely abolished with P2X7 blockade.
91
 ROS production may be 
linked to activation of the pathogen recognition receptor NLRP3 by P2X7.
92
 However, others 




Fourthly, membrane blebbing and other morphological changes can be halted upon P2X7 
deletion or blockade.
83
 Similarly, the release of cathepsins and other lysosomal proteases is 
dependent on the endocellular permeability of P2X7 to calcium
95, 96
 and can be halted with 
P2X7 blocking.
97
 Additionally, it is involved in the regulation of phagocytosis, as suggested by 
the acquired ability of HEK293 cells to take up fluorescently labelled bacteria or latex beads 
upon transfection with P2X7, albeit only in the absence of ATP stimulation.
98
  





It can directly activate the transcription of inflammatory and cell metabolism genes through 
interaction with the nuclear factor-κB
103, 104
 and it is involved in the induction of apoptosis.
105, 106
 
Conversely, in certain P2X7 splice variants expressed in microglia and T-cells the receptor 
appears to have the opposite role of promoting cell proliferation,
60, 107-109
 suggesting that subtle 
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differences in receptor activation may induce drastically different downstream effects. This effect 





1.2.4 The P2X7 inflammatory pathway 
Despite its exact mechanism of action is yet only partly understood due to its complexity, 
several models have been able to depict in broad terms the way P2X7 is involved in the 
initiation and maintenance of a chronic inflammatory cascade, particularly in the brain, where its 
expression is highest.  
The P2X7 dilation model by Pelegrin describes the receptor as a gradually permeable 
transmembrane protein acting in synchrony with pannexin-1.
113
 Exposure of P2X7 to ATP leads 
to sequential distortion of the symmetrical trimeric structure, thus reducing the affinity of the 
remaining binding sites for ATP. Higher ATP concentrations dilate the pore rendering it 
permeable to small cations. However, it is only upon binding of the third agonist molecule, at 
high ATP concentrations, that the receptor allows full cation permeation, that the previously 
P2X7-associated pannexin-1 pore detaches and that downstream inflammatory signalling 
commences.  
This model is pleasingly complemented by the Sperlágh P2X7-centric neuroinflammatory model 
(Figure 5).
77
 According to the latter, neuronal depolarisation signals produce an initial synaptic 
release of ATP capable of reaching pre- and post-synaptic P2X7 receptors (Figure 5A). This is a 
state consistent with normal functioning of P2X7 receptors as described in section 1.2.2.  
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Figure 5 Sperlágh hypothetical pathway model of P2X7 activation in the brain
 
 
Neuroinflammatory cells, instead, become activated in consequence to further ATP release 
following LPS, mechanical, metabolic or inflammatory stress, cellular injury as well as changes 
10 
 
in the ionic environment (Figure 5B). In these conditions ATP initiates an inflammatory cytokine 
and chemokine release sufficient to deliver an acute inflammatory response to an insult. Full 
blown inflammation instead commences when cell apoptosis and necrosis start occurring 
(Figure 5C). This induces large bursts of ATP which fully open the P2X7 channel and 
exacerbate the inflammatory response turning it into a chronic condition.  
The way P2X7 receptors mediate neuroinflammation is known with a certain level of detail 
(Figure 6). Insults activate neuroinflammatory cells via the mediation of Toll-like receptors 
(TLRs, 1).
114
 The process is also gated by lipopolysaccharide (LPS) chains that prime the 
inflammatory cells enabling cytoplasmic signalling. This directly involves P2X7 via its C-terminal 
intracellular LPS-binding motif.
115, 116
 Downstream signalling triggers the activation of the 
nuclear factor (NF)-κB signal transduction pathway.
117
 This is a gene expression regulator that 
enables the transcription of pro-IL-1β and other cytokines.
118
 Pro-IL-1β must be activated and 
converted into mature IL-1β before being released extracellularly via exocytosis.
119
 Instead, IL-
18 is transcribed, translated and secreted integrally.
120
 NF-κB also indirectly triggers the release 
of neurotoxins such as reactive oxygen species (ROS) and nitric oxide species (NO), which in 
turn feedback to NF-κB in a manner that is largely still a matter of intense debate.
121-125
 
 Altogether, the cytokines and neurotoxic factors act in a dual manner; on one hand some 
induce phagocytosis and clearance of the inflammatory stimulus, thus aiding neuronal survival 
(2).
126, 127
 On the other hand, some are detrimental to neurons (3).
128, 129
 Meanwhile, a 
contrasting effect is exerted by neuroprotective (M2) microglia. These promote insult clearance 
(4) so as to lead to an overall homeostatic balance.
130
  
Neuronal death results in an abundant release of extracellular ATP, which signals to the P2X7 
receptor (5) the secretion of an assortment of proteins (secretome), notably pro-caspase-1, later 
activated to caspase-1.
131
 The secretome composition considerably varies depending on the 
type and strength of stimulus, thus enforcing distinct pro- or anti-inflammatory cellular profiles.
112
 
Catalysis by caspase-1 and the NLRP3 inflammasome leads to the release of further 
cytokines,
132-134
 which are responsible for an amplification of the inflammatory cascade and 








Figure 6 Simplified scheme representing the role of P2X7 in microglial activity 
 
 
1.2.5 P2X7’s involvement in disease 
The inflammatory response regulated by P2X7 is the leading or accompanying cause of many 
diseases.
137
  This section focuses on the most relevant cases in which P2X7’s involvement has 
been found to have a most crucial role. 
 
Alzheimer’s disease 
A growing number of reports discuss the role of P2X7 in relation to the formation of amyloid-β 
(Aβ) plaques in Alzheimer’s disease (AD) and related CNS diseases characterised by the 
presence of misfolded proteins. P2X7 presents significantly increased expression in human AD 
primary microglial cultures, Aβ-exposed foetal microglia, intracranially Aβ-injected rat 
hippocampi
138
 and in a transgenic mouse model of Alzheimer’s disease (Tg2576).
91
  Moreover, 
in primary microglial cultures treated with Aβ as well as in live mice intracranially injected with 
Aβ, P2X7 deletion abolishes IL-1β secretion, a common biomarker for neuroinflammation.
127
 
Regarding the potential therapeutic and diagnostic potential of P2X7 targeting in relation to 
Alzheimer’s disease, microglial P2X7 receptor expression has been shown to precede Aβ 
12 
 
plaque formation and it is accompanied by ROS production and extensive neuronal damage in 
the cerebral cortex in APPswe/PS1dE9 transgenic mouse models of AD.
139
 In vitro inhibition of 
P2X7 in P2X7-transfected HEK293 cells and neuroblastoma N2a cells favours the non-
pathogenic processing of the amyloid-precursor protein (APP) via α-secretase rather than β-
secretase. Likewise, in vivo inhibition of the receptor in the human APP TgJ20 mice significantly 
reduced the amyloid plaque burden in the hippocampus.
140
 Given this picture, P2X7 among 
other inflammatory markers appears crucial at the early stages of AD and could be a viable 




Other misfolded protein diseases 
In other misfolded protein diseases, targeting P2X7 has proven equally promising. In the R6/1 
transgenic model of Huntington’s disease (HD) where P2X7 shows an increased expression, 
P2X7 pharmacological blockade prevents weight loss and ameliorates cognitive and motor 
functions. Additionally, mutant huntingtin-expressing neurons show increased apoptosis when 
P2X7 is stimulated.
145
 In the unilateral 6-oxidopamine rat model of Parkinson’s disease (PD), 
P2X7 blockade significantly prevents striatal dopaminergic depletion.
146
 In prion protein cell and 
mice models of Prion disease, treatment with a P2X7 blocker significantly reduces prion protein 
accumulation, although it does not halt the disease progression.
147
 Finally, in the SOD1-G93A 
microglia mouse model of amyotrophic lateral sclerosis (ALS) P2X7 activity and expression 
dysregulates the NADPH oxidase 2 (NOX2) pathway,
148
 while P2X7 blockade improves motor 





Another CNS disease which P2X7 displays strong links to is depression.
150
 It is well established 
that depressed individuals suffer from an increase in brain inflammation which is worsened 
during major depressive episodes.
151
 P2X7 appears in particular to be crucial in its role as 
regulator of inflammatory cytokines, which in turn correlate with the severity and occurrence of 
depression.
152-154
 Inflammatory cytokines can influence neurotransmitter metabolism, 
neuroendocrine function and regional brain activity. Additionally, depression-linked psychosocial 
stress can induce neuroinflammatory processes.
155, 156
 P2X7 knock-out and pharmacological 
13 
 
blockade in mice models of depression has resulted in an anti-depressant-like profile and 
supports neurochemical changes in the hippocampus.
157-159
 Furthermore, large-cohort, non-
synonymous single nucleotide polymorphisms (SNPs) of the human P2RX7 gene supported by 





Epileptic seizures are strongly entwined with neuroinflammation.
161
 P2X7 activation has in 
particular been shown to strongly modulate hippocampal mossy fibre excitability, leading to 
synaptic depression, while P2X7 blockade can halt this effect.
162
 Also, the severity of seizures 
increases with P2X7 activation and blockade reduces seizure-induced hippocampal damage.
163
 
The upregulation of hippocampal P2X7 receptors (and only P2X7 out of all P2X receptors) 
correlates strongly with seizure induction in rodent models of epilepsy.
164, 165
 Finally, drug 





Traumatic brain injury (TBI) following percussion of the cranium is characterised by the ATP-
induced activation of P2X7,
166
 which has now become a priority target in TBI experimental 
therapy. In particular, P2X7 genetic deletion or blocking reduces cerebral oedema and long-
term neurological injury in mice
167
 and rats subject to cortical impact injury.
168
 Recently, also 
radiation brain injury (RBI) was correlated with P2X7 via the production of extracellular ATP. 
Blockade or deletion of the receptor suppresses radiation-induced microglial activation and 
proliferation in the hippocampus, and restores the spatial memory of irradiated mice.
169
 
Similarly, ATP releases from peritraumatic regions following acute spinal cord injury (SCI) in rats 
activate P2X7,
170
 although blocking did not corroborate the long-term beneficial outcomes when 





Also related to the P2X7 response to abnormal increases in extracellular ATP levels in the CNS 
are two forms of neuronal scleroses, amyotrophic lateral sclerosis (ALS) and multiple sclerosis 
(MS). In ALS, P2X7 impacts the cytokine release and oxidative damage following microglial, 
14 
 
astrocytic and neuronal P2X7 activation. It contributes to glutamate-induced excitotoxicity, 
mitochondrial dysfunction and apoptosis, RNA processing abnormalities, axonal trafficking 
defects, oligodendrocyte dysfunction, and, ultimately, muscle atrophy.
172, 173
 
In MS, several P2X7 correlations have been found.
174
 In experimental autoimmune 
encephalomyelitis (EAE) models of MS, Pfizer P2X7 knock-out mice
175
 develop significantly 
worse symptomatology than wild type EAE mice.
176
  However, the reverse occurs
177
 when the 
Glaxo-Smith-Kline strain of P2X7-null mice
178
 is used, pointing to a crucial role of the receptor in 
regulating lymphocyte production and that different P2X7 strains can lead to compensatory 
responses to P2X7 deficiency leading overall to beneficial effects on the disease 
pathogenesis.
177, 179
 Moreover, a rare P2X7 variant with absent pore formation function has 





P2X7 is also relevant to brain injuries in the form of ischemic strokes as well as to myocardial 
ischemias. Ischemia is a restriction in blood supply to tissues, causing the reduced availability or 
lack of glucose, oxygen and other molecules key to cell survival. Hypoxic ischemic strokes, in 
particular, are characterised by neuronal necrosis and extensive neuroinflammation.
181, 182
 It is 
thought that P2X7 responds to ischemic insult-generated ATP, leading to oligodendrocyte 
precursor cell (OPC) damage and white matter loss.
183
 It has been shown that oxygen-glucose 
deprived (OGD) BV-2 microglia can be rescued from death by pharmacological blockade of 
P2X7. Additionally, in OGD P2X7 knock-out mice, pharmacological blockade reduced cell death 
by half.
184
 Conversely, in middle-cerebral artery occlusion (MCAO) mice models of cerebral 
ischemia P2X7 deletion or blockade did not reduce cell death, differently from IL-1 antagonism, 
suggesting a lack of direct link between P2X7 and neuronal death in this model.
185
 However, in 
a different MCAO mice study P2X7 expression was shown as upregulated post-ischemically in 
the peri-infarct region
186




Ischemia can also occur in the myocardium, as demonstrated by the altered P2X7 expression in 
the isolated heart following ischemia/reperfusion injury.
189
 Similarly, P2X7 antagonism in 
myocardial ischemic injury models inhibits the nociceptive signalling of the sympatho-excitatory 
15 
 






Pain has the multiple purpose on one hand of protecting and repairing tissue injury by directly or 
indirectly activating the somatosensory system, while on the other hand it is a pathological 
consequence of an excessive release of nociceptive stimuli, otherwise known as neuropathic 
pain.
193
 Such delicate balance is regulated by a complex “soup” of inflammatory mediators, 
which may target nociceptive receptors (nociceptors) directly, via complex cascades or may 
instead exploit low-threshold sensory fibres to elicit painful stimuli. This complex disease 
presents a range of potential CNS targets in the opioidergic, serotonergic, GABAergic, 
adrenergic and inflammatory systems, among which is COX-2, the target of many NSAIDs.  
The role of neuroinflammation in the induction and maintenance of chronic pain is gaining 
increasing interest.
194
 Among the most attractive targets in this sense is P2X7, as suggested by 
the correlation with reduced pain upon receptor blockade.
195-198







 and may work via the pore 
functionality of P2X7.
200
 For example, the disruption of the P2X7 receptor gene is able to 
abolish neuropathic pain as measured by analysis of local and systemic cytokines.
135
 Moreover, 
the loss of antihyperalgesic activity with P2X7 antagonism in IL-1αβ KO (lacking both IL-1α and 






The role of the P2X7 receptor is not limited to the above-mentioned CNS disorders. In fact, it 
encompasses so many conditions that in this context, for sake of relevance, only just a mention 
of the implicated non-CNS diseases will be made. 
Of widespread interest to the pharmaceutical community is its role in relation to rheumatic 
diseases such as rheumatoid arthritis, due to P2X7’s mediatory role in the release of IL-1β and 
the activation of the NLRP3 inflammasome.
202
 Moreover, it is a target for the treatment of renal 
diseases such as glomerulonephritis as its involvement in the response to abnormal levels of 
16 
 
ATP appears to exacerbate renal conditions.
203, 204
 Similarly, P2X7 ATP-sensing ability and 
downstream signalling gives it a prominent role in respiratory diseases including asthma, 
chronic obstructive pulmonary disorder and pulmonary fibrosis.
205
 Further, P2X7 is genetically 
and functionally associated to the innate immune response to intracellular pathogens. In 




On a different note, a non-functional conformation of P2X7 (nfP2X7) has recently been 
recognised as a novel and ubiquitous target specific to cancerous cells due to its role as a 
mediator of proliferation and cell death
206-210 207
 This loss of ability to form an apoptotic pore but 
a calcium channel is induced by point mutations at residues K193 and K311.
208
 In epithelial 
cancer cells, responsible for 80% of human tumours, including pancreatic, genital-urinary and 
bone cancers, the presence of nfP2X7 is particularly notable.
209
  
Furthermore, P2X7 receptors are involved in the healthy functioning of the eye photoreceptor 
and rod bipolar cell responses as well as in the death of retinal neurons, making them an 
interesting target for ocular diseases such as glaucoma and optic nerve injury. In particular, the 
stimulation of P2X7 receptors is known to impact the health of retinal ganglion cells (RGCs).
210, 
211
 The role of P2X7 in eye health is particularly crucial in diabetic subjects, where increased 





To further study the pathophysiological features of P2X7 in a living being often requires the use 
of molecular probes capable of reporting on abnormal biochemistry at the site of pathology. In 
this sense, non-invasive imaging is perfectly suited to probe the site of disease and report 
information helpful to devise therapy or prevention strategies. Molecular imaging is often the first 
of many steps towards a cure. It is key in the diagnosis of complex diseases and to the 
understanding of underlying biological dysfunctions at a molecular level. It is used to monitor the 
efficacy of clinical trials for novel drugs and to fast-track pharmaceutical development by aiding 
drug dosage trails, by clarifying the metabolic and excretory profile of molecules and by 
illustrating their kinetic behaviour in living systems. Additionally, some imaging techniques can 




1.2.6 P2X7 agonists and antagonists 
Two broad compound classes have historically been the focus of much work on purinergic 
receptor pharmacology: ATP analogues and charged sulfonated dyes. Both classes do not 
conform to the typical physicochemical and pharmacological criteria used for selecting drug 
candidates as their high molecular weight and charged nature result in poor permeation through 
lipidic environment.
213
 Additionally, both species are P2X7 activators, which clashes with the 
need to dampen P2X7 activity to tackle disease. However, ATP analogues have remained the 
standard for receptor activation. ATP itself as the endogenous agonist is poorly active at P2X7 
receptors when compared to its aromatic derivative BzATP (Figure 7). The latter is thus used 
routinely in experimental settings, most often at its EC50 concentration (Table 1). 
 
Figure 7 Common P2X7 agonist structures. 
 
Table 1 Agonist activity at P2X7 
P2X7 Agonist pEC50 at mP2X7 (M) pEC50 at rP2X7 (M) pEC50 at hP2X7 (M) Refs 
ATP 2.62±0.05 3.89±0.20 4.13±0.02 
214
 




Nanomolar potency antagonists have been identified since the early 2000’s. A number of 
unselective antagonists are used to assess the physiology of purinergic receptors as a whole. 
However, many specific antagonists are now available as detailed in Table 2. Many efforts have 
been spent since to develop potent yet more orally bioavailable and metabolically stable 
molecules. Compound Brilliant Blue G (BBG) is widely employed as selective blocker for P2X7 
in pharmacological assays.
215
 Despite its high potency in murine models, however, it suffers 
from low affinity for the human P2X7 receptor despite the >80% sequence homology, making 
BBG unsuitable for clinical use. The latter is quite a common feature in P2X7 receptor 
18 
 
antagonists including KN-62, PPADS and oATP, which are not equally selective for all P2X7 
homologues.
214
 A large library of aryl amides was synthesised by AstraZeneca, resulting in a 
couple of adamantane-functionalised compounds with optimal properties yet excessively 
lipophilic. The library was later expanded by Evotec and Neurogen who achieved higher 
potencies by employing larger aromatics (quinolines, quinolones or benzimidazoles) compared 
to the original phenyl rings. Moreover, Pfizer entered clinical trials for rheumatoid arthritis with a 
cycloheptane arylamide of LogP 1-3. Yet, more promising structures have been uncovered 
meanwhile. Abbott’s A-740003, A-804598 and A-438079 and GSK’s GSK1482160 are all 
particularly strong leads. However, recently, A-740003 was shown to be poorly brain 
penetrant.
216
 The cyanoguanidine compounds will be examined in greater detail in chapter 2. 
Another aspect of increasing potency is the largely consistent behaviour across the functional 
spectrum of P2X7 in the presence of potent antagonists. Hence, if calcium influx assays reveal 
high IC50, assays relying on pore formation or IL-1β release are more likely to produce similar 
data. In Table 2 only the binding measured against the variation of calcium influx has been 
reported for conciseness. 
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Table 2 P2X7 receptor antagonists 
Compound class Antagonist 
pIC50 at hP2X7  
(M) 
pIC50 at rP2X7 
(M) 
pIC50 at mP2X7 (M, 
BALB/c) 
Selectivity LogP Refs 
Unselective P2X 
antagonists 
PPADS 5.49±0.03 5.08±0.02 4.39±0.07 





  PPNDS 6.39±0.02 6.03±0.01 5.10±0.09 





  Suramin <2 <2 <2 





  NF279 4.70±0.05 <4 4.80±0.30 





  oATP <2 <2 <2 





Isoquinolines KN-62 4.97±0.12 <4 <4 





  KN-04 4.26±0.19 <2 n/a  








7.6±1.1 n/a n/a Good ADMET 4.51 
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Serendipitous hits BBG <4 5.09±0.06 <4 High, inactive at other P2 receptors -3.7 
214
 
  MRS 2159 5.76±0.03 5.33±0.04 4.80±0.05 









  A-804598 7.96 8.04±0.01 n/a 






Azoles A-438079 6.91±0.01 6.51±0.03 6.01±0.12 High, inactive at other P2 receptors 3.3 
219, 220
 
  Compound A 7.75±0.14 6.62±0.14 n/a  Brain penetrant 5.64 
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Table 2  
Compound class Antagonist 
pIC50 at hP2X7 
(M) 
pIC50 at rP2X7 
(M) 
pIC50 at mP2X7 (M, 
BALB/c) 
Selectivity LogP Refs 
Aryl amides Various Up to 8.4  n/a  n/a  n/a   
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  Compound 7 8.3±0.08 7.2±0.08 7.5±0.08 





  Compound 8 7.7±0.07 7.8±0.1 7.1±0.2 Poor, high affinity for hSERT 4.35 
223
 













Figure 8 Selection of the best known P2X7 antagonists   
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1.2.7 Radiolabelled P2X7 imaging agents 
Several tritiated P2X7 radioligands can be found in the literature. [
3
H]Compound 13 is a KN62 
analogue presenting an additional ortho-methyl group at the phenyl piperazine ring also 
presenting a tritium atom in the para position (Figure 9). The compound was employed for 
radioligand binding assays in HEK293 cells, indicating good affinity.
226
 
It was not until 2007 that a second radiotracer, [
3
H]Compound 17 was synthesised from its ethyl 
ester analogue by reduction with tritiated LiAlH4. The tracer was evaluated in HEK293 and U-2 
OS P2X7 transfected cell membranes and showed higher binding compared to wild type 
controls. It was then also used to show binding kinetics, competitiveness and the presence of 
cooperative binding in the presence of P2X7 receptor ligands ATP, decavanadate and by self-
blockade.
222, 227, 228
 In 2009, Donnelly-Roberts and co-workers at Abbott Laboratories released a 
third tritiated antagonist based on the structure of A-804598 (Figure 9). They reported 
radioligand binding data demonstrating high selectivity and affinity for rP2X7 expressed in 
recombinant 1321N1 cell membranes.
229
 This radioligand was then taken forward by Able et al. 
at Pfizer for the study of the receptor occupancy in rat. Upon incubation of brain slices, they 
found widespread expression of the target receptor. However, only 60% specific binding was 
observed in homogenate assays at equilibrium. Finally, they showed ex vivo concentration-
dependent inhibition of the binding upon incubation with triazole Compound A.
67
 In 2014, others 
employed the tritiated ligand to assess the IC50 and Ki of a large panel of antagonists in 1321N1 
cell membranes.
230
 Recently, the new radioligand [
3
H]JNJ-54232334 with rat pKi of 9.3±0.1 was 
described. This compound improved on the specific binding of the previous tritiated compound 
as demonstrated by the reduced non-specific binding in P2X7
-/-
 in vitro brain autoradiography. 
Also, the radiotracer showed homogenous binding, confirming the ubiquitousness of P2X7 
observed in the same study by immunohistochemical staining, while retaining the ability to show 
more reliably than [
3







Figure 9 Chemical structures of selected P2X7 tritiated ligands. 
 
In the last decade instead, a small library of P2X7 radioligands amenable for Positron Emission 
Tomography (PET) has become available (Figure 10). A radiofluorinated version of a derivative 
of compound A with nM affinity appeared in a patent in 2010. The latter included synthetic 




 The binding of 
the cold tracer was tested in a Yo-Pro dye uptake-associated P2X7 pore formation assay. Upon 
inhibition by the non-selective P2X blocker PPADS, the tracer was inhibited by >69%, 
suggesting good affinity for P2X receptors.  No further work with this compound has appeared in 
the literature since, possibly due to poor selectivity to a specific P2X receptor. 
 
Figure 10 Chemical structures of selected P2X7 radiotracers. 
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In 2014, Janssen and co-workers at the VU University Medical Centre in Amsterdam reported 
the first radiolabelled P2X7 antagonist to be tested in vivo. Their compound, [
11
C]A-740003, was 
radiolabelled by iodomethylation in the presence of base and heat. However, biodistribution 
studies in wild type rats showed low brain uptake, possibly due to low receptor distribution in 
this model, and low metabolic stability.
216
 The tracer was shown to target the inflamed site when 
brain slices from two different rat models of neuroinflammation were incubated with [
11
C]A-
740003. Both models were injected intrastriatally with LPS or an adenoviral-associated viral 
vector expressing hP2X7R (AAV-hP2X7), respectively. Autoradiographic scanning revealed 
mildly increased striatal uptake in the AAV-hP2X7 model, but less than half in the LPS model, 
suggesting that different inflammation patterns might be generated in the two cases.
233
  
Moreover, the uptake of another P2X7 radiotracer developed by the Windhorst group at the VU 
University, [
11
C]SMW64-D16, was very similar to that of [
11
C]A-740003 in both models, but no 
significant brain binding was observed by PET. 
233
  




 based on 
the BBB penetrant hit GSK1482160, which possesses a 3 nM affinity for hP2X7.
224, 225, 235
 The 
tracer was produced in just one synthetic and one radiosynthetic step with a 40-50% 
radiochemical yield and optimal radiochemical purity and specific activity. However, in vivo 
bioavailability and stability studies for the radiolabelled tracer have not been reported to date. 





54173717 from its tritiated analogue [
3
H]JNJ-54232334 (see above in this section). The tracer 
showed nanomolar affinity for P2X7, reversibility of binding, the ability to cross the BBB and an 
ideal lack of brain metabolites. Evaluation in a rat model intrastriatally-injected with a viral vector 
expressing fluorescent-labelled hP2X7 showed selective binding of the radiotracer with rapid 
washout from the non-injected control striatum. Additionally, [
11
C]JNJ-54173717 binding in 
monkey brain was blocked with two distinct P2X7-selective antagonists. This is currently the 
most promising tracer available. 
To the best of my knowledge, no further P2X7 radiotracers have been described, which leaves 
opportunity for the development of a novel 
18




1.3 Nuclear imaging with Positron Emission Tomography 
1.3.1 Principles of Positron Emission Tomography 
This work intends to investigate the P2X7 receptor and neuroinflammation by developing a 
tracer suitable for Positron Emission Tomography (PET) imaging. But why use PET? 
PET is a non-invasive functional imaging technique which exploits radioactive decay as a 
means of signal detection. The related nuclear imaging technique of single photon emission 
computer tomography (SPECT) differs from PET in that it involves gamma (high energy photon) 
emitting radionuclides rather than the high energy beta emitters used in PET. Magnetic 
resonance imaging (MRI) is yet another non-invasive imaging technique, whose signal is 
generated by the relaxation of nuclear spins previously aligned to a strong magnetic field. 
In PET, radionuclide decay results in the emission of positrons. These collide and annihilate 
with surrounding electrons (known as an “event”), generating two anti-parallel gamma rays of 
511 keV along a so-called line-of-response (LOR) (Figure 11). Correlation of the two signals by 
coincident detection results in the 3D localisation of an event. Millions of signals need to be 
acquired for the signal-to-noise ratio (SNR) to reach adequate levels and for an image to be 




Figure 11 PET imaging  
 
Coincidence detection of the antiparallel gamma rays enables resolutions of up to 1 mm, a limit 
set by the spatial resolution of the PET camera. This limit can lead to partial volume effect 
distortions in the measurements of true radioactivity concentration if the object of interest is 
smaller than about 10 mm.
238
 The resolution value is also limited by the inherent distance 
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travelled by the positrons from the emitting nuclides before annihilation occurs. Positrons in fact 
have the same rest mass of electrons and as such the two experience extensive Coulomb 
interactions before the positron’s kinetic energy is dissipated and annihilation can occur. The 
loss of resolution due to tissue-derived annihilations and scattering and varies according to the 
density of the tissues. Furthermore, variations in the momentum of the annihilating particles 
induce an angular deflection in the two antiparallel gamma rays generated, and are responsible 
for an inaccuracy of up to 3 mm. In contrast, SPECT relies on single photon emissions, meaning 
that coincidence events do not need to occur for a signal to be registered. Incident photons are 
only filtered by collimators to reduce false events and, especially with pinhole collimators, 
SPECT can reach higher resolutions than PET.
239
 However, SPECT is less sensitive than 
clinical PET due to its ability to acquire coincidences in three dimensions, without the loss of 
signal associated with the use of collimators or gamma ray technology.
240
 Also, PET treats only 
coincident events along a LOR as true positive signals, thus inherently eliminating much noise 
(Figure 12). This is in spite of false positives still getting recorded as scattered and as accidental 
coincidences. Finally, the revival of time-of-flight (ToF) PET has pushed the boundaries further 




Once PET images are acquired, they need to be further reconstructed and processed so as to 
remove noise, motion effects and improve accuracy of the signal visualised and of the 
quantitative pharmacodynamic data.
243
 The regional concentration of the tracer can then be 
determined by drawing regions of interest (ROI) using computational methods and by co-
registration with structural images such as CT or MRI. 
In terms of utility, PET surpasses the other functional imaging modalities for sensitivity and 
ability to inform directly about the metabolic fate of molecules at the receptor level. Conversely, 
it is an expensive procedure due to the need to prepare the radiotracers with highly trained staff 
and complex equipment. In the UK, a routine PET/CT scan costs in the range of £635–
£1,300,
244












Figure 12 Types of coincident events and time-of-flight (TOF) PET data acquisition   
  
Moreover, the rapid decay of radionuclides requires most radiopharmaceuticals to be produced 
on site or in proximity of the site of application. Most commonly, PET exploits positrons emitted 
from decaying 
11
C (t1/2: 20.3 min, positron energy (pE): 960 keV), 
18
F (t1/2: 109.8 min, pE: 640 
keV), 
13
N (t1/2: 9.97 min, pE: 1190 keV), or 
15
O (t1/2: 2.1 min, pE: 1700 keV), but also radiometals 
such as 
68
Ga (t1/2: 68 min, pE: 1890 keV), 
64
Cu (t1/2: 12.7 h, pE: 1350 keV), 
89
Zr (t1/2: 78.41 h, 
pE: 909 keV) and 
82
Rb (t1/2: 1.27 min, pE: 3150 keV).
245
 A relatively long lived radionuclide such 
as 
18
F provides a partial solution to this problem, permitting off site production, longer scan 
times and longitudinal studies to be performed. 
The production of positron emitting (β
+
) radionuclides starts from the bombardment of stable 
parent isotopes, typically with high energy protons derived from a charged particle beam. 
Protons are accelerated by electromagnetic fields which curve the trajectory of the protons and 
a high alternating voltage between the acceleration chamber electrodes (dees) which induce an 
outwards spiral motion. The accelerated protons are then made to hit a target in the 
bombardment chamber, leading to a nuclear reaction and the production of the desired isotope. 
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F is produced by bombardment of 
18
O-
enriched water, which is found in nature in 0.2% abundance. Upon bombardment, a neutron is 




O (p, n) 
18
F 
More rarely, fluorine is instead produced from deuteron bombardment of 
20
Ne and the release of 
an α particle: 
20
Ne (d, α) 
18
F 










F can be made to react by either electrophilic or nucleophilic 
attack. Electrophilic fluorinations rely mostly on the reactive reagent [
18
F]F2. However, this 
diatomic reagent is generally unspecific and is commonly produced with the addition of carrier, 
leading to low specific activities.
246, 247
 Nevertheless, other electrophilic fluorination reagents 







. Despite the historically prominent role played by electrophilic 
radiofluorination,
250
 it is the nucleophilic approach that is currently most in vogue, thanks to its 
greater potential to label compounds selectively and with high specific activity, key for receptor 
imaging, quantitation of the binding and PET micro-dosing studies. Radiolabelling strategies 
involving nucleophilic radiofluorination will be explored in depth in the radiochemistry chapter of 
this thesis. 
 
Radiolabelled molecules are made to closely resemble compounds present in an organism 
without altering their chemical structure. Thus, they can be usefully employed to observe the 
behaviour of their endogenous analogues, such as glucose metabolism for [
18
F]FDG. 
Importantly, PET involves the use of trace amounts of radioactive compounds, usually less than 
10 μmol for small molecules, enabling target visualisation without toxicological or 
pharmacological effects.
251
  For this to happen, radiotracers necessitate high specific activities 
and sufficiently low amounts of carrier compound so as not to interfere with physiological 
processes. In the following sections a number applications of PET tracers in routine individual 
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patient management, experimental clinical research and industrial pharmaceutical settings are 
laid out. 
 
1.3.2 Applications of Positron Emission Tomography 
PET for individual patient management in clinical practice 
PET imaging plays a pivotal role in clinical practice. [
18
F]FDG is used routinely to diagnose a 
variety of conditions that alter cellular metabolism and glucose processing, be them related to 
cardiovascular, oncological, respiratory or central nervous system disorders. Importantly, it is 
able to indicate the increased cell metabolism of tumour cells, the occurrence of metastases, an 





F]FDG falls short when it comes to distinguishing fast-growing tumours from 
healthy fast-growing, glucose-hungry tissues. Similarly, it poorly highlights slow-growing 
tumours. Moreover, [
18
F]FDG’s relative non-specificity means it struggles to distinguish inflamed 
or infected tissues from highly metabolic cells, albeit the two sometimes coincide. Finally, it has 
restricted applications which limit the potential of PET for individualised patient management.
252
 
CNS PET is a field of intense research yet only a limited number of tracers are routinely 









F]flutemetamol, are employed to image amyloid-β sheet aggregates and 







dihydroxyphenylalanine) is used to image amine transport and decarboxylation and inform 
about the functional state of the nigrostriatal dopaminergic pathway in Parkinson’s disease as 
well as to identify neuroendocrine tumours.
254
  A wider variety of PET tracers are used clinically 
in oncology, where PET is employed to determine the exact functional tumour volume and 
boundaries prior to surgical intervention, to characterise cancers and to assess the tumour 
response to a treatment regimen. [
11
C]Methionine is used as a marker of amino acid transport 





F]fluorothymidine) is a marker of thymidine nucleoside transport and [
11
C]choline of 
phospholipid synthesis, both of which can determine the cell proliferation rate by indicating DNA 







F]fluoromisonidazole) visualises the enzymatically active intracellular reductive environment 
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within viable cells that maintain the capacity to transport substrates, which is typical of fast-




PET in experimental clinical research 
PET imaging also plays a crucial role in clinical research. Primarily, tracers with a clinical 
translation can assist in elucidating the pathophysiology of disease or the role of their target. 





has been employed to assess the target’s involvement in food and addiction disorders, as well 







promising tracers being investigated for the diagnosis of tauopathy, a hallmark of dementia, 
most likely linked to an exacerbation of the neurodegeneration in dementias.
259
 The serotonin 




F]altanserin instead, have been employed to 
study the role of their target in depression and schizophrenia.
260, 261
  
Moreover, other tracers are taken to the clinical stage to overcome the deficiencies of the 
currently available ones. This is the case for the dopamine transporter (DAT) tracer 
[
18
F]FE@CIT, which presents an improved specificity of binding to the desired target with 






  For imaging 
the 18 kDa translocator protein (TSPO) receptor correlated with the extent of 
neuroinflammation, the benchmark tracer [
11
C](R)-PK11195 comes short in terms of its 











C]PBR06 among others have been developed 
to fill the gaps in the TSPO PET imaging market. Nonetheless, [
11
C](R)-PK11195 has been 





PET in drug development 
Drug discovery and development is a long and expensive process. Yet, fewer than 10% of the 






PET is increasingly employed in industrial settings to reduce these costs, particularly by 
allowing early termination of unsuitable compounds.
266
 In the early phases of drug discovery, 
PET can facilitate the understanding of a compound’s pharmacodynamics and provide 
pharmacokinetic and occupancy measures useful to guide dose selection. It can act as a 
benchmark to validate the pharmacological activity of novel compounds and inform about 
potential toxicological effects by indicating where the compounds are likely to accumulate.
267
 
PET is ideally fit for the first phase of translation of compounds into the clinic with limited 
toxicological concerns. Target occupancy analysis and pharmacodynamic data are then useful 
to inform phase I and II clinical trials. PET is also ideal to help stratify patients based on the 
potential for treatment efficacy and to monitor their response to treatment. This is particularly 
key in neurology, where PET may help to improve the disease classification or exact diagnosis, 
thereby avoiding the targeting of conditions present only in a subset of the diseased subjects 




Finally, on a more financial side, PET can help to pharmacologically differentiate a new drug 
from competitor drugs and it can support the case for EMA/FDA approval. It can also help 
expand the market size, by anticipating detection of the disease, and monitor the course of 
treatment. 
 
1.3.3 The current state of nuclear imaging of inflammation  
Current routine clinical PET imaging of inflammation far too often relies on detecting 




  Despite its 
successes,
270
 the scientific community has understood the need for and has taken steps 
towards more specific biomarkers to image inflammation.
271
 Choline imaging already provides 
some improvements, choline processing in cell membranes being much lower than glucose in 
certain tissues such as the myocardium and thus enabling a much higher contrast during 
inflammatory episodes.
272, 273
 Moreover, mannose receptor imaging correlates better than 
[
18
F]FDG with macrophage activation, especially in relation to arteriosclerotic plaque tracking.
274
 
Nevertheless, the current focus of most research in PET imaging of inflammation is towards 





TSPO is a multifunctional protein located on the outer membrane of the mitochondria of 
(predominantly) macrophages, mast cells, microglia and astrocytes.
275
 Its expression is low in 
their quiescent state and high during pro-inflammatory cellular activity, as demonstrated by the 
ability of TSPO blockade to substantially reduce microglial activation and neuronal death in 
quinolinic acid-injected rat striatum.
276
 Among many radiotracers targeting TSPO, the most 
widespread is certainly [
11









C]PBR111, acting via alternative 
binding modes are also available.
277
 Their applications range from in vitro and in vivo imaging of 





lacks a strong blood-brain barrier (BBB) penetration, has moderate target specificity a low 
signal-to-noise ratio and variable kinetic profile, second generation TSPO tracers demonstrate 
an improved affinity and bioavailability, which have recently enabled quantitative TSPO  
PET.
284, 285
 The second generation tracers however cannot overcome the hurdle of TSPO 
displaying polymorphism between subjects. Thus, the categorisation of the population according 
to TSPO gene polymorphism is essential for true second generation TSPO tracers image 
interpretation.
286
 Further, several TSPO radiotracers lack good binding correlation between 
human and rodent receptors.
287
 Thus, their translation to the clinic is problematic and gives rise 
to alternative interpretations of the clinical data collected up to the present date depending on 
what is thought to be the true target of the tracers.
264, 288
 Finally, TSPO’s link to inflammation, 
aside from its increased expression, is unclear, which raises further questions as to what TSPO 
imaging is actually capturing of inflammatory events.
263
 An advancement in the field is 
represented by the discovery of the third generation tracer [
18
F]GE180. This tracer presents 







 whereas, similarly to the second generation tracers, it 
still falters with the receptor polymorphism issue.
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In this context, in the last decade a spree of development of new PET tracers targeting 
inflammation biomarkers has occurred. The list of radiopharmaceuticals for each biomarker 
outlined in this section is extensive, hence a selection is presented here, while comprehensive 
reviews on the subject have been published by Wu et al.
271





One of the targets under investigation is the type 2 cannabinoid receptor (CB2R) due to its 
strong links to inflammation. While CB2R presents minimal expression in resting microglia and 
macrophages, it is strongly upregulated in concomitance to immune activity.
294
 Only a small set 
of compounds have reached the preclinical stage for CB2R PET imaging to date, with promising 







Also the circulating inhibitory G-protein-coupled somatostatin receptor 2 (SSTR2) is an attractive 
target due to its involvement in neuroendocrine and inflammatory activity and its high 
expression on activated macrophages. 
68
Ga-DOTATATE has demonstrated particular potential 
as SSTR2 tracer, correlating positively with calcified arteriosclerotic plaques in two studies.
297, 298
 
A large amount of effort has gone as well in the development tracers against inflammatory 
cytokines. Among these is cyclooxygenase-2 (COX-2), an integral membrane glycoprotein 
responsible for converting arachidonic acid into prostaglandin
299, 300
 and a crucial mediator of 
peripheral and central inflammation.
301
 COX-2 imaging is championed by [
99m
Tc]Celecoxib, 
which has shown strong binding in cells strongly expressing COX-2, although specific binding 
has not been demonstrated.
302
.  
Additionally, some have imaged matrix metalloproteinases (MMPs), responsible for the 
processing of extracellular proteolysis, a critical step in many inflammatory conditions, 
particularly of the cardiovascular system.
303, 304
 MMPs are found predominantly on microglia, 
astrocytes and monocytes and their expression is modulated in tune with the release of 
inflammatory cytokines and prostaglandins, resulting in excitotoxicity, neuronal damage and 
BBB disruption.
305















SPECT probes employed 
predominantly in vascular inflammation imaging
308
 and radiolabelled C-5-disubstituted 
pyrimidine 2-4-6-triones, which have recently been modified to feature 
18
F-triazoles and 
demonstrate strong potency against MMP-2, MMP-8, MMP-9 and MMP-13.
309
 
Furthermore, interleukin-2 (IL-2, a cytokine) PET tracers have enabled indirect imaging of 
activated T lymphocytes, on the surface of which IL-2 receptors become expressed during 





















Moreover, TNF-α is a cytokine that is abundantly expressed during the acute phase of the 
immune system activation, as it sustains white blood cell transport to inflammation sites. 
Conversely, it becomes downregulated in the later stages, where it supports the apoptotic 




Cu-DOTA-etanercept is a PET radiotracer targeting TNF-
α which was preclinically validated in tetradecanoyl phorbol acetate (TPA) rodent models of 
inflammation,
315
 and was retained in the CNS only in the initial acute inflammatory phase. 
Moreover, [
11
C]tricyclic Nec3 necroptosis inhibitors of structure 3,3a,4,5-tetrahydro-2H-




Another active area of research is the direct labelling of migratory inflammatory cells. Direct 
leukocyte SPECT imaging via [
99m
Tc]HMPO labelling is the gold standard in cell labelling, which 




 However, their complex and hazardous 
production has prompted the development of techniques to image homing-associated 
molecules, involved in leukocyte migration.
318
 Endothelial adhesion molecules mediate 
leukocyte tissue infiltration and have been labelled with a range of PET and SPECT 





Tc, participate in the rolling step of the cell-blood vessel adhesion 
cascade.
319-323
 Antibodies and peptides targeting the vascular cell adhesion molecule-1 (VCAM-






F to image leukocyte extravasion.
324-326
 Moreover, 






F, providing an 
image of endothelial cell migration through the basement membrane during blood vessel 
formation and can support a diagnosis of angiogenesis.
327-329
 Finally, the vascular adhesion 




Ga-labelled peptides and 




 VAP-1 is involved in the 






1.4 Project novelty and need 
With the development of a novel 
18
F radiotracer targeting P2X7, this project intends to address 
the scientific need for: 
- A quantitative diagnostic tool for imaging P2X7 in vivo. 
- An alternative to TSPO tracers to visualise neuroinflammation (see section 1.3.3). 
- Assessing the type and degree of involvement of P2X7 receptors in health and disease. 
- Tracking clinical trials targeting P2X7, monitoring clinical outcomes and assisting in 
drug development (see section 1.3.2). 
- Differentiating pro-inflammatory and anti-inflammatory phenotypes in vivo. 
 
The project intends to innovate the field of neuroinflammation imaging by providing a new BBB-
penetrant 
18





The aim of this project is to develop a novel radiotracer suitable for imaging P2X7 in vivo. 




Chapter 2: Radiotracer design and pharmacokinetic considerations. To design a library of 
structures analogous to the lead radiotracer A-804598 amenable for 
18
F PET tracer 
development. The two approaches employed were the computational estimation of a set of 
physicochemical parameters and the in silico molecular docking of a set of structures to achieve 
a semi-quantitative and visual estimation of the target binding. 
Chapter 3: Synthesis. To synthesise, purify and characterise all non-radioactive chemical 
compounds required for this study. 
Chapter 4: Radiochemistry. To develop radiolabelling strategies suitable to produce the 





techniques were employed: fluoroethyl azide fragment labelling followed by a “click” copper 
catalysed alkyne-azide cyclisation, boronic ester aromatic substitution and quaternary 
ammonium substitution followed by a reduction and a nucleophilic conjugation. 
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Chapter 5: Cell binding assays. To assess and quantify the radiotracer uptake in P2X7 cell 
models using two approaches: a radioligand binding assay and a functional calcium-influx 
binding assay, aiming to rank the tracers in terms of their target affinity and selectivity. 
Chapter 6: Radioligand tissue binding assays. To evaluate the radiotracer binding in a tissue 
model of neuroinflammation, with the ultimate aim of achieving a semi-quantitative picture of the 
specificity of tracer binding in a native setting. 
Chapter 7 In vivo evaluation. To assess the best radiotracer in a lipopolysaccharide (LPS) rat 
model of neuroinflammation, with the goal of measuring the degree of blood-brain barrier 
penetration and P2X7-rich tissue binding to make a preliminary assessment of whether the 






















Receptor-binding radiotracer design and pharmacokinetic 
considerations 
1.7 Introduction 
The design of a good radiotracer for high-affinity receptor targeting is not a trivial task. This 
chapter presents the case for the design and selection of a library of radiotracers targeting 
P2X7. The introductory section in divided in three parts: the first discusses the quantitative 
measures of ligand pharmacokinetics; the second encompasses further design considerations 
predominantly of a qualitative nature; the third presents the case for the lead radiotracer scaffold 
selection. 
 
1.7.1 Quantitative measures of ligand pharmacokinetics 
In a biological context, a radiotracer’s behaviour at the site of binding can be simplified to the 
equilibrium between dissociated receptor (R) and ligand (L) and the receptor-ligand complex 
(RL) (Figure 13). 
 
Figure 13 Schematic depicting the receptor-ligand complex equilibrium. 
 
Radiotracers can inform about this equilibrium process via dynamic association and dissociation 
to their target. Qualitatively, in vivo PET scanning allows us to appreciate this equilibrium 
process visually by showing how the tracer accumulates and is cleared from the target sites 
over time. However, only quantification can provide full insight into the pharmacokinetics of 
radiotracers. Since pharmacokinetic parameters are key to the lead tracer selection process, a 
number of concepts need to be defined, which will also be encountered later in the biological 
evaluation chapters 5-7. 
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The association and dissociation rates for a molecule binding to a receptor are denoted by the 
terms Kon and Koff, respectively (Figure 13). The ratio of the two gives the dissociation constant, 
Kd, described by the following equation.
333
 







Kd is an indication of the affinity of a molecule for its target receptor, as is the association 
constant Ka, the reciprocal of Kd.
334
 The receptor-ligand complex concentration is further linked 
to the dissociation constant by the following expression, derived from the Michaelis-Menten 
equation, a description of the rate of binding of a substrate to an enzyme.
333
 




where BMAX is the total number of binding sites present. At high ligand concentrations, L >> Kd, 
resulting in BMAX = [RL]. Thus, BMAX also represents the maximal receptor occupancy. At low 
ligand concentrations (as is often the case for PET tracers) L << Kd, resulting in BMAX / Kd = [RL] 
/ [L], i.e. the amount of complex formed versus the unassociated ligand, known as binding 
potential (BP). In other words, if [RL] corresponds to the bound radioligand concentration [B] 
and [L] is the free radioligand concentration [F], the Michaelis-Menten equation becomes 











These parameters can be conveniently quantified in vitro by plotting the specific binding versus 
concentration of tracer (saturation plot) or the bound to free ratio versus the bound fraction 
(Scatchard plot) as shown in Figure 14.
333
 Note that in vitro the specific binding curve is the 
result of the difference between total binding and non-specific binding (NSB) and that the latter 
increases linearly while specific binding increases hyperbolically up to BMAX. Also, these 
equations hold only if the assumption that the system is in equilibrium (e.g. the free and bound 
ligand are constant over the time of measurement). For [F] to be considered “constant”, Hulme 
and Trevethick
335
 recommend an occupancy of <10% for in vitro studies. For in vivo, others 
recommend <5%
334















































Figure 14 Saturation curve and Scatchard plot  
  
A further measure of receptor-ligand interactions is the IC50, defined as the concentration at 
which 50% of the binding to the receptor is inhibited.
335
 To measure this value, competition 
assays are employed. Increasing concentrations of non-radioactive ligands are co-incubated 
with the radiotracer, producing a concentration-dependent response from which IC50 values can 
be extracted (Figure 15). This assay is particularly useful to measure the affinity of compounds 
relative to other compounds or targets, providing data on the selectivity and modality of binding 
of a tracer. However, IC50 values are relative to the measures of outcome and to the 
experimental setup, so their interpretation is only valid in relation to similar experimental 
conditions. This matter will be further expanded upon in chapter 5. 
Competition binding curve




















Figure 15 Competition binding curve 
 
One further type of plot is a kinetic binding curve, which displays binding over time at 
incremental concentrations (association study) or with such a radioligand concentration as to 
provide high initial receptor occupancy (dissociation study). The ligand will associate and 
dissociate with hyperbolic or inverse hyperbolic dependence to time, respectively, until a plateau 
41 
 
is reached. When expressing the total binding as a Log function, the dissociation curve 
becomes a straight line with slope │Kon│and │Koff│. 
Saturation, competition and kinetic binding experiments are also useful to assess the modality 
and type of binding of ligands to their target. Ligands can either be irreversibly or reversibly 
bound. The former is traditionally seen as less desirable as covalent binding prevents the 
displacement and washout of the tracer, leading to a lack of true equilibrium. This is however an 
acceptable modality of binding if the receptor has a high turnover.
337
 Reversible binding itself 
can be comprised of competitive, non-competitive, uncompetitive or mixed reversible binding 
(Figure 15). 
 
Figure 16 Schematic depicting the receptor-ligand complex equilibrium in the presence of a 
reversible competitor 
 
Competitive ligands (L and L2) contend the same binding site. Therefore, complex RL’s rate of 
formation is dependent on the difference between the Kd of both RL and RL2 complexes and a 
higher Kd is necessary for RL formation to outcompete RL2. In contrast, uncompetitive binding 
does not directly compete against RL’s complex formation, actually driving its formation to 
further bind L2 to the RL complex, hence decreasing the BMAX. Finally, non-competitive binding 
solely depends on the concentration of L2, as while L2 binds to the same site as L1, its binding 
does not prevent RL complex formation and can lead to both L and L2 to bind to R (RLL2). 
Furthermore, a fourth type of reversible binding exists and is usually referred to as mixed, 
cooperative or allosteric binding. Similarly to non-competitive binding, both L and L2 bind 
concomitantly to the target, but in this instance L2 affects the binding of L. Most often, this is due 
to binding to a site other than the orthosteric site, inducing a change in the target’s conformation 
that affects positively, neutrally or negatively the binding of L. Allosteric binding can be 
assessed with an affinity ratio plot, where the modulated (Kdapp) to non-modulated (Kd) rate 
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constants (defined as the dose ratio), minus 1, is plotted against the concentration of allosteric 
modulator increased up to the receptor-saturating value. The degree of cooperativity is 
measured as α, the factor by which Kd is affected. When α>1, there is positive cooperativity, α=1 





























Figure 17 Affinity ratio plot 
 
 
1.7.2 Design considerations 
Similarly to non-radioactive drugs, radiotracer development is an iterative process which is 
prone to failure. In order to minimise the high attrition rates, PET scientists routinely take into 
account a number of physicochemical and biological factors which by no means represent a 
recipe for perfection, but nonetheless enable to streamline the lead radiotracer selection 
process and its chances to come to human fruition. These considerations start from the choice 
of the biomedical question and the selection of the biological target. In particular, targets ideally 
display a strong as possible a density difference between healthy and diseased state to 
facilitate detection.  However, the most fundamental considerations lie in the chemical probe 
design strategy. The following section is limited to CNS receptor-targeting small molecule 
radioligands and discusses in particular the importance of: affinity and specificity, bioavailability, 





Binding affinity and specificity  
Binding is strongly governed by the structure-activity relationship (SAR) between the ligand and 
its target, consisting in the degree of molecular fit that the substrate demonstrates with respect 
to the binding site. It can be estimated by computational modelling, although true binding affinity 
can only be determined by experimental means. 
Usually, low nanomolar (nM) affinity is desired. However, tracers can in principle succeed with 
lower potency, particularly if they image a high-density target and as long as the compound is 
specific and selective for the desired target.
338
 Binding selectivity implicates predominant affinity 
for the desired target. This is different from specificity, which denotes sole binding to the desired 
target. In this sense, diagnostic radioligands differ from therapeutic drugs, since in the former 
case aspecific binding may lead to inaccurate images, whereas often for the latter low enough 
aspecific affinity to avoid adverse effects may be sufficient to reach an appropriate therapeutic 
window.  
In order to determine a compound’s affinity and specificity, in vivo or in vitro screening in cells 
expressing the target receptor or in native tissue homogenates or slices (autoradiography) is 
performed. The co-incubation with a homologous compound or knock-out animal model gives 
data on a compound’s specificity of binding, whereas heterologous compound co-incubation 
informs about the binding selectivity.
339
 Specificity of binding is best tested against a set of 
potentially homotopic targets and against target receptor subtypes. So, for a putative CNS P2X7 
tracer, specificity is ideally verified by performing affinity assays against human, rat and mouse 
P2X7, P2X1-6, P2Y receptors as well as unrelated brain receptors such as adrenoceptors, 
dopamine, serotonin and histamine receptors.
196, 229, 340
 
The initial design of a novel radioligand can take after a known potent ligand. However, this 
strategy does not guarantee low non-specific binding of the adapted radiotracer, nor optimal 
washout for quantitative PET imaging.
339
 Additionally, if the parent ligand is endogenous, it does 
not necessarily satisfy the low mass requirements of PET receptor imaging. Sometimes tissue 
binding studies with analogues labelled with long-lived isotopes such as tritium can be found in 
the literature, which provide invaluable information on the candidate molecule’s binding kinetics. 
44 
 
An alternative design strategy is to synthesise de novo libraries of compounds amenable to 
radiolabelling, possibly offering multiple potential radiolabelling sites. High-throughput screening 





Upon in vivo administration, a chemical interacts with blood and tissue-based species, such as 
albumin proteins and lipids, which limits its concentration as a free species in the blood. This 
effect is otherwise known as bioavailability and has profound consequences on the amounts of 
radiotracers that reach the brain. Therefore, during the radiotracer design phase it is important 
to take into account a few factors which frequently lead to enhanced binding to such species, 
although many successful exceptions to these rules of thumb are known. 
The most popular way of assessing the suitability of a compound is to follow a modified version 
of Lipinski’s rule of five ():
341
 
 Maximum 500 g/mol molecular weight 
 Maximum 5 hydrogen bond donors 
 Maximum 10 hydrogen bond acceptors 
 Lipophilicity of Log P 1.5-3 
342
 
Limiting the molecular weight of a molecule enhances its ability to penetrate layers of tissue and 
reach the target site. However, very small and hydrophilic molecules can have a limiting low 
plasma circulation time, rendering them too easily excreted for PET detection. The hydrogen 
donor and acceptor rules of thumb are particularly useful to limit the weak interaction of 
compounds with the surrounding biomolecules and tissues and facilitate the passive diffusion of 
the tracer.
343
 Finally, the overall lipophilicity should be such as to ensure a degree of aqueous 
solubility but maintaining some hydrophobic character to enable tissue permeation. High 
lipophilicity often results in considerable non-selective binding to lipophilic tissues and fatty acid 
residues on cell membranes, which severely impacts the signal-to-noise in PET acquisitions. 
Lipophilicity is commonly expressed as Log P, the partition coefficient, equal to the ratio of 
concentrations of compound X in a mixture of two immiscible phases (octanol and water) at 
equilibrium. Another useful measure of lipophilicity is the Log D, which takes into account both 
ionised and unionised species at a specific pH, usually physiological (pH 7.4). Furthermore, the 
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polar surface area (PSA), defined as the surface sum over all polar atoms has been shown to  
be a good descriptor of drug absorption, bioavailability and brain penetration. In particular, 
values should be smaller than 140 Å
2





 This rule extends to the preference for molecules lacking a formal 
charge, which considerably increases hydrophilicity and hinders cell penetration and retention. 
 
Metabolism 
Blood metabolising enzymes act on compound within minutes from the time of administration, 
often times derivatising it in such a way as to lose its target affinity. Compounds are often 
fragmented to more hydrophilic species which can easily be washed out and excluded from 
BBB entry.
345
 However, sometimes lipophilic fragments form which can penetrate through 
endothelial and epithelial barriers. Both if the fragments are alternatively active metabolites 
(alternative specific binders) and if they are inactive fragments (non-specific binders), the 
background noise is increased.
346
 This results in a lower signal-to-noise ratio, as PET cannot 
discern between radioactive signals arising from different molecular species, although to some 
extent biomathematical modelling can be employed to adjust the output image for 
radiometabolite formation. Nonetheless, not all metabolism is detrimental. In fact, the enzymatic 
degradation of compounds impermeable or pumped out from the BBB enables better 
pharmacological clearing, which in turn sustains tracer washout from the brain and enables 
simpler biomathematical analysis for quantitative imaging. 
Metabolism occurs at varying degrees and increasingly slowly the higher the species complexity 
is.
345
 Thus, small animal testing is not always predictive of the compound behaviour in humans. 
Nevertheless, it is common practice to analyse metabolites ex vivo in small animals or non-
human primates, as well as in vitro in human serum. Radiometabolites are detected and 
analysed with the use of radio-high performance liquid chromatography (radio-HPLC), instant 
thin-layer chromatography (iTLC) and solid-phase extraction (SPE).
346
 These techniques are 
able to quantitatively separate different chemical species and identify them by comparison with 
non-radioactive analogues or with the use of mass spectrometry. 
To assist in a metabolism-safe design of PET probes, some rules of thumb originated from 
experimental trial-and-error exist. Generally speaking, if the metabolic fate of a scaffold is 
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known, it is preferable for the radioisotope to sit on the hydrophilic fragment. For 
11
C tracers, the 































 uptake, with 
consequent signal leach-over into the brain cortex. Defluorination can also occur spontaneously 
by intramolecular elimination processes, thus moieties susceptible to defluorination such as 
[
18
F]fluoromethoxy are best avoided.
351
 Moreover, aliphatic fluorine chains such as [
18
F]2-
fluoroethyl are sometimes subject to dealkylation.
352
 
The simplest strategy to circumvent unwanted metabolism is to change the label position, 
possibly without modifying the compound’s structure. Moreover, deuteration (especially on 
aliphatic carbons) can facilitate metabolic retardation;
353, 354
 otherwise, if the metabolising 




Blood-brain barrier permeability 
The blood-brain barrier (BBB) is a selectively permeable dynamic interface composed of 
endothelial cells connected by tight junctions and isolating the brain from the circulation. 
Radiotracers may penetrate the BBB via either passive diffusion or carrier-mediated transport, 
depending on their chemical nature. Lipophilic substances have preferential access through the 
BBB. However, they give rise to the non-specific binding issues described earlier in this section. 
Aside from the challenges posed by the entry into the brain, it is the retention within the brain 
which is most crucial to ensure a sufficiently high signal-to-noise ratio for CNS PET imaging. 
Upon BBB influx, some CNS compounds get metabolised and trapped within the brain, such as 
[
18
F]FDG, which undergoes phosphorylation. Instead, other compounds remain unchanged. In 
either instance, compounds may washout from the brain at various rates, and again either via 
passive diffusion or via carrier-mediated transport. Therefore, most often, BBB penetration is a 
balance between the capacity to passive entry and efflux transporter susceptibility, notably to 






For what concerns radiotracer design, BBB influx can be facilitated by the glycosylation of 
radiotracers with hexose rings (substrates of glucose influx pumps),
358
 or by derivatisation with 
carboxylates (substrates of the monocarboxylate transport system).
359
 Additionally, organic 
anion and cation transporter systems are known to facilitate influx, among many, of cardiac 
glycosides and monoamine neurotransmitters.
358
 Among the efflux pumps, the P-gp is known to 
interact and transport lipophilic and cationic drugs to the outside of the brain. Hence, aside from 
the high NSB, excessively high LogP can have the further consequence of limiting the BBB 
retention. Additionally, strongly aromatic compounds are frequently P-gp substrates.
360
 For all 





 as well as to the species under consideration.
362
 
In order to explore BBB-penetration independent of efflux, in animals it is legally accepted in 





 and computational predictions
373
 of BBB permeability  are available 
which can predict to a certain extent whether a candidate tracer has suitable properties for brain 
penetration. Finally, transporter-specific in vitro assays can inform about the potential binding of 




Synthetic and radiosynthetic accessibility 
Another important set of considerations during the design phase are the choice of radioisotope, 
the radiolabelling strategy and the ease of synthesis of the chemical precursors. Radioisotopes 
differ both in their decay modality, decay energy and their half-life. 
18
F is a particularly useful 
isotope since its decay is 97% β
+
; its half-life is long relative to 
11
C, which offers the opportunity 
of producing the radioisotope off-site, of carrying out multiple imaging scans with one injection, 
of selecting a later time point to achieve an optimal imaging signal. Finally, 
18
F’s positron energy 
is lower than that of 
11
C, which results in a nearly halved positron range in water, which 
positively affects the image resolution. 
Nevertheless, the choice of radioisotope is also dictated by its atomic number: a large majority 





offer the opportunity of radiolabelling most species without any structural modification. Despite 
this, the choice of radioisotope is also governed by the ease of synthesis or commercial 
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availability of the precursor needed to perform the radiolabelling and by the structure of the 
target tracer. The ideal radiolabelling strategy involves less than 2 steps and less than 3 isotope 
half-lives. Moreover, it needs to be reproducible, ideally automated and capable of producing a 
radiotracer in high radiochemical yield, radiochemical purity, specific activity and concentration. 
Some issues frequently encountered in the radiosynthesis stage are the isolation of the 
radiotracer from the precursor species,
376







and unwanted addition of carrier tracer (such as [
12






Pros and cons on the use of 
18
F labelling 
In this work, the isotope of choice is 
18
F. Fluorine is present in about 20% of all pharmaceuticals 
and 30% of all agrochemical compounds as of 2007.
379
 Fluorine has not always been seen as a 
convenient atom in pharmaceutically active compounds, but the huge commercial success of 
fludrocordisone, an analogue of hydroxycortisone, of 5-fluoroacil, an alternative to natural uracil, 
as well as that of [
18
F]FDG, an analogue of glucose, has led this atom to become widely used to 
explore structural affinity to biological targets.
380
 As the most electronegative atom of the 
periodic table, it is undoubted that fluorine cannot simply be considered an orthologous 
replacement for hydrogen atoms as it introduces electrostatic and steric variations at the desired 
site of binding that cannot be overlooked.
381
 Most commonly, fluorine is employed in drug 
analogue designs to constructively improve the molecules’ disposition, in terms of its adsorption, 
distribution, metabolism and excretion (ADME) profile.
382
 For instance, the introduction of 
trifluoromethyl groups can increase the lipophilicity, whereas fluorine-hydrogen substitutions in 
aromatic rings can both affect the lipophilicity as well as reduce the rate of oxidation by limiting 
the substrate’s interaction with oxidative enzymes.
383
 In other cases, metabolic processing can 
result in the loss of radioactive fluoride or 
18
F-containing fragments, with consequent positive 
and negative effects on the clarity of the target-specific signal, as [
18
F]fluoride is taken up by 
bones,
384
 lipophilic fragments can reach new targets, remain in tissues or get further 
metabolised, whereas hydrophilic fragments usually get readily cleared from the circulation.
382
 
On the target affinity side of the equation, the introduction of fluorine can sometimes be 
beneficial to better exploit electrostatic interactions and affect selectivity at binding sites. 
Fluorine can lead to improved H-bonding and introduce new molecular interactions as a 
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consequence of its effect on the pKa of protonated amines, carboxylic and hydroxyl groups.
385
 
There are multiple examples in which fluorine has positively impacted the properties of 









 whereas there are many examples in which it has brought detrimental 
changes, such as in the dopamine D2/D3 receptor antagonist [
18
F]F-PHNO, where the 
introduction of a fluorine atom prevented all the specific binding to the targets.
388
 
To conclude, the use of fluoride labelling in otherwise fluorine-free compounds cannot be 
treated as a ubiquitously advantageous choice, yet it should not be discarded a priori as it can 
bring along positive modifications to bioactive molecules. 
 
1.7.3 Lead radiotracer scaffold selection 
Among the many antagonists described in section 1.3.5 (chapter 1), our attention was captured 
by the cyanoguanidine P2X7 antagonist series, many compounds of which display exceptionally 
strong pharmacological activity and selectivity for P2X7.  First discovered in 2006 in the Abbott 
Laboratories, they were championed by A-740003
196
 and compound 1 (Figure 18).
389
 A-740003 
showed affinity for the human P2X7 (hP2X7) with an IC50 of 40 nM for calcium influx, 156 nM for 
IL-1β release and of 92 nM for pore formation as observed by Yo-Pro uptake. However, they 
subsequently found that different substitutions at both sides of the cyanoguanidine could further 
increase its potency. On the left hand side (LHS) (Figure 18), the addition of a 2-methyl 
substituent in the quinolinyl group conferred higher microsomal stability in whole blood. 
Nevertheless, aside from this, the LHS moieties tested did not beat the potency observed with 
5-quinolinyl, and included 2-tolyl, indole, benzofurane and pyridine.
389, 390
 Further, on the right 
hand side (RHS) the SAR was explored by insertion of a piperazine with a range of substituents 
in the region linking the guanidine and the aromatic ring. The variety of piperazine substituents 
included o-, m- and p-methyl, methoxy and chlorophenyl rings, linked by either alkyl chains, an 
amide or carbonyl groups, the latter two resulting in the most potent compounds of the series 
(up to 30 nM in hP2X7).
391, 392
 Instead, when a shorter linker was introduced, such as that in A-







Figure 18 P2X7 cyanoguanidine antagonist series. 
  
Some further insights into the binding modality of P2X7 antagonists with the receptor’s ATP-
binding pocket were given by a recent in silico molecular docking study.
394
 Molecular docking is 
a molecular modelling technique that allows the determination of the predominant binding 
modes of a ligand with a protein of known three-dimensional structure. The binding modes are 
determined algorithmically via iterative three-dimensional ligand-protein approximations and 
ranked by a scoring function, a value representative of the overall energetic favourability of the 
ligand-protein interaction.
395
 The three-dimensional conformation of the protein can be derived 
from X-ray crystallographic structures published in the protein data bank repository (RCSB PDB, 
www.rcsb.org).
396
 Despite the absence of a published P2X7 X-ray crystal structure, the group 
performed P2X7 homology modelling on the zebrafish P2X4 crystal structure, where the 
relevant amino acid mutations were accounted for by means of computational simulations. 
Docking of cyanoguanidine compounds showed that the strongest interactions incurred via 
means of polar H-bond acceptance by the cyanoguanidine moieties. Likewise, triazole and 
tetrazole antagonists were found to interact with their azole moieties in similarly favourable ways 
(Figure 19). This matching function suggests that cyanoguanidine might similarly provide rigidity 
to the molecular scaffold. As for the substituent, the quinoline moiety was confirmed as the best 
fitting, displaying energetically favourable hydrophobic interactions in the innermost part of the 
cavity. Instead, the RHS of the compounds showed some hydrophobic behaviour, but given the 






Figure 19 Superimposition of docking conformations of compounds A-740003  and A-438079 at the 
inactive-state hP2X7 binding site 
Antagonist A-740003 displays two methoxy groups at an extreme of the molecule. These 
appeared to rest externally to the core of the pocket, thus we presume that they bare low impact 
on the compound’s affinity. A-804598, instead, engaged all its cyanoguanidine substituents in 
hydrophobic interactions at the active site, corroborating the experimentally observed high 
affinity.
229
 Given the stronger potency displayed by A-804598 and its ease of synthesis, we 
decided to focus our attention on assessing this compound’s pharmacokinetic suitability as a 
radiotracer and amenability for radiolabelling. Most of the data are available from two key 




 Selectivity to P2X7 against a 
wide range of common alternative binding targets has been exhaustively explored. A-804598 is 
a competitive inhibitor when, under Bz-ATP stimulation, IL-1β uptake was monitored. Also, the 
52 
 
uptake of DNA-binding fluorescent die Yo-Pro (indicative of P2X7 pore activity) was potently 
blocked in the presence of the candidate antagonist.
229
 
Furthermore, A-804598’s binding is rapid, stable for up to 3 hours and reversible. The Kd 
obtained from the ratios of Koff/Kon (3.38 nM)
67





). The BMAX is of 0.112 pmol/mg in rat brain cortex homogenate
67
 
and of 0.560 pmol/mg in P2X7-transfected 1321N1 human astrocytoma cells.
229
 These values 
give a BMAX / Kd of ca. 36, which is in the ideal range for PET imaging of BMAX / Kd ≥10.
334
 
Further, in vitro autoradiography studies using [
3
H]A-804598 showed widespread binding in the 
wild type Sprague-Dawley rat’s CNS. In vitro rat cortex homogenate occupancy assays 
determined a 60% specific binding of the tracer at equilibrium.
67
 Collectively, these data are 
highly desirable for achieving an optimal signal-to-noise ratio upon translation of the ligand for 
PET imaging.  
 
On the down side, A-804598 does not possess any halogen in its structure. Hence, direct 
radiofluorination cannot be achieved without structural modifications. Moreover, A-804598’s 
LogP of 3.4-4.8 (Table 3, section 1.9.1) violates Lipinski’s modified rule-of-5. This presented us 
with an opportunity to impart structural modifications that would lower the LogP while providing 
a site for radionuclide attachment. Understandably, these modifications change the functional 
binding of the compound which therefore requires re-evaluation in a biological setting 
(discussed in chapters 5-7).  
Nonetheless, as previously discussed, relative tolerance to the nature of the aromatic groups on 
the LHS and RHS of the cyanoguanidine centre (Figure 18) is apparent from the literature.
397
 
Thus, we sought to explore structural modifications in the periphery of the molecule via in silico 








The work outlined in this section aimed at investigating which structural modifications to the lead 
scaffold A-804598 were most likely to yield a useful PET tracer targeting P2X7.  
Firstly, our design strategy involved the analysis of which structural modifications could impart a 
decrease in LogP coupled with the introduction of a fluorine atom in a position amenable for 
radiofluorination, whilst keeping in mind the modality of receptor binding of the parent structure. 
The structures were filtered down to those viable for synthesis and, among those, the 
compounds for which synthetic precursors were commercially available. Next, in silico molecular 
docking of the remaining scaffolds was performed so as to provide a visual and semi-
quantitative estimate of binding. 
 
1.8 Methods 
1.8.1 Physicochemical parameter calculations 
LogP 
The LogP was estimated computationally from the ChemDraw software’s Crippen 
fragmentation-based lipophilicity estimation method.
398
 the Viswanadhan's fragmentation 
method
399
 and the MolInspiration miLogP estimation method.
400
 Fragmentation methods 
essentially segment molecules into groups of atoms, each of which is given an individual LogP 
value based on their steric and electronic contribution to the total molecular LogP. Moreover, the 
final LogP estimation includes whole-molecule steric and electronic corrections. Furthermore, 
the miLogP adjusts the LogP estimates to experimentally calculated LogPs for over 12,000 
drug-like compounds. 
 
Topological Polar Surface Area 
The Topological Polar Surface Area (TPSA) was calculated with the Molinspiration TPSA 
estimation method. This is based on the summation of surface contributions from all polar 
fragments, calculated by least squares fitting to a single conformer 3D PSA for over 34,000 
drugs from the World Drug Index. TPSAs differ from classical 3D PSAs by the amount of 
conformers taken into account. Despite some loss in accuracy, the calculations are up to three 





1.8.2 Molecular docking 




All molecular modelling studies were performed as described in Dal Ben et al.
394
 on a Core i7 
CPU (PIV 2.20 GHZ) PC workstation. Homology modelling and docking studies were carried out 
using Molecular Operating Environment (MOE by C.C.G., Montreal, CA, version 2012.10) suite. 
All ligand structures were optimized by semi-empirical RHF/AM1 calculations using the 
MOPAC
402
 package implemented in MOE. 
The homology model of the human P2X7 (hP2X7) receptor was built using the inactive and 
ATP-bound X-ray structures of the zP2X4 receptor as templates (PDB code 4DW0, 2.9 Å 
resolution and 4DW1, 2.8 Å, respectively). First, alignment of the zP2X4 and hP2X7 receptor 
primary sequences was performed within MOE. The original zP2X4 receptor boundaries were 
applied for the corresponding hP2X7 sequence. The missing domains were built by the loop 
search method implemented in MOE. Once the heavy atoms were modelled, all hydrogen 
atoms were added and the protein coordinates were then minimized with MOE using the 
AMBER99 force field
403
 until the root mean square (RMS) gradient of the potential energy was 




. Reliability and quality of these models were checked using the 
Protein Geometry Monitor application within MOE, which provides a variety of stereochemical 
measurements for inspection of the structural quality in a given protein (backbone bond lengths, 
angles and dihedrals, Ramachandran φ-ψ dihedral plots, sidechain rotamers and non-bonded 
contact quality). 
 
Molecular docking  
The ligand structures were docked individually into the binding site of the P2X receptor using 
the AutoDock tool (PyrX interface) by the Scripps Institute.
404, 405
  
This method is divided into four stages. 1) A set of unique coordinates for both the receptor and 
the ligands was generated, maintaining all information about flexible side chains, charges, 
atoms types and torsional degrees of freedom. 2) The software Autogrid generated a three-
55 
 
dimensional lattice of regularly spaced points (grid map) described in Cartesian space. Each 
point represents a “probe” atom to which specific values of energy of interaction with the protein 
are assigned. AutoGrid affinity grids are calculated for each type of atom in the ligand, typically 
carbon, oxygen, nitrogen and hydrogen, as well as grids of electrostatic and desolvation 
potentials. 3) Conformational analysis of the ligands was performed with an Autodock algorithm 
taking into account various bond rotations and angles and overlaying the structures on the 
Autogrid-generated grid maps. The free energy was calculated with the AMBER force field.  4) 
Analysis of conformationally similar complexes and the interaction between ligands and proteins 
was employed together with the free energy scores to select the final docked complexes. The 
Binding_Energy parameter was used as an estimate of the variation in free energy (ΔG) arising 
from the docking. 
 
Post-docking analysis 
The docking poses of each ligand-receptor complex were then further subjected to AMBER99 
force field energy minimization in MOE until the RMS gradient of the potential energy was less 




. Receptor residues within 6 Å distance from the ligand were allowed to 
move, while the remaining receptor coordinates were kept fixed. AMBER99 receptor partial 
charges and MOPAC output ligand partial charges were utilized. Upon completion of the 
compound-binding site energy minimization, receptor coordinates were fixed and a second 
energy minimization with MMFF94 force field
406, 407
 was performed allowing only the ligand 
atoms to move. For each ligand, the minimized docking poses were then rescored using the 
dock-pKi predictor. The latter tool estimates the pKi for each ligand using the “scoring.svl” script 
retrievable at the SVL exchange service (Chemical Computing Group, Inc. SVL exchange: 
http://svl.chemcomp.com). The algorithm is based on an empirical scoring function consisting of 
a directional hydrogen-bonding term, a directional hydrophobic interaction term, and an entropic 
term (where rotatable bonds in the ligand are immobilized). The obtained pKi values must be 
considered as docking scores and not as prediction of binding affinity. For each compound, the 
top-score docking poses according to at least two out of three scoring functions were selected 
for final ligand-target interaction analysis. The use of two different softwares based on different 
56 
 
algorithms and scoring parameters was deliberate and aimed at increasing the degrees of 




1.9.1 Physicochemical compound library evaluation 
Following initial selection of a range of permutations of A-804598 incorporating 
18
F, 14 
structures were identified as having commercially viable building blocks and reasonably 
moderate structural modifications from the parent structure A-804598. A set of physicochemical 
parameters of these structures were computationally derived to assess their degree of 
compliance with Lipinski’s rule-of-5 and the CNS-modified version for heightened BBB 
permeability (Table 3). The analysis revealed that both the parent molecule A-804598 and its 
desmethylated version (1) have an excessive LogP value. The cyclotriazole series 2-4 and the 
fluorinated analogues 5-7 of compound 1 demonstrated good adherence to Lipinski’s rule-of-5 
(LRO5). The amide analogues 8 and 9 showed improved LogP with respect to compound 1, yet 
not sufficiently so to comply with the modified LRO5. Understandably, compound 10 had high 
LogP due to the addition of an aromatic ring. Finally, the pyridinyl compounds 11 and 12 
showed an overall acceptable compliance with the modified LRO5, especially upon resizing of 


























































































































































































































































































































































































































































































































































































































































































































Figure 20 Library of A-804598 analogues examined in this work. 
 
1.9.2 Molecular docking SAR evaluation 
The compounds shown in Figure 20 were docked to the hP2X7 receptor by homology modelling 






Figure 21 Molecular docking into the hP2X7 receptor ATP-binding pocket of a representative 

































Next, gains in free energy and estimates of affinity were calculated for each compound structure 
(Table 4). 




A-804598 -6.31 5.14 
1. EF1 -5.92 4.87 
2. EFA -7.01 5.16 
3. AFA -6.02 4.50 
4. OFA -5.65 4.26 
5. p-EFB -5.72 4.90 
6. m-EFB -6.02 4.11 
7. o-EFB -5.57 3.23 
8. p-EFC -6.01 5.54 
9. EFC2 -6.04 5.38 
10. p-EFD -7.52 6.31 
11. EFE -5.85 4.49 
12. AFE -5.50 3.47 
 
Taken together, the visual and quantitative estimations of ligand-receptor binding showed the 
following trends. 
1. Removal of the benzyl methyl group did not prevent good ligand-receptor fitting. The methyl 
group appeared to sit into an area not particularly hydrophobic either, suggesting that if 
anything it might serve as a structural constraint for the phenyl group to sit in the 
hydrophobic region between Phe218 and Lys66. However, upon removal of the methyl 
group an overall estimated ΔG reduction of 0.39 kcal/mol and an estimated pKi reduction of 
0.27 were observed. 
2. The triazole ring in compounds 2-4 appeared to sit comfortably in the binding pocket and 
somewhat interacted with Lys66. Instead, the fluoroethyl chain seemed not to interact with 
the receptor, preferring rather to sit flexibly in the outer part of the pocket. In the case of 
compound 2, the rest of the molecule retained the same 3D conformation and fit to the 
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pocket, while the molecule overall displayed a greater degree of flexibility. In this instance 
the binding energy difference was increased by 0.70 kcal/mol compared to the parent 
structure, while the pKi remained unvaried. In the case of compounds 3 and 4, the 
hydrophobic region at the core of the pocket became less exploited. In both cases, the 
binding energy and pKi scores reflected a progressive decrease in affinity for the binding 
pocket as the LHS aromatic ring is reduced in size and is decorated with a polar group. 
3. The fluorine atom on the aromatic ring of compounds 5-7 appeared to fit in the opening of 
the binding pocket. None of the compounds in this series showed much variation in binding 
compared to compound 1. However, the pKi estimates showed a dramatic drop in affinity for 
the ortho and meta positions. Conversely, the para position retained its affinity. The binding 
energy differences instead followed a different trend, showing better fit for the meta-
fluorinated ring, followed by the para- and lastly by the ortho-fluorinated compound 1. 
4. The addition of hydrophilic or hydrophobic functionalities at the benzylic position in 
compounds 8-10 did not alter the 3D conformations within the core of the binding pocket. 
However, the presence of a polar moiety deformed the conformation in the outer part of the 
pocket so as to orient the newly introduced carbonyl oxygen towards residues Gln143 and 
Lys66, thereby stiffening the overall conformation both via polar as well as multiple H-
bonding interactions. Moreover, the RHS phenyl ring became twisted by 90°, possibly to 
exploit some π-π stacking interaction with Phe218. The addition of a fluorine atom in 
compound 8 did not seem to affect the binding, both in terms of ΔG and of pKi. Conversely, 
the introduction of a phenyl functionality at the benzylic position (compound 10) induced a 
major boost in binding according to both measures, suggesting the filling of a previously 
untouched hydrophobic pocket.  
5. The removal of the methyl spacer between the guanidine and the RHS phenyl ring resulted 
in an increasingly constrained molecular conformation. For compound 11, this was only 
partially detrimental to binding, as observable from the similar binding energy and pK i 
estimate to compound 6, whereas a net loss was observed in comparison to the more 
flexible compound 2 scaffold. Moreover, the lack of methyl spacer combined with the 
modification of the LHS aromatic into a phenyl ring severely impacted the affinities, scoring 
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worse than the related compound 3 and nearly all quinoline guanidine compounds (1, 2, 5, 6, 
8-11). This is indicative of a deterioration of the ligand fitting within the binding pocket. 
 
1.10 Discussion 
The findings outlined in this chapter give an estimate of the physicochemical properties and 
binding modality of a set of A-804598 analogues to the P2X7 receptor’s ATP-binding pocket. 
The molecular structures were designed according to four parameters: 
- Maintenance of the cyanoguanidine moiety and the presence of aromatic 
substituents on its left and right hand side, key features to the selective binding to 
P2X7. 
- Likelihood to possess LogP and BBB-penetration potential in accordance to 
Lipinski’s modified rule-of-5. 
- Amenability for radiofluorination and metabolic stability of the label. 
- Synthetic accessibility (ideally < 3 synthetic steps) and synthetic precursor 
commercial availability. 
According to these criteria, a number of potentially interesting scaffolds such as methyl- and 2-
ethyl-fluoropyridine guanidines had to be discarded. Initially, it was evaluated whether the 
removal of the chiral benzylic methyl group would enable a greater synthetic accessibility. This 
modification did not appear to affect the binding at a visual level, but it did lower considerably 
the estimated free energy gain and pKi. Conversely, the LogP was improved, while the other 
physicochemical parameters under consideration were not affected. Next, the desmethylation 
was assessed in conjunction with a change in aromatic functionality on the RHS of the scaffold 
to include a triazole moiety, very widely employed in radiochemistry to conveniently fluorinate 
substances via click chemistry with minimal impact on the overall binding and high 
radiosynthetic yields.
408, 409
 Interestingly, the triazole ring was found to improve the estimated 
free energy gain of the parent compound as well as maintaining its estimated pKi. In turn, the 
lipophilicity was lowered to the target range for BBB permeability. Conversely, the PSA was 
beyond the target range. Modification of the quinoline moiety to a simpler aromatic system 
(compound 3) rendered this molecule fully optimal in terms of physicochemical parameters, but 
in spite of a loss in affinity with respect to both the parent compound and the quinoline triazole 
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analogue 2. Similarly, inclusion of a polar hydroxyl group in the LHS aromatic system 
(compound 3) further reduced the target affinity whilst restoring some violations to the rule-of-5, 
particularly because of excessive hydrophilicity. However, both compound 2 and compound 3 
were included in the final library of compounds as a spectrum of hydrophilic, mildly lipophilic and 
lipophilic triazole-containing structures were deemed useful to test for cellular and BBB 
permeability in an experimental setting. 
Next, a set of RHS aryl-fluorinated A-804598 structures was assessed. This modification did not 
particularly impact binding for the para-fluorinated structure, while losses in binding energy 
gains only or coupled with decreased estimated pKi were found for the meta- and ortho- 
fluorinated scaffolds, respectively. All three compounds showed good adherence to the rules-of-
5. Given this and the lower synthetic accessibility of the meta- compared to the para-fluorinated 
structure, only the latter was included in the final compound library. 
Additionally, two fluorinated compounds presenting benzyl substituents were considered, one of 
which polar and small (compound 8) while the other one non-polar and bulky (compound 10). 
Both compounds showed no issues from a conformational point of view and they both 
demonstrated improved binding both in comparison to the desmethylated parent molecule as 
well as compared to the parent molecule. Despite the interesting binding insight arising from 
these structures, both structures had to be excluded from the final compound library because of 
their excessive lipophilicity and for synthesis-related time-efficiency reasons. Moreover, the 
strong ligand-receptor binding that they display could actually compromise the reversibility of 
binding. 
Finally, the two fluoropyridinyl compounds 11 and 12 were tested. Both demonstrated 
reasonable adherence to the rule-of-5, despite a minor Log P violation for compound 11. 
However, both compounds showed decreased binding affinities in comparison to their 
respective triazole derivatives (2 and 3), thus they were discarded. 
This work stands by the assumption that all compounds only interact with the target’s ATP-
binding pocket, the only one adequately described to date to enable molecular docking.
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Despite the latter might not hold true for all cases, as previously suggested by several 
groups,
227, 228, 235
 it facilitates a preliminary structural categorisation of the candidate scaffolds. 




In conclusion, a library of cyanoguanidine-containing scaffolds were computationally analysed 
with respect to their physicochemical properties and SAR to the ATP-binding pocket of P2X7. 
The former highlighted that alteration of the aromatic structures on the LHS and RHS of the 
guanidine centre, specifically into heteroaromatics and functionalised aromatics, could positively 
impact the LogP. Moreover, a more accessible desmethylated version of A-804598, was found 
by molecular docking to be an acceptable compromise between target affinity, bioavailability 
and synthetic accessibility, particularly in the presence of the aforementioned structural 
modifications. However, complete removal of the benzylic carbon position proved detrimental to 
the conformational flexibility of the molecule. This work resulted in the four candidate structures 























This chapter concerns the synthesis of the proposed library of tracers (Figure 22). In particular, 
the focus is on all non-radioactive compounds, including the radiotracer precursors and cold 
standards, while the radioactive synthesis is discussed in the following chapter. 
 
Figure 22 Proposed library of tracers 
 
All intermediate compounds in this synthesis are novel, unless otherwise stated in the 
experimental section at the end of this chapter. The synthesis of the radiotracer library followed 
the closely related synthetic procedures adopted by Donnelly-Roberts et al.,
229
 Glaser and 
Årstad
410




1.13.1 Retrosynthesis and nomenclature 
The proposed library of tracers was synthesised via the routes represented in Figure 23 via a 
retrosynthetic scheme. The complete IUPAC nomenclature of all compounds can be found in 
the experimental section of this chapter, whereas abbreviated names were assigned to most 
structures to facilitate the discussion. The key steps for the formation of the cyclotriazole-
functionalised tracers (XFA compounds) are a copper alkyne azide cycloaddition reaction 
between terminal alkynes (XYL) and a fluoroethyl azide fragment (FEA) and the formation of a 
trisubstituted guanidine (XYL) via a thiourea intermediate (QSMe, ASMe and OSMe). The latter 
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step is also relevant to the formation of the bisphenyl cyanoguanidine tracer EFB and its boronic 
ester precursor (QPB). In this chapter, also the synthesis of the XFA indole analogue IMBB from 
the isothiocyanoindole INCS is described, although this compound has only been indirectly 
useful for this project. 
Other synthetic steps described include the formation of arylthioureas (XSMe) from 
arylisothiocyanates (XNCS) and the latter from primary arylamines (XNH2). Instead, fluoroethyl 
azide (FEA) was synthesised from its tosylate analogue (TsEA), which in turn is derived from 2-
fluoroethanol. 
 




The yield-limiting and thus most crucial step of the synthesis of the tracer precursors was the 
formation of trisubstituted guanidines. The most widely reported procedure involves the 
acylation of nucleophilic amines with cyanocarbonimidates, where good leaving groups are 
crucial to the success of the reaction. Most frequently, these are phenol, alkoxy or methanethiol 
groups.
412-414
 The reaction generally proceeds in a variety of solvents and only rarely requires 
transition metal catalysis. An example is Buschauer’s two-step synthesis of an N-alkyl-N’-cyano-
N’’’-propynylguanidine from diphenyl cyanocarbonimidate for the synthesis of novel histamine 
H2-receptor antagonists.
415
 In this work, the amine substituents were introduced around the 
carbon centre one at a time with isolation of the intermediate urea (Figure 24).  
  
Figure 24 Example of a trisubstituted guanidine synthesis via stepwise diphenyl 
cyanocarbonimidate acylation 
Hashimoto et al., alternatively employed thiomethyl leaving groups for the two-step synthesis of 





Figure 25 Example of a trisubstituted guanidine synthesis via stepwise dimethyl 
cyanodithioiminocarbonate acylation 
 
Another common strategy is the addition of cyanoamines to ureas or thioureas.
417, 418
 This 
strategy circumvents the need for rare cyanoimidate starting materials (Figure 26), but is not 







Figure 26 Trisubstituted guanidine synthesis via cyanamide addition to a disubstituted urea 
Furthermore, many reported guanidine formations by multiple amine additions, particularly from 
isothiocyanates (Figure 27) or more rarely from dicyanamides (Figure 28).
389, 420, 421
 For 
instance, the synthesis of N-aryl-N’-cyanoguanidines was performed in the presence of sodium 




Figure 27 Trisubstituted guanidine synthesis via concerted isothiocyanate amination  
 
  
Figure 28 Trisubstituted guanidine synthesis via dicyanamide amination  
  
In some cases instead, disubstituted guanidines were exploited as intermediate steps, where 




Figure 29 Trisubstituted guanidine synthesis via stepwise amine addition to a dicyanamide  
  
Despite the abundance of methods reported in the literature, it is rare to encounter successful 
additions of propargyl groups and no synthetic strategy to date reports boronic ester-
functionalised compounds. Only Donnelly-Roberts and co-workers attempted the preparation of 
trisubstituted N-cyano-N’-quinolinylguanidines, either via mercury-catalysed concerted amine 
addition to isothiocyanates (Figure 27)
229
 or uncatalysed, with the assistance of a benzotriazole 






1.13.3 Copper catalysed alkyne-azide cycloaddition reactions 
Several different reaction mechanisms have been proposed for the copper catalysed alkyne 
azide cycloaddition click reaction employed in this work for the synthesis of the XFA compound 
series, suggesting the reaction is much more complex than one would presume.
424
 
The first mechanistic insights were given by the inventor of the reaction itself, Barry Sharpless at 
The Scripps Research Institute (Figure 30). He suggested that following alkyne deprotonation 
and σ coordination to the in situ sodium ascorbate-reduced metal centre, a cyclic movement of 
electron density allows the formation of an alkyne-azide bond linked with copper (III) in a six 
membered metallacycle. This species then undergoes a ring contraction to release the metal 




Figure 30 Sharpless mononuclear CuAAC reaction mechanism 
 
This mononuclear mechanism was later refined by Rodionov, Fokin and Finn
426
 While testing 
the effects of BPDS ligand chelation on the reaction mechanism, they identified a second order 
reactivity with respect to copper, indicative of a dinuclear mechanism. They then showed the 
same reaction order in ligand-free copper alkyne-azide cycloaddition (CuAAC) chemistry. 
However, at high copper concentrations the rate order decreased to about 1.3, which suggested 
a decreased ability of the ligands to bind to the metal centre in the rate-determining step for the 
reaction (the formation of the C-N triazole bond). Upon finding that commercial copper 
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acetylides were catalytically inactive, the group demonstrated that double alkyne coordination 
inactivates the catalyst, whereas single coordination is beneficial (Figure 31). This could be 
achieved in particular in the presence of highly labile ligands (such as BPDS), which allow easy 
access to new coordination sites.  
 
Figure 31 Fokin and Finn dimetallic CuAAC reaction mechanism 
 
Despite the remarkable advances in this field, it is still unclear how the rate determining step 
can be overcome in the dinuclear catalytic mechanism. Without doubt a range of conditions 
affect the catalysis, including reagent concentrations, pH, buffering and the presence of 
ligands.
427
 It is also apparent that a number of catalytic mechanisms take place synchronously 
or sequentially in this reaction, giving little insight into the best parameters to fit each specific 
CuAAC reaction. 
 
Very recently however, yet another plausible mechanism was suggested by the Bertrand group 
at the University of California at San Diego upon reporting the isolation of biscopper 
intermediates from the CuAAC reaction and as well as abundant kinetic experimental data.
428
 
This study concluded that both mono and biscopper intermediates are involved in the reaction, 
but that the kinetic profiles of the catalytic reaction of phenyl acetylene with benzyl azide 
demonstrate the superior catalytic activity of the dinuclear complexes over their mononuclear 
counterparts (Figure 32). Moreover, protodemetallation is performed by the alkyne, which 





Figure 32 Bertrand group CuAAC reaction mechanism 
  
1.14 Materials and methods 
General methods  
All reactions, unless otherwise stated, were carried out at room temperature, with magnetic 
stirring and in a fume hood. Microwave heating was performed with a CEM Discover Analyser. 
Organic extracts were dried with anhydrous magnesium sulfate and evaporated using an ice 
cooled rotary evaporator. All synthetic products were dried under vacuum in a desiccator with 
activated anhydrous calcium carbonate, sealed and stored at 4°C under an inert atmosphere. 
When specified, samples were dried with an Edwards Modulyo freeze dryer. 
 
Solvents and reagents  
Commercial grade reagents and solvents were purchased from Sigma Aldrich, Alfa Aesar, VWR 
International, Fisher Scientific Ltd., SLS and Santa Cruz Biotechnology and used without further 
purification, unless otherwise stated.  
 
Chromatography  
Flash column chromatography (FCC) was performed on silica gel (Merck Kieselgel 60 F
254
 230-
400 mesh, all solvents are reported as v/v herein). Thin Layer Chromatography (TLC) was 
performed on aluminium-backed plates pre-coated with silica (0.2 mm, 60 F254) which were 
developed using UV fluorescence, vanillin, potassium permanganate, iodine or ninhydrin 
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staining. Chemical and radiochemical analysis and purification was performed manually on an 
Agilent 1200 series quaternary pump HPLC, coupled to a UV detector (254 nm). Column 
parameters, mobile and stationary phase are specified in the text. Spectra were recorded and 
analysed with Laura 4 (LabLogic), GINA Star 5.8 (Raytest) or Chemstation (Agilent 
Technologies). Chemical mass analysis was performed on an Agilent 1200 HPLC with an 
Agilent 6520 Accurate Mass QTOF LC/MS with ESI. The instrument was equipped with an 
autosampler, UV detection (254 nm) and samples were injected directly or through an Agilent 
Eclipse C18 4.6 mm x 100 mm, 5 μm column or a Phenomenex Kinetex XB-C18 4.6 mm x 150 
mm 5 μm column. Spectra were recorded and analysed with MassHunter Workstation 2009 
B.02.01 and Analysis 2009 B.03.01, respectively. 
 
Spectroscopy 
Infra-red spectra were recorded from solid substances on a Perkin-Elmer Spectrum 100 FT-IR 
spectrometer. Only selected absorbances (νmax) are reported. 
1
H NMR and 
13
C proton 
decoupled NMR spectra were recorded at 400 MHz in 5 mm tubes on Bruker AV-400 
spectrometers. Spectra were analysed with ACD/NMR processor (academic edition), V12.01. 
Chemical shifts (δH and δC, respectively) are quoted in parts per million (ppm) and referenced to 
the appropriate residual solvent peak.
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1.15.1 5-Isothiocyanato-quinoline (QNCS) 
 
This method was adapted from Donnelly-Roberts et al.
229
 A solution of 5-aminoquinoline (0.72 
g, 5.0 mmol) in DCM (15 mL) and saturated aqueous Na2HCO3 (1.47 g in 15 mL, 17.25 mmol) 
at 0°C was added dropwise over 10 min to a solution of thiophosgene (0.38 mL, 5.0 mmol) in 
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DCM (3 mL). The reaction quickly turned dark red but was stirred at 0°C for further 2 h. TLC 
monitoring was carried out until completion (9:1 hexane/ethyl acetate, QNCS Rf 0.17). The 
biphasic mixture was separated with more concentrated Na2HCO3 (10 mL) and DCM 
backwashes (3 x 10 mL). Then the organic layer was washed with brine (2 x 15 mL), dried with 
MgSO4 and concentrated under reduced pressure to generate 1.88 g of crude product. 
Purification was carried out with flash column chromatography (ethyl acetate 25% to 50% 
gradient in hexane). The pale yellow powder isolated in 62% yield, 0.58g (3.1 mmol) was dried 
and characterised as 5-isothiocyanato-quinoline. mp 30-40°C; 
1
H NMR (CDCl3) δ (ppm): 9.00 
(dd, 1H, H1, J = 4.3 Hz, 1.6 Hz), 8.47 (dd, 1H, H3, J = 8.5 Hz, 1.6 Hz), 8.07 (dd, 1H, H4, J = 8.6 
Hz, 1.0 Hz),  7.68 (dd, 1H, H5, J = 8.6 Hz, 7.5 Hz), 7.55 (dd, 1H, H2, J = 8.5 Hz, 4.3 Hz), 7.51 (dd, 
1H, H6, J = 7.5 Hz, 1.0 Hz). 
13
C NMR (CDCl3) δ: 151.45, 131.24, 129.23, 129.00, 124.74, 
123.93, 122.08. HRMS (ESI+): calcd. for C10H6N2S (M-H) 187.0325, found 187.0492. IR (ν, cm
-
1
) 2129 (N=C=S). Elemental analysis: calc. for C10H6N2S C, 64.49; H, 3.25; N, 15.04; S, 17.22; 
found: C, 64.60 64.63; H, 3.33 3.29; N, 14.92 14.94. 
 
1.15.2 Isothiocyanatobenzene (ANCS) 
 
This method was adapted from Donnelly-Roberts et al.
229
 A solution of aniline (0.9 mL, 10 
mmol) and saturated aqueous  Na2HCO3 (70 mmol) at 0°C was added dropwise to a solution of 
thiophosgene (0.76 mL, 10 mmol) in DCM (15 mL). The reaction quickly turned dark red but was 
stirred at 0°C for further 2 h. TLC monitoring was carried out until completion (3:1:0.02 
hexane/ethyl acetate/triethylamine, ANCS Rf 0.84). The biphasic mixture was separated with 
more concentrated Na2HCO3 (10 mL) and DCM backwashes (3 x 10 mL). Then the organic 
layer was washed with 10 mL brine, dried with MgSO4 and concentrated under reduced 
pressure. Purification was carried out with flash column chromatography (1:5-2:1 ethyl 
acetate/hexane). The pale red powder was isolated in 12.4% yield (0.92 g), dried and 
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characterised as isothiocyanatobenzene. 
1
H NMR (CDCl3) δ (ppm): 7.25 (dt, 2H, H3, J = 7.8 Hz, 
2 Hz), 7.18 (tt, 1H, H1, J = 7.2 Hz, 2 Hz), 7.12 (td, 2H, H2, J = 7.2 Hz, 7.8 Hz). 
13
C NMR (CDCl3) 
δ: 135.19, 131.13, 129.46, 127.23, 125.65. HRMS (ESI
+
): calcd. for C7H5NS (M+H) 136.0126, 
found 136.0182. IR (ν, cm
-1
) 2165 (N≡C-S), 2042 (br, N=C=S). 
 
1.15.3 3-Isothiocyanatophenol (ONCS) 
 
This method was adapted from Donnelly-Roberts et al.
229
 M-aminophenol (2 g, 18.3 mmol) in 
ethyl acetate (100mL) and saturated aqueous Na2HCO3 (6.15 g, 73.2 mmol) were added 
dropwise over 10 min to a solution of thiophosgene (1.4mL, 18.3 mmol) in ethyl acetate (140 
mL). The mixture was stirred for 2 hours at 0°C until completion as indicated by TLC monitoring 
(3:2 hexane/ethyl acetate). The product was extracted with further saturated  Na2HCO3 (50 mL) 
and ethyl acetate (3 x 20 mL), followed by brine (30 mL), drying with MgSO4 and concentration 
under reduced pressure. The product was isolated as brown crystals in 83% yield (2.29 g). 
1
H 
NMR (CDCl3) δ (ppm): 7.21 (t, 1H, H4, J = 8.1 Hz), 6.82 (ddd, 1H, H1, J = 8 Hz, 1.8 Hz, 0.8 Hz), 
6.76 (ddd, 1H, H3, J = 8.2 Hz, 2.4Hz, 0.9 Hz), 6.72 (dd, 1H, H2, J = 2.1 Hz, 2 Hz), 1.64 (s, 1H, 
H5). 
13
C NMR (CDCl3) δ (ppm): 156.10, 132.14, 130.47, 118.44, 114.74, 112.68. HRMS (ESI
-
): 
calcd. for C7H5NOS (M-H) 150.0019, found 150.0118. IR (cm
-1
) 3268 (ArOH), 2092 (C=N). 




To a solution of thiophosgene (0.29 mL, 3.79 mmol) in DCM (3 mL), 4-aminoindole (0.5 g, 3.79 
mmol) in DCM (2.5 mL) and saturated aqueous  Na2HCO3 (2.23 g, 26.5 mmol) were added 
dropwise. The mixture was stirred for 2 hours at 0°C until completion as indicated by TLC 
monitoring (3:1:0.002 hexane/ethyl acetate/triethylamine). The product was extracted with 
further 10 mL saturated  Na2HCO3 and 3 x 10 mL DCM, followed by 10 mL brine, drying with 
MgSO4 and concentration under reduced pressure. The product was isolated as green crystals 
in 86% yield (0.57 g). 
1
H NMR (CDCl3) δ (ppm): 8.36 (br s, 1H, H1), 7.34 (d, 1H, J = 8 Hz, H6), 
7.28 (t, 1H, J = 4 Hz, H3), 7.12 (t, 1H, J = 8 Hz, H5), 6.99 (d, 1H, J = 8 Hz, H4), 6.73 (t, 1H, J = 4 
Hz, H2). 
13
C NMR (CDCl3) δ: 124.30, 124.07, 121.17, 115.61, 109.78, 99.28. IR (CHCl3): 3477 
(N-H), 2129 (-N=C=S). HRMS (ESI
+
): calcd. for C9H6N2S (M+H) 175.0325, found 175.0324. 
 
1.15.5 N'-cyano-N-(quinolin-5-yl)carbamimidothioate (QSMe) 
 
A mixture of 5-aminoquinoline isothiocyanate (6.38 g, 34.3 mmol) and sodium 
hydrogencyanamide (2.19 g, 34.3 mmol) in DMF (30 mL) was stirred at room temperature for 1 
h. Methyl iodide (2.13 mL, 34.3 mmol) was added at 0°C and the reaction was stirred at room 
temperature for 2 h. The reaction was poured into water (5 mL) and stirred for further 20 min. 
The orange precipitate was filtered and washed with water (10 mL). Further purification was 
performed by flash chromatography on SiO2 (EtOAc:CH2Cl2, 1:1) to obtain methyl N'-cyano-N-
(quinolin-5-yl)carbamimidothioate as an orange solid in 70.0% yield (5.77 g). 
1
H NMR (400 
MHz, CDCl3) δ (ppm): 9.02 (dd, 1H, H1, J = 4.2 Hz, 1.6 Hz), 8.74 (br s, H7), 8.32 (dd, 1H, H3,  J 
= 8.5 Hz, 1.6 Hz), 8.22 (dd, 1H, H6, J = 8.5 Hz, 1.1 Hz), 7.77 (dd, 1H, H5, J = 8.5 Hz, 7.4 Hz), 
7.59 (dd, H4, J = 7.4 Hz, 1.1 Hz), 7.55 (dd, H2, J = 8.5 Hz, 4.2 Hz), 2.38 (s, 3H, H8); 
13
C NMR 
(400MHz, CDCl3) δ (ppm): 14.59, 37.37, 122.30, 127.19, 128.80, 130.71, 131.52, 151.36. IR (ν, 
cm
-1
) 3195 (N-H), 2161 (C≡N), 1509 (N-C=S), 1490 (N-C-N). HRMS (ESI
+
): calcd. for C12H10N4S 
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(M-H) 243.0699, found 243.0695. Elemental Analysis: Calc. For C12H10N4S C, 59.48; H, 4.16; N, 
23.12; S, 13.23; found: C, 59.37, 59.42; H, 4.14  4.22; N, 22.96 23.03. 
 
1.15.6 Methyl N'-cyano-N-phenylcarbamimidothioate (ASMe) 
 
A mixture of isothiocyanatobenzene (0.91 g, 6.78 mmol) and sodium hydrogencyanamide 
(0.434 g, 6.78 mmol) in DMF (8 mL) was stirred at room temperature for 1 h. Methyl iodide 
(0.422 mL, 6.78 mmol) was added at 0°C and the reaction was stirred at room temperature for 
90 min until completion as assessed by TLC (1:1 DCM/ethyl acetate, ASMe Rf 0.8). The 
reaction was poured into 25 mL water and stirred for further 20 min. The precipitate was filtered 
and washed with water (5 mL). Following overnight drying in a vacuum desiccator, the 




-DMSO) δ (ppm) 10.16 (s, 1H, H4), 7.42 (dt, 2H, H3, J = 8 Hz, 2 Hz), 7.41 (dt, 2H, 
H2, J = 8 Hz, 8 Hz), 7.26 (tt, 1H, H1, J = 8 Hz, 2 Hz), 2.69 (s, 3H, H5). 
13
C NMR (400MHz, d
6
-
DMSO) δ (ppm): 137.26, 128.90, 126.47, 124.34, 114.88, 14.88. IR (ν, cm
-1
) 3224 (N-H), 2159 
(C≡N), 1514 (N-C=S), 1495 (N-C-N). HRMS (ESI
+
): calcd. for C9H9N3S (M+H) 191.0590, found 
192.0581. Elemental Analysis: Calc. for C9H9N3S C, 56.52; H, 4.74; N, 21.97; S, 16.76; found: 




1.15.7 Methyl N'-cyano-N-(3-hydroxyphenyl)carbamimidothioate (OSMe) 
 
3-Isothiocyanatophenol (2g, 13.2 mmol) and sodium hydrogencyanamide (849 mg, 13.2 mmol) 
in dry DMF (60 mL) were stirred overnight at room temperature under an inert atmosphere. 
When TLC monitoring (7:3 hexane / ethyl acetate) indicated that the staring material had been 
depleted, methyl iodide (0.82 μL, 13.23 mmol) was added at 0°C and the mixture was stirred 
room temperature for 2 hours. The mixture was then poured into water (100 mL) and extracted 
with DCM (5 x 20 mL) and water (3 x 10 mL) to remove DMF. After concentration by rotary 
evaporation of the combined organic layers, the resulting yellow powder was filtered and dried 
under a high vacuum overnight. The product was obtained in 43% yield (1.18 g). 
1
H NMR 
(DMSO) δ (ppm): 10.05 (br s, 1H, H6), 9.63 (s, 1H, H5), 7.17 (dd, 1H, H2, J = 8.2 Hz), 6.91 (dd, 
1H, H4, J = 2 Hz, 2 Hz), 6.84 (ddd, 1H, H1, J = 8.2 Hz, 2 Hz, 0.8 Hz), 6.63 (ddd, 1H, H3, J = 8.2 
Hz, 2 Hz, 0.8 Hz), 2.67(s, 3H, H7). 
13
C NMR (CDCl3) δ (ppm): 157.54, 138.20, 129.47, 114.77, 
114.45, 113.32, 110.84, 14.85. HRMS (ESI
+





) 3386 (N-H), 3134 (O-H), 2137 (N=C=S, C≡N), 1601, 1492 (C=N). 
 




1-(4)-Bromophenyl ethylamine (0.17 mL, 1.17 mmol) was added to 4-isothiocyanato-indole 
(0.205 g, 1.17 mmol) in anhydrous THF (5 mL) and stirred for 1 h at room temperature. 
Following addition of mercury acetate (0.373 mg, 1.17 mmol) and then sodium 
hydrogencyanamide (0.225 g, 3.51 mmol), the mixture was stirred for 3 h until a red precipitate 
was observed. The reaction was quenched with water (15 mL). The sluggish mixture was 
filtered under reduced pressure through a short pad of celite. The filtrate was concentrated by 
rotary evaporation and purified by flash chromatography in 7:2:0.9 hexane/ethyl 
acetate/methanol. The product was isolated as a dark orange powder in 28% yield (124 mg). 
1
H 
NMR (DMSO) δ (ppm): 
1
H NMR (CDCl3) δ (ppm): 8.54 (s, 1H, H7), 7.44 (d, 2H, J = 8.6 Hz, H12), 
7.43 (d, 2H,  J = 8.6 Hz, H11), 7.30 (dd, 1H, J = 5.0 Hz, H5),  7.23 (t, 1H,  J = 8.0 Hz, H2), 7.18 
(d, 1H,  J = 5.0 Hz, H6), 7.07 (d, 1H, J = 8.0 Hz, H3), 6.97 (d, 1H, J = 5.0 Hz, H4), 6.44 (br s, 1H, 
H1), 5.05 (m, 1H, H9), 1.61 (br s, 1H, H8), 1.37 (d, 3H, J = 6.6 Hz, H10). 
13
C NMR 157.43, 137.12, 
131.13, 128.87, 128.52, 125.20, 121.28, 99.13, 22.11. IR (CHCl3) cm
-1
: 3361 (N-H), 2253 
(C≡N), 2173 (-S-C≡N). HRMS (ESI
+






A mixture of 4-(aminomethyl)phenylboronic acid pinacol ester hydrochloride (0.5 g, 1.86 mmol) 
and 0.391 mL triethylamine (2.78 mmol) was added to 5-isothiocyanato-quinoline (0.346 g, 1.86 
mmol) in anhydrous THF (15 mL) and stirred for 1 h at room temperature until it appeared 
cream white. Following addition of mercury acetate (0.592 mg, 1.86 mmol) and then sodium 
hydrogencyanamide (5.55 mmol), the mixture was stirred for 4 days until dark black. The 
reaction was quenched with water (15 mL). The sluggish mixture was filtered under reduced 
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pressure through a short pad of celite and was washed with ethyl acetate (30 mL). The filtrate 
was concentrated by rotary evaporation and purified by flash chromatography with a gradient of 
1-10% methanol in ethyl acetate. The product was isolated as a white solid in 18.4% yield (147 
mg). 
1
H NMR (DMSO) δ (ppm): 9.45 (br s, 1H, H7), 8.94 (dd, 1H, H1, J = 4 Hz, 1.6 Hz), 8.18 (m, 
1H, H4), 8.02 (d, 1H, H3, J = 8.2 Hz), 7.79 (dd, 1H, H5, J = 8.6 Hz, 7.6 Hz), 7.64 (d, 2H, H11, J = 
7.6 Hz), 7.59 (dd, 1H, H2, J = 8.2 Hz, 4 Hz), 7.51 (d, 1H, H6, J = 7.6 Hz), 7.24 (d, 2H, H10, J = 
7.6 Hz), 4.35 (s, 2H, H9), 1.30 (s, 12H, H12). 
13
C NMR (DMSO) δ (ppm): 159.34, 150.71, 148.43, 
134.42, 131.31, 129.31, 128.55, 126.38, 125.89, 125.47, 121.66, 117.18, 83.56, 44.47, 24.64. 
HRMS (ESI
+





(C≡N), 1515 (B-aryl), 1363 (B-O). 
 
1.15.10 Mixture of Mono-N-Boc-QPB and Mono-N’-Boc-QPB  
 
A mixture of QBP (80 mg, 0.187 mmol) and (Boc)2O (367 mg, 1.68 mmol) was dissolved under 
magnetic stirring into an excess of DIPEA (ca. 1 mL). Following addition of DMAP (69 mg, 0.562 
mmol), the reaction was warmed to 60°C and monitored by LC/MS. After 6 hours, the reaction 
was diluted with DCM and concentrated by rotavaporation. Then, a flash chromatography 
column was run in a 30% to 60% gradient of ethyl acetate in hexane. This synthesis was only 
sufficient to afford a mixture of Mono-N-Boc-QPB and Mono-N’-Boc-QPB as a yellow paste in 
6.9% yield (6.7 mg). 
1
H NMR (CDCl3) δ (ppm): 9.34 (dd, 1H, H1, J= 8.4 Hz, 1.6 Hz), 9.02 (dd, 
1H, H3, J = 4.6 Hz, 1.6 Hz), 8.95 (m, 1H, H4), 7.90 (d, 1H, H5, J= 9.2 Hz), 7.71 (d, 1H, H6, J = 
9.2 Hz), 7.56 (dd, 1H, H2, J = 8.4 Hz, 4.6 Hz), 7.43 (d, 2H, H10, J = 8 Hz), 7.09 (d, 2H, H9, J = 8 
Hz), 5.57 (br s, 1H, H7-H14), 5.27 (s, 2H, H8), 1.54 (s, 12H, H11), 1.46 (s, 9H, H12-H13). 
13
C NMR 
(CDCl3) δ (ppm): 159.64, 157.66, 154.01, 152.14, 151.88, 150.35, 149.78, 137.10, 133.58, 
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127.96, 125.87, 121.74, 120.88, 108.16, 83.34, 81.09, 52.73, 28.90, 28.18, 27.71. MS (ESI
+
): 
found 518.27 (unknown fragmentation). 
 
1.15.11 2-Cyano-1-(prop-2-yn-1-yl)-3-(quinolin-5-yl)guanidine (QYL) 
 
To a mixture of triethylamine (110 μL, 820 umol) and propargylamine (1 mL), 410 umol of N'-
cyano-N-(quinolin-5-yl)carbamimidothioate (QSMe) were added and stirred until fully dissolved. 
The solution was then stirred for 60 min in a microwave reactor at 50°C, 300 W. The reaction 
was left to cool slowly and the precipitate was collected by removal of the supernatant and 
overnight evaporation in a fume hood of the residual propargylamine. The precipitate was then 
purified by vacuum-assisted hot EtOH filtration to obtain QYL as a white powder in 89% yield 
(91 mg). 
1
H NMR (400 MHz, DMSO) δ (ppm): 9.53 (br s, 1H, H7), 8.94 (dd, 1H, H1, J = 4.2 Hz, 
1.6 Hz), 8.25 (dd, 1H, H3, J = 8.2 Hz, 1.6 Hz), 8.01 (dd, 1H, H4, J = 8.6 Hz, 0.9 Hz), 7.78 (dd, 
1H, H5, J = 8.6 Hz, 7.3 Hz), 7.60 (dd, 1H, H2, J = 8.2 Hz, 4.2 Hz), 7.47 (dd, 1H, H6, J = 7.3 Hz, 
0.9 Hz), 7.35 (br s, 1H, H8), 3.91 (br s, 2H, H9), 3.20 (s, 1H, H10).
13
C NMR (DMSO) δ: 156.78, 
150.53, 131.12, 129.08, 128.34, 125.52, 121.51, 30.66. HRMS (ESI
+
): calcd. for C14H11N5 
(M+H) 250.1087, found 250.1101. Elemental Analysis: Calc. for C14H11N5 C, 67.46; H, 4.45; N, 
28.10; found: C, 67.32; H, 4.60; N, 28.15. IR (ν, cm
-1
): 3260, 3194 (N-H), 2167 (C≡N), 1579 




1.15.12 2-Cyano-1-phenyl-3-(prop-2-yn-1-yl)guanidine (AYL) 
 
To a mixture of triethylamine (366 μL, 2.63 mmol) and propargylamine (2 mL), methyl N'-cyano-
N-phenylcarbamimidothioate (ASMe, 1.31 mmol) was added and stirred until fully dissolved. 
The solution was then stirred for 60 min in a microwave reactor at 50°C, 300 W, and the 
reaction progress was monitored by analytical HPLC on a 4.6 mm x 150 mm, 5 um pore C18 
Zorbax column with a 5-95% MeOH gradient in 0.1% TFA water over 12 min. The reaction was 
left to cool slowly and the precipitate was collected by removal of the supernatant and overnight 
evaporation in a fume hood of the residual propargylamine. The precipitate was then 
recrystallized from ethanol/water and the product was isolated as red crystals in 76% yield (198 
mg). 
1
H NMR (MeOD) δ (ppm):  7.41 (dt, 2H, H3, J = 7.8 Hz, 3.6 Hz), 7.28 (m, 2H, H2), 7.25 (m, 
1H, H1), 4.03 (d, 2H, H6, J = 2.5 Hz), 2.63 (t, 1H, J = 2.5 Hz, H7). 
13
C NMR (MeOD) δ (ppm): 
180.29, 137.94, 130.75, 127.90, 126.56, 118.78, 80.57, 72.66, 32.09. HRMS (ESI
+
): calcd. for 
C11H10N4 (M+H) 199.0978, found 199.0982. IR (ν, cm
-1
): 3285 (alkyne C-H), 2175 (C≡N/C≡C), 
1595 (guanidine C=N), 1345 (wagging alkyne C-H). 
 
1.15.13 2-Cyano-1-(3-hydroxyphenyl)-3-(prop-2-yn-1-yl)guanidine (OYL) 
 
3-Isothiocyanatophenol (200 mg, 0.97 mmol) and 2 mL propargylamine (31.22 mmol) were 
added under inert atmosphere to triethylamine (267 μL, 1.9 mmol),. The mixture was stirred until 
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it had become a homogeneous solution, and stirred at 50°C for 60 min in a microwave reactor, 
300 W. The red crude product was then concentrated under reduced pressure to afford red 
crystals of 2-cyano-1-(3-hydroxyphenyl)-3-(prop-2-yn-1-yl)guanidine in 56% yield (116 mg). 
1
H 
NMR (DMSO) δ (ppm): 7.13 (t, 1H, H2, J = 8.1 Hz), 6.66 (t, 1H, H4, J = 1.6 Hz, 2.2 Hz), 6.63 
(ddd, 1H, H1, J = 8.1 Hz, 1.6 Hz, 0.8 Hz), 6.57 (ddd, 1H, H3, 8.1 Hz, J = 2.2 Hz, 0.8 Hz), 3.95 (s, 
2H, H8), 2.08 (s, 1H, H9). HRMS (ESI
+
): calcd. for C11H10N4O (M+H) 215.0928, found 215.0923. 
 
1.15.14 2-Azidoethanol  
 
This procedure was previously reported by Demko and Sharpless.
430
 Bromoethanol (5.7 mL, 80 
mmol) in 25 mL water and sodium azide (13.65 g, 210 mmol) were stirred at reflux for 16 h 
before cooling, saturation with magnesium sulfate and extraction with DCM (3 x 15 mL). The 
combined organic layers were dried over magnesium sulfate and transferred to a new round 
bottomed flask under inert atmosphere for the subsequent reaction. 
1
H NMR (CDCl3) δ (ppm): 
3.74 (t, 2H, H2, J = 6 Hz), 3.40 (t, 2H, H1, J = 6 Hz), 3.04 (br s, H3). 
 
1.15.15 2-Azidoethyl-4-methylbenzenesulfonate (TsEA) 
 
The previously synthesised 2-azidoethanol (80 mmol) in DCM (30 mL) was protected from light 
and mixed with triethylamine (15.61 mL, 112 mmol) and methylbenzenesulfonyl chloride (18.30 
g, 96 mmol). After four hours the solution had turned brown. Glycine (1.20 g, 16 mmol) was 
added and the solution was stirred for two further hours. The organic layer was then washed 
with 1N NaOH (2 x 80 mL), dried over MgSO4 and the crude was purified by flash 
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chromatography with a 5:1 to 2:1 hexane/diethyl ether gradient. The product was isolated as a 
clear yellow oil in 18% yield, 3.4 g and remained stable at room temperature for up to a year 
before turning dark yellow. 
1
H NMR (CDCl3) δ (ppm): 7.80 (dd, 2H, H3, J = 8.6 Hz, 0.8 Hz), 7.36 
(dd, 2H, H4, J = 8.6 Hz, 0.8 Hz), 4.13 (t, 2H, H1, J = 4 Hz), 3.46 (t, 2H, H2, J = 4 Hz), 2.43 (s, 3H, 
H5). 
13
C NMR (CDCl3) δ (ppm): 145.09, 132.24, 129.78, 127.65, 68.06, 49.31, 21.34. HRMS 
(ESI
+




This method was adapted from Glaser and Årstad.
410
 2-Fluoroethanol (2 g, 31.22 mmol) and 
pyridine (5.1 mL, 62.44 mmol) were added successively under inert atmosphere to p-
toluenesulfonyl chloride (8.9g, 46.8mmol) in dry DCM (8mL). The mixture was then stirred 
overnight at room temperature until reaction completion as indicated by TLC. Then HCl (12 mL, 
1.2 mmol) and DCM were added in succession, and the two layers were separated. The 
aqueous layer was further extracted with DCM (3 x 5 mL) and the combined organic layers were 
washed with potassium carbonate (3 x 4 mL), dried over MgSO4, filtered and concentrated 
under reduced pressure. The crude product was purified by flash chromatography on silica gel 
(6:4 hexane/ethyl acetate), giving 2-fluoroethyl-4-methylbenzenesulfonate in 22% yield, 1.47 g. 
HRMS (ESI
+
): calcd. for C9H11FO3S (M+H) 218.0486, found 219.0491. 
 




This method was previously reported in Glaser and Årstad.
410
 To a solution of 2-fluoroethyl-4-
methylbenzenesulfonate (1.47 g, 6.7 mmol) in dry DMF (12 mL) sodium azide (482 mg, 7.41 
mmol) was added. The mixture was left to react for 24 h at room temperature, filtered and the 
filtrate used as a stock solution in subsequent reactions without further purification or 





): calcd. for C2H4FN3 (M+H) 90.0462, found 90.0378 . 
 
1.15.18 General procedure for the cycloaddition of 2-fluoroethyl azide with alkyne-
functionalised cyanoguanidines (XFA) 
An alkyne-functionalised cyanoguanidine (1 eq.) and a mixture of copper sulfate pentahydrate 
(0.05 eq.) and sodium ascorbate (0.1 eq.) in 0.3 mL water were added under argon in a 
microwave vial to a solution of 2-fluoroethyl azide (FEA, 1.2 eq.) in DMF. The reaction was 
heated in a microwave reactor until all starting material was depleted. The product was then 
diluted with DCM and extracted with water (4 x 5 mL) and DCM (4 x 5 mL) washes. The residue 





2-Cyano-1-(prop-2-yn-1-yl)-3-(quinolin-5-yl)guanidine (QYL, 200umol, 50 mg) and a mixture of 
copper sulfate pentahydrate  (10 μmol, 2.5 mg) and sodium ascorbate (20 μmol, 4 mg) in 0.3 
mL water were added under argon in a microwave vial to a solution of 2-fluoroethyl azide (FEA, 
0.17M) in DMF. The reaction was heated in a microwave reactor to 80°C for 40 min until all 
starting material was depleted as assessed by TLC (1:2:10 methanol/hexane/ethyl acetate, Rf 
0.27). The mixture was then diluted with DCM (10 mL) and washed with DCM (5 x 8 mL) and 
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water (5 x 6 mL) to remove DMF. The organic phase then underwent flash column 
chromatography with a 3-6% methanol gradient in a 10:1 mixture of DCM and ethyl acetate (Rf 
0.08) and the product was isolated as an off white powder in 14% yield (27 μmol). 
1
H NMR 
(DMSO) δ (ppm):  9.43 (s, 1H, H7), 8.94 (d, 1H, H1, J = 4.1 Hz), 8.16 (s, 1H, H8), 8.01 (d, 1H, H3, 
J = 8.4 Hz), 7.79 (t, 1H, H4, J = 8 Hz), 7.63 (d, 1H, H5, J = 8 Hz), 7.59 (dd, 1H, H2, J = 8.4 Hz, J 
= 4.1 Hz), 7.50 (d, 1H, H6, J = 8 Hz), 7.24 (d, 1H, H10, J = 7.4 Hz), 4.34 (s, 2H, H9), 1.29 (s, 4H, 
H11-H12). 
13
C NMR (DMSO) δ (ppm):  159.35, 150.71, 148.43, 142.42, 134.42, 131.31, 129.31, 
128.55, 126.38, 125.89, 125.46, 121.65, 117.18, 83.57, 44.47, 24.64. HRMS (ESI
+
): calcd. for 
C16H15FN8 (M+H) 339.1477, found 339.1501; calcd. for (M+Na) 361.1296, found 361.1297. IR 
(ν, cm
-1
) 2167 (C≡N), 1592 (Guanidine C=N), 1569 (conjugated C=N), 1025, 801 (C-F). Purity 
was confirmed by UV-HPLC using method B (Table 8, Section 1.19.1), as shown in Figure 33. 
 





2-Cyano-1-phenyl-3-(prop-2-yn-1-yl)guanidine (AYL, 200 μmol) and a mixture of copper sulfate 
pentahydrate  (25 mg, 10 μmol) and sodium ascorbate (5.6 mg, 28 μmol) in water (2 mL) were 
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added under argon in a microwave vial to 2-fluoroethyl azide (FEA, 240 μmol, 0.05M) in DMF. 
The reaction was heated in a microwave reactor for 20 min at 80°C and 300 W. The mixture 
was then diluted with DCM (4 mL) and extracted with washed with DCM (3 x 5 mL) and water (3 
x 5 mL) to remove DMF. The residue was purified by flash chromatography with a gradient from 
5:1 hexane/ethyl acetate to 100% ethyl acetate. The product was isolated as a white powder in 
38% yield (22 mg). 
1
H NMR (MeOD) δ (ppm): 7.95 (s, 1H, H7), 7.41 (dt, 2H, H3, J = 2 Hz, 8 Hz), 
7.27 (dt, 2H, H2, J = 2 Hz, 8 Hz), 7.26 (dd, 1H, H1, J = 2 Hz, 8 Hz), 4.75 (dd, 2H, H9, J = 4 Hz, 7 
Hz), 4.69 (m, 2H, H8), 4.52 (s, 2H, H6). 
13
C NMR (MeOD) δ (ppm): 130.80, 127.88, 126.58, 
125.15, 83.81, 82.11, 52.07, 51.88, 37.94. HRMS (ESI
+
): calcd. for C13H14FN7 (M+H) 288.1368, 
found 288.1408 (M+H)
+
; calcd. for (M+Na) 310.1187, found 310.1182. IR (ν, cm
-1
) 3219, 3141 
(N-H), 2166 (C≡N), 1546 (Guanidine C=N), 1518 (conjugated C=N), 1025, 694 (C-F). Purity was 
confirmed by UV-HPLC using method D (Table 8, Section 1.19.1), as shown in Figure 33. 
 








2-Cyano-1-(3-hydroxyphenyl)-3-(prop-2-yn-1-yl)guanidine (OYL, 930 μmol) and a mixture of 
copper sulfate pentahydrate  (11.5 mg, 46 μmol) and sodium ascorbate (18.4 mg, 93 μmol) in 
water (0.5 mL) were added under inert atmosphere to 2-fluoroethyl azide (FEA, 1.12 mmol, 
0.05M) in DMF.  The reaction was stirred at room temperature for 30 h. The mixture was then 
poured into water (5 mL), and extractions with DCM (3 x 5 mL), saturated  Na2HCO3 (3 x 5 mL) 
and brine (1 x 5 mL) followed. The residue was then dried over anhydrous sodium sulfate, 
filtered and concentrated under reduced pressure. The crude was then purified with flash 
chromatography on silica with 19:1 ethyl acetate/methanol. Further purification was carried out 
on an HPLC C18 Zorbax 9.4 x 250 mm, 5 μm pore column, with a 5-95% gradient of acetonitrile 
in water. The product was isolated as 28 mg of white powder (10% yield). 
1
H NMR (D2O) δ 
(ppm):  7.92 (s, 1H, H9), 7.23 (t, 1H, H2, J = 8 Hz), 6.75 (dd, 1H, H3, J = 8 Hz, 2.3 Hz), 6.75 (d, 
1H, H1, J = 8 Hz), 6.68 (t, 1H, H4, J = 2.3 Hz), 4.64 (m, 2H, H11), 4.45 (m, 2H, H10), 3.26 (s, 2H, 
H8); 
13
C NMR (D2O) δ (ppm): 158.17, 154.43, 140.05, 137.48, 129.90, 125.41, 118.5, 108.81, 
103.72, 82.26, 49.27, 40.67. HRMS (ESI
+
): calcd. for C13H14FN7O (M+H) 304.1317, found 
304.1323. IR (ν, cm-1) 3307 (O-H), 3201, 3178 (N-H), 2244 (C≡N), 1498 (C=N), 1011, 670 (C-
F). Purity was confirmed by UV-HPLC using method E (Table 8, Section 1.19.1), as shown in 
Figure 33. 
 






1.15.22 2-Cyano-1-(4-fluorobenzyl)-3-(quinolin-5-yl)guanidine (RefEFB) 
 
A mixture of 0.62 mL 4-fluorobenzyl amine (5.36 mmol) and 1.12 mL triethylamine (8.04 mmol) 
was added to 5-isothiocyanato-quinoline (1g, 5.36 mmol) in anhydrous THF (25 mL) and stirred 
for 1 h at room temperature. Following addition of mercury acetate (5.36 mmol) and then 
sodium hydrogencyanamide (16.08 mmol), the mixture was stirred for 24 h until dark black. The 
sluggish mixture was filtered under reduced pressure through a short pad of celite and was 
washed with acetone (30 mL). The filtrate was concentrated by rotary evaporation and purified 
by flash chromatography with a gradient of 0.8:10:0 – 1:10:0 – 1:7.5:2.5 methanol/diethyl 
ether/ethyl acetate. The product was then dried by rotary evaporation and recrystallized from 
acetone. 2-cyano-1-(4-fluorobenzyl)-3-(quinolin-5-yl)guanidine was isolated as a white powder 
in 8% yield (140 mg). 
1
H NMR (MeOD) δ (ppm): 8.94 (dd, 1H, H1, J = 4 Hz, 1.6 Hz), 8.29 (dd, 
1H, H3, J = 8 Hz, 1.6 Hz), 8.17 (d, 1H, H4, J = 8.6 Hz), 7.88 (dd, 1H, H5, J = 8 Hz, 8.6 Hz), 7.67 
(d, 1H, H6, J = 8 Hz), 7.64 (dd, 1H, H2, J = 8 Hz, 4 Hz), 7.37 (dd, 2H, H11, J = 5.4 Hz, 7.7 Hz), 
7.07 (dd, 2H, H10, J = 5.4 Hz, 7.7 Hz), 6.96 (s, 1H, H8), 4.47 (s, 2H, H9). HRMS (ESI
+
): calcd. for 
C16H15FN8 (M+H) 339.1477, found 339.1501; calcd. for (M+Na) 320.1306, found 320.1307. IR 
(ν, cm
-1
): 2181 (C≡N), 1706 (guanidine C=N), 1509 (N-CN), 1025 (C-F). Purity was confirmed 








1.15.23 4-Cyano-N,N,N-trimethylanilinium tri-fluoromethanesulfonate (4-TBACN) 
 
This method was previously reported in Haka et al.
431
 4-(dimethylamino)-benzonitrile (2.43g, 
16.6 mmol) and methyl trifluoromethanesulfonate (2.1 mL, 18.3 mmol) were dissolved in DCM 
(30 mL) under an inert atmosphere. Upon overnight stirring under argon at room temperature 
the solution turned cloudy. The precipitate was collected by vacuum filtration, washed with ethyl 
acetate and recrystallized in MeOH/EtOAc to give the product as pale yellow crystals in 10% 
yield (0.562 g). 
1
H NMR (400 MHz, D2O): 8.01 (s, 4H, H1-H2), 3.65 (s, 9H, H3). 
13
C NMR (400 
MHz, D2O): 134.67, 121.17, 56.84. IR (ν, cm
-1
): 2242 (C≡N), 1500 (
+






In this work, the synthesis of trisubstituted cyanoguanidines is inspired by Donnelly-Roberts et 
al.
229
 This protocol consists of a one-pot mercury-assisted substitution at the carbon centre of 
an isothiocyanate of both (S)-(-)-1-(4-bromophenyl)ethylamine and sodium cyanamide in 
anhydrous THF. The reaction is described to proceed under mild conditions and a short reaction 
time. In our hands, the reaction was repeated under the same conditions with the indole 
isothiocyanate analogue INCS as starting material, successfully producing in 28% yield the 
trisubstituted cyanoguanidine indole product IMBB (see experimental and Figure 23 for 
structures). 
 
1.16.1 Synthesis of QPB and EFB  
The same protocol was employed for the synthesis of the para-benzyl boronic ester substituted 
guanidine analogue QPB and the para-benzyl fluoride analogue EFB (Figure 37). 
 
Figure 37 QPB and EFB synthetic scheme. 
 
In both cases, the reagents showed quantitative conversion by TLC (20:4:1 ethyl 
acetate/hexane/triethylamine) and LC/MS, indicating good tolerance of mercury catalysis by the 
benzyl boronic ester moiety. However, while the HPLC purification method described in 
Donnelly-Roberts et al.
229
 failed to yield more than 1% product, flash chromatography afforded 
higher yields. This could be further improved by recrystallization of impure fractions in acetone. 
92 
 
1.16.2 Introduction to QYL synthesis 
Only few successful syntheses of terminal alkyne-substituted cyanoguanidines have been 
reported to date.
432-435
 All these reactions share a similar mechanism involving cyanocarbon 
imidate formation in alcoholic solvents, which are problematic in terms of solubility for the 
scaffolds in question. Additionally, all present remarkably differently functionalised R groups on 
the LHS N-terminus compared to the aromatic groups of the structures under scrutiny. 
Therefore, the Donnelly-Roberts protocol
229
 appeared more closely related despite the lack of 
alkyne substituents. Despite the success in synthesising the previously described trisubstituted 
cyanoguanidines via this method, significant refinements proved to be necessary to prepare the 
propargyl quinoline-substituted analogue QYL, the aniline-substituted analogue AYL and the 
phenol-substituted analogue OYL (see Figure 23 for structures). A number of chemical 
differences between these species and the benzyl guanidine species should be noted. Firstly, 
propargyl groups are more susceptible to deprotonation by a base than benzyl groups. In 
particular, cyanoguanidines can act as bases (Figure 38), possibly with the assistance of metal 
coordination to the triple C–C bond. 
 
Atom N1 N2 N3 N4 N5 C6 C7 N8 S9 O10 N11 
pKa 4.4 23.9 -8.3 N/A 1.8 24.5 24.6 23.9 -8.3 8.8 24.3 
            
Figure 38 pKa estimates for reagent and product hydrogen-accepting or donating atoms. 
 
  
                                                     
1
 Estimates based on University of Kentucky’s ChemAxon software. Acidity and basicity values 
were calculated with the ACE modification of the JChem formula. 
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Secondly, the product QYL could cyclise given the proximity between the nitrile, the imine and 
the alkyne unsaturations. Thirdly, propagylamines mix well with all other reagents, whereas 
acetylenic cyanoguanidines are not soluble in most solvents, except for high boiling polar 
aprotics. Finally, the stability of the intermediates may vary, as π-π interactions might favour 
benzyl-aryl to alkyne-aryl proximity.  
This chapter outlines all approaches explored, as shown in Figure 39, and speculates as to why 
several attempts resulted unsuccessful. Table 5 is also provided as a guide to the large body of 
work that went into the optimisation of this reaction. 
  




Table 5 Summary of reactions leading to the production of trisubstituted guanidines.  
Starting 
material 
Product Conditions Yield Notes 
INCS IMBB Stoichiometric Hg(OAc)2 28% 
 
QNCS QPB Stoichiometric Hg(OAc)2 18% FCC purification 
QNCS EFB Stoichiometric Hg(OAc)2 8% FCC purification 






Stoichiometric Hg(OAc)2 0%  
QNCS QYL 
rt or reflux, with NEt3 
and Hg(OAc)2 
0% FCC purification 
DPCI QYL 





observed with both PA and 5-
aminoquinoline 
DPCI QN3 With/without MW 0% As above 












6.5% Double FCC purification 
QSMe QYL 
Stoichiometric 






Neat with NEt3 
with/without Hg(OAc)2 







Neat with NEt3, no 
catalyst, MW, 50°C, 1h 
35% 
Evaporation, then FCC 
purification 
QSMe QYL 
Neat with NEt3, no 
catalyst, MW, 50°C, 1h 
89% Hot filtration 
ANCS AYL (via ASMe) 
Neat with NEt3, no 
catalyst, MW, 50°C, 1h 
>99% Hot filtration 
ONCS OYL (via OSMe) 
Neat with NEt3, no 
catalyst, MW, 50°C, 1h 





1.16.3 Attempted 1-step mercury-assisted QYL synthesis 
 
Figure 40 Scheme describing the mercury-assisted route to synthesise QYL. 
 
The Donnelly-Roberts reaction protocol was applied to the propargyl analogue QYL but LC/MS 
inspection of the crude indicated a failure in obtaining the correct product even after heating the 
mixture at reflux overnight. A large extent of degradation was visible by TLC (1:4:5 
methanol/hexane/ethyl acetate) and was not found to be due to silica sensitivity, as assessed 
by 2D TLC. All products were isolated by FCC for further analysis but none of the masses 
corresponding to each TLC spot could be matched with a plausible side reaction. It is possible 
that extensive degradation had been occurring over time and that any or a combination of 
guanidine substituent migration, formation of three membered ring structures and expulsion of 
nitrogens had been taken place.
436
. 
The reaction was repeated with pure and fresh starting materials. The mixture was kept in an 
inert atmosphere, shielded from light and kept at <30°C. 1 eq. triethylamine was also added to 
the mixture to ensure full deprotonation of the propargylamine and act as secondary catalyst.
437
 
However, no product was formed as determined by LC/MS of the crude, although TLC (1:2 ethyl 
acetate/hexane) indicated exhaustion of the starting 5-isothiocyanato quinoline and a lower 
extent of product degradation. Following addition of Hg(OAc)2 and NaNHCN, a new spot at Rf 
0.47 was isolated by flash chromatography and analysed by LC/MS. Frustratingly, the masses 
obtained could again not be associated to any plausible side reaction. The most likely culprit 
was postulated to be the alkyne functional group characteristic of this reaction, or its 
combination with mercury and other functionalities present in the compound. However, given 
the lack of plausible explanations for the observed reactivity, a different route to yield the 
product was sought. 
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1.16.4 Further attempts to QYL synthesis 
 
Figure 41 Scheme describing further routes to synthesise QYL. 
  
In order to circumvent the issues caused by the synthesis of the cyanoguanidine fragment, the 
stepwise amine addition to a cyanocarbon imidate as described for compounds 12a and 31 in 
Buschauer et al. was investigated.
415
 In this publication, a variety of different electron rich and 
electron poor amines are tested, affording yields >50%. The procedure involves the initial 
formation of a urea intermediate after 2 h room temperature mixing in acetonitrile before 
continuing to full guanidine formation in methanol or ethanol. In our hands, initial quinoline 
addition to form the intermediate QPIU was inspected by TLC (1:1 ethyl acetate/hexane, Rf 
DPCI: 0.82, Rf 5-aminoquinoline: 0.25, Rf propargylamine with NEt3: 0.49; Rf QPIU: 0.91) and 
LC/MS (QPIU MS (ESI
+
) m/z 289.1094 (M+H)
+
) indicating successful product formation. 
However, addition of the second amine did not yield QYL as desired following overnight room 
temperature stirring or heating to reflux. This could be explained by the possible high steric and 
electronic hindrance prohibiting propargylamine access to the diaryl urea carbon in the 
intermediate. In line with this argument, no reports of aryl amine addition in good yields were 
found in the literature. Additionally, alkyl-aryl π- π interactions might have prevented the 
propargylamine approaching the urea. Nonetheless, attempts to functionalise with an azide the 
RHS guanidine substituent with 1 eq. sodium azide resulted in no reactivity after overnight 
stirring at room temperature and heating for a further hour. 
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Additionally, in an attempt to corroborate the steric hindrance hypothesis, the effect of stepwise 
addition of propargylamine prior to aminoquinoline was investigated. The intermediate akyl-urea 
PAPIU could be observed by TLC (1:1 ethyl acetate/hexane, Rf PAPIU: 0.64) and LC/MS 
(PAPIU MS (ESI
+
) m/z 200.0834 (M+H)
+
). However, subsequent addition of 1 eq. 5-
aminoquinoline under argon did not yield the desired product overnight at room temperature nor 
after 1 h reflux (reaction monitoring: TLC, LC/MS).  
At this point, it appeared that steric hindrance was unlikely the key impediment to the desired 
reactivity. Rather, it appeared that the removal of the second phenol could be improved by the 
use of a stronger driving force, such as the formation of a P=O bond in presence of 1 eq. 
triphenylphosphine.
419
 Nevertheless, after 2 h reflux or 1 h microwave heating at 120°C, 300W 
in DMF, no reactivity was observed by LC/MS or TLC. 
 
1.16.5 QYL synthesis via the QSMe intermediate 
 
Figure 42 Scheme describing the QSMe route for the synthesis of QYL. 
 
Given the difficulty in driving the substitution of the second phenol group, the leaving group was 
substituted with a methyl thiol. This functional group was shown to be easily removable by 
precipitation as a mercury salt.
421
 This approach required the synthesis of the intermediate 
thiourea QSMe, by a protocol also described within the patent. In this reaction, the primary 
amine attacks the isothiocyanate at the δ+ carbon. Rather than proceeding with a second 
conjugate substitution as in the previous synthetic strategy, the sodium salt is trapped with 
methyl iodide in high yield (Figure 43). 
 
  




The synthesis of QYL then proceeded with the attack of the thiourea carbon and the release of 
methyl thiol. An examination of the literature suggested to employ either mercury acetate or 
triethylamine catalysis,
421
 although Betschmann et al. reported on several occasions the use of 
zinc chloride catalysis or no catalysis at all 
391, 392, 438
. In our hands, the reaction was initially 
performed in a 100 mg scale in the presence of mercury acetate, as the reaction appeared 
mechanistically simpler. After stirring as a suspension at 40°C for 48 h in anhydrous THF, TLC 
analysis (1:1 ethyl acetate/ DCM, QSMe Rf 0.31, QYL Rf 0.18) showed depletion of the starting 





Double flash chromatography (1-5% methanol in DCM, then 4:1-2:1 ethyl acetate/ DCM) was 
necessary to isolate the product obtaining just trace amounts. Scaling up the production also did 
not yield more than 44 mg (4.2% from 1 g starting material) of pure product. Finally, in order to 
increase the dissolution of the reagents the reaction was attempted first in DCM, then in diethyl 
ether. The latter improved the yield to 6.5% starting from a 150 mg scale. A neat reaction in 
solvating propargylamine was also attempted, although violent mercury acetate reactivity with 
the latter was observed. 
TLC analysis showed that extensive byproduct formation was present in the crude product both 
when performed with silica, alumina and neutral silica as stationary phases, suggesting a lack of 
involvement of the analytical procedure in the decomposition process. Consequently, low yields 
were imputed to two reasons: the reaction was producing extensive unknown byproduct 
alongside the desired product (hence the need of extensive isolation steps) and the purification 
procedure was suboptimal and prone to product loss. In order to tackle the first issue, a way to 
monitor more closely than by TLC spot formation or LC/MS mass appearance the formation of 
the desired product had be introduced. Having isolated a small amount of product, an HPLC 
method suitable for the identification of the starting materials propargylamine and QSMe, the 
product QYL, and the formation of byproducts could be designed (HPLC method: 150 x 4.6 mm 
150 x 4.6 mm Agilent Zorbax C18 column; 1 mL/min flow; A: water with 0.1% TFA; B: methanol 
with 0.1% TFA; gradient: 5% B for 3 min, then ramp to 95% B over 7 min and 2 min at 95%. 
Inverse ramp to 5% in 1 min and then 5% for 3 min. Injection as 50:50 methanol/water filtered 
solution. QSMe Rt: 13.56 min; QYL Rt: 13.92 min). Although the separation achieved was sub-
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optimal and the propargylamine was not eluted as a single peak, the compounds could be 
distinguished when monitoring the reaction under different conditions and when assessing the 
effect of different workups. The section that follows lists the data collected from the HPLC 
analysis, which led to improved reaction and workup conditions.  
  
1.16.6 QYL synthesis: optimisation of reaction conditions by HPLC monitoring 
 
Figure 44 Scheme describing the two routes employed to optimise the synthesis of QYL. 
 
The aim of this optimisation work was to maximise the amount of QYL (product) by identifying 
which conditions would lead to maximum conversion of the reagents, regardless of the extent of 
byproduct formation. Previous attempts at this reaction had in fact shown that the reaction 
proceeded slowly and already after a short time presented byproducts detectable by TLC. The 
variation of reagent HPLC peaks was monitored to analyse the composition of the crude 
reaction mixtures. 
All reactions were performed in a microwave reactor at 300 W, as the same extent of byproduct 
formation had been observed, but with much shorter reaction times than in the case of 
conventional heating. Secondly, all reactions were performed with 2 eq. triethylamine and in 
neat propargylamine, aside from the mercury catalysed reaction which was performed in diethyl 
ether due to near propargylamine-mercury acetate incompatibility. Four different HPLC peaks 
were analysed: the starting material, QSMe, eluting at 13.5 min; the product, QYL, eluting at 
12.6 min; and two byproducts eluting at 12.3 min and 14 min. Reaction time, temperature and 
the effect of catalysis were investigated. As can be seen from the graphs (Figure 45), the 
conversion varied considerably over time, reaching its peak at 60 min and 20 min for the 
catalyst-free and mercury catalysed reactions, respectively, whereas at later time points 
decomposition outweighed product formation. Instead, the zinc catalysed reaction displayed a 
continuous increment in yield, yet reaching about half the maximum yield of the neat reaction 
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after 90 min. Analysis of the product yield at 60 min and 40°C showed that the absence of 
transition metal catalysis could provide enhanced conversion rates compared to the mercury 
catalysed case. Zinc catalysis instead, resulted in intermediate conversions (Table 6). 
 
A 














































Figure 45 Effect of time and catalysis on the conversion rate of QSMe to QYL 
Table 6 Effect of catalysis on the QYL conversion rates 
Reaction conditions at 40°C  




material (QSME %) 
Other 
products (%) 
Neat in triethylamine 20 55 25 
Zinc chloride catalysis, in THF 5 24 71 
Mercury acetate catalysis, in THF 0 5 95 
 
The observed effect is probably due to a detrimental side reaction between mercury and the 
alkyne moiety (Figure 46). Compared to mercury, zinc is a harder metal, hence less attracted to 
soft alkynes. Nonetheless, its double positive charge is still capable of desulfurisation.
439
 
Triethylamine could instead catalyse the reaction by both assisting in propargylamine 
deprotonation and methyl sulfide protonation (Figure 47). Moreover, while zinc and mercury act 
as stoichiometric byproduct precipitation agents, triethylamine would be regenerated at each 






Figure 46 Possible side reaction
 
Figure 47 Proposed triethylamine catalysed conjugate substitution mechanism 
 
The effect of temperature variation on the conversion rates was then analysed. Upon heating 
the reaction mixture in a microwave reactor at 300 W for 60 min between 40°C and 80°C, 
product formation peaked at 50°C. The product then was degraded or decomposed linearly, 















Figure 48 Effect of temperature on the conversion rate of QSMe to QYL 
In conclusion, despite the identification of the byproducts was unsuccessful, ideal conditions to 
maximise product formation were devised by HPLC analysis of the crude mixtures. Thus, it was 
found that without metal catalysis at 50°C, microwave heating at 300 W for 60 min could afford 





1.16.7 QYL synthesis: optimisation of the purification procedure 
In the previous attempts, the isolation of the desired product was performed by flash 
chromatography, with considerable product losses and poor overall yields. QYL suffers from 
poor solubility in most solvents other than partially in a combination of DCM and methanol and 
fully only in DMSO or DMF. Hence, purification by flash chromatography was unsuitable. HPLC 
also was not ideal. A 10 mg scale fraction of the celite-filtered crude could be dissolved in 
MeOH, diluting in water to a 30:70 methanol/water 9 mL solution and then filtering the 
precipitates. This method remained applicable only to such small scale purifications. Starting 
from the analytical method, the HPLC method was scaled up proportionally to a 150 x 21 mm, 5 
μm, C18 Hypersil silica Thermo Scientific column, achieving optimal separation with a 5-30% 
0.1% TFA methanol gradient in 0.1% TFA over 20 min at 20 mL/min. However, predictably, the 
freeze-dried collected fractions resulted only in sub-milligram amounts of product, rendering this 
procedure inefficient and time-consuming. 
Interestingly, it was observed that precipitation occurred in the crude metal catalyst-free neat 
reaction mixture after cooling the reaction mixture in a long and narrow microwave tube. It was 
therefore deduced that the poor solubility of the product could be exploited as a means of 
purification. The precipitate was only mildly insoluble in the crude supernatant, as a thick 
suspension was forming upon shaking. Both precipitate and supernatant were analysed by TLC 
and HPLC. The precipitate was found to contain >90% of the desired product, but also several 
impurities. After allowing the residual propargylamine to evaporate overnight, the precipitate 
was purified by flash chromatography, obtaining the pure product in 35% yield. However, the 
poor solubility of the precipitate greatly reduced the yield. 
As an alternative method, recrystallisation was attempted by exploiting the product’s mild 
solubility in alcoholic solvents. Addition of nearly boiling ethanol to the precipitate lead to a 
yellow ethanolic solution and to a white precipitate. This was possibly due to the decreased 
solvent-solute interaction. Upon isolation of the white precipitate, nearly boiling water was added 
to the hot ethanolic supernatant. This induced further precipitation, which upon cooling lead to 
the combined isolation of the pure product in up to 89% yield. The protocol was later simplified 




1.16.8 Synthesis of AYL and OYL  
The extensive work carried out on the quinoline compound of the XYL series proved fruitful also 
for the synthesis of its analogues. AYL was synthesised in solventless conditions with excess 
propargylamine and with triethylamine in a microwave reactor under the same conditions as 
QYL. This afforded quantitative conversion. Following removal by evaporation of 
propargylamine, the compound could then be isolated in high yields by recrystallization in 
ethanol and water. It is interesting to note this compound’s higher solubility in ethanol, probably 
an effect of the altered polarity induced by the reduction in aromaticity and the decrease in 
molecular size. Finally, OYL was synthesised in the same conditions as above, but afforded a 
clean product which did not require further purification.  
 
1.16.9 Synthesis of EFA, AFA and OFA (collectively XFA)  
The precursor was not found to be soluble in any solvent other than DMF and DMSO. This ruled 




 Instead, the closer related Glaser protocol was 
adopted.
410
 Monitoring of the reaction progression was executed by LC/MS and TLC (10:1:1 
DCM/ethyl acetate/methanol). Among the variety of methods reported for copper alkyne azide 
cycloaddition chemistry,
410, 441, 443, 444
 maximum conversion rates were achieved by heating at 
80°C for 40 min in a microwave reactor and by washing with DCM/weakly alkaline water to 
remove the DMF prior to flash chromatography. However, product loss was high both in the 
DMF extraction procedure and in the flash column chromatography, due to partial solubility of 
the product in water and the low solubility in the organic solvent. This resulted in an imperfect 
protocol, yet sufficient to isolate and identify the product required. A similar procedure was 
employed for the rest of the XFA compound series with similarly moderate yields. This reaction 
can certainly be improved with additional work, particularly by iteratively exploring a range of 
temperatures and times of reaction and by exploring other purification methods. 
 
1.17 Conclusions 
In this chapter the synthesis and purification of all the novel materials that constitute this work 
was presented. Extensive part of the discussion concerned compound QYL, the synthesis and 
optimisation of which is complex. While a detailed study would be necessary to further elucidate 
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why many of the attempted synthetic routes to QYL failed, it is apparent that mercury is 
incompatible with propargylamine. Solubility issues with both the thiourea starting material as 
well as the trisubstituted guanidines in most solvents often times lead to poor conversions. Neat 
reactant mixtures were finally adopted, employing an excess of the liquid propargylamine both 
ensuring good catalysis and solvation. However, the product was not afforded in good yields 
until hot filtration was identified as a most convenient purification methodology affording >80% 
product. This novel synthetic strategy is much more robust than the original method and was 
able to afford in a straightforward manner the related compounds AYL and OYL. 
Finally, the synthesis of all cold reference standards was presented. Despite the modest yields 
which call for further work particularly in the purification stages, sufficient amounts of products 






















This chapter concerns the radiochemical manipulations necessary to synthesise the target 
radioactive molecules and the context in which these radiosynthetic techniques lie within. 
 
1.18 Introduction to the radiochemistry of [18F]fluoride 
Radiofluorination chemistry dates back to 1948 when Cady and co-workers devised ways to 
catalytically radiolabel hypofluorite compounds such as trifluoromethylhypofluorite and explored 
the radiosynthesis of xenon hexafluorite.
445
 Since then, interest in radiofluorination has 





F]FDG, used to image cell metabolism. Yet, many other fluorinated 
radiotracers are employed in the clinic. To name a few, [
18
F]FLT is used to track cell proliferation 
in oncology; [
18
F]FMISO is used to image tissue hypoxia; [
18
F]fallypride is a high affinity 
dopamine receptor antagonist while [
18
F]haloperidol is the labelled version of a drug targeting a 
range of neurotransmitter receptors to control psychosis.  
18
F can be produced in the form of electrophilic fluorine [
18










 The reactivity of this synthon is very strong, which results in low radiofluorination 
selectivity. Moreover, the production of [
18
F]F2 usually involves the addition of carrier fluoride, 
resulting in much lower specific activities than for nucleophilic fluoride. Despite the advent of 
post-target production of F2
447
 and the development of milder and more regioselective 
electrophilic fluorinating reagents
249, 448, 449
 have substantially advanced this field, nucleophilic 
fluorination is to date a more widespread and versatile technique to incorporate radioactive 
fluorine into chemical structures and it is the radiolabelling methodology of choice throughout 
this work. Nucleophilic [18F]fluoride is produced in a cyclotron by irradiation of [
18
O]H2O with 
high energy particles. The resulting aqueous radiofluoride produced is highly solvated by water 
molecules, which renders it a poor nucleophile. Trapping on cation exchange cartridges and 
elution with alkali metal cations complexed to a phase transfer catalyst, such as the cryptand 
Kryptofix-222 (K222) leads to much higher nucleophilicity of this radionuclide, making it suitable 
to carry out radiofluorinations. Alternatively, elution with tetrabutylammonium hydrogen 
carbonate gives [
18






1.18.1 Nucleophilic aromatic radiofluorinations 
This and the following section focus on describing the current landscape of nucleophilic 
fluorinations, which are at the heart of this project (Figure 49). Nucleophilic fluorinations can be 
further divided in direct and indirect fluorinations, the latter which indicate the labelling of a 
fragment with ensuing incorporation into a more complex scaffold. We will start by exploring 
direct nucleophilic fluorinations at aromatic rings, then to move to aliphatic structures. 
 
Figure 49 Types of nucleophilic fluorinations discussed in this chapter 
 
Nucleophilic aromatic fluorinations traditionally involve the use of good leaving groups. Initial 
attempts at performing radiofluorinations in the 80s involved the use of the Balz-Schiemann 
reaction and the Wallach reaction (Figure 50). Both leveraged the strong leaving group ability of 
diazide-containing groups.
451
 However, both produced low radiochemical yields (RCYs) or 
specific activities due to presence of carrier fluoride in the reactant.  
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These reactions were soon outperformed by more efficient nucleophilic substitutions: an 
electronic pull by electron withdrawing substituents in the ortho or para positions is capable of 
promoting substitution of the leaving group by resonance stabilisation of the anionic 
intermediate (Figure 51). Electron withdrawing substituents are not always desirable, but they 
can be either removed or transformed to chemically useful functional groups to introduce 









Figure 51 The nucleophilic substitution mechanism 
 
Each of these methods has its own advantages and limitations. Trimethylammonium salts are 
high yielding, and the product is easily separated from the leaving triethylamine group. 
However, this and all other methods in this series require high temperatures and can be 
unsuitable for delicate substrates.
463
 Fluorination of aromatic rings with meta leaving groups 
require even harsher conditions or proceed only with the use of microwave irradiation.
464
 More 
commonly, synthons and prosthetic groups are employed to circumvent degradation issues or 




Figure 52 Example of synthon strategy: synthesis of [
18




The most widely used aromatic synthons are the trimethylammonium- and nitro-benzonitrile and 
benzaldehyde groups, although also ketones and halides are commonly exploited for indirect 
synthesis.
466
 The chemical simplicity inherent to these groups enables straightforward labelling. 
Nevertheless, many further chemical modifications of the resulting radiolabelled molecules are 
possible, including reductions, oxidations, halogenations and functionalisations with entirely new 
substituents, making the synthesis of an extensive array of radioaryl compounds possible. 
Among these, indirect palladium-mediated aromatic radiofluorinations are common. For 
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example, para-fluoroiodobenzene can undergo a Sonogashira coupling with terminal alkynes,
467
 
a Stille coupling with organotin compounds
468-471




Moreover, there is extensive research on the use of iodonium salts for radiofluorinations. 
Attractive from the point of view of the amenability of radiolabelling of electron neutral and 
electron-rich aryls, iodonium salt radiofluorinations can yield radioactive fluoroarenes in high 
specific activity (Figure 53a).
473
 However, the precursors’ stability wanes when functional 
substitutions are introduced to the aryl rings. So far, this represents the major limitation to their 
use.
474
 Extensive research into synthetic routes to aryliodonium salts has found that electron 
rich arenes such as anisoles, thiophenes, arylstannenes and arylborates lead to high 
fluorinating regioselectivity, especially when combined with specific diaryliodonium 
counterions,
475
 while the use of inorganic hypervalent iodonium salt reactants can facilitate their 
synthesis. The often poor stability of the latter has driven the field in the direction of one-pot 
precursor syntheses, as detailed in a recent review by Merritt and Olofsson.
476
 
Further oxidation of the iodine to iodonium ylides further expanded the application of the 
hypervalent iodine radiofluorinations.
477
 These species demonstrate moderate-to-high RCYs 
and good stability (Figure 53b).
478
 The spirocyclic ylides (Figure 53c) developed in the Vasdev 
group at the Massachusetts General Hospital at Harvard University also appear relatively 
straightforward to synthesise, virtually removing all barriers to this electron-rich aromatic 
radiofluorination route,
479
 the exception being primary amine-functionalised rings. Similarly, a 
recent patent on the radiofluorination of iodyl benzene derivatives (iodites) reported higher 
yields with a range of electron-donating and electron-withdrawing groups and excellent specific 
activities.
480
  This route has also the advantage of appearing more straightforward than other 
iodine routes. Harsh radiofluorination conditions are necessary, however, despite this, 
applications have started to crop up in the literature (Figure 53d), though again, this labelling 






Figure 53 Reactions of aryl iodonium salts and iodonium ylides with 
18
F 
Despite the apparent large variety of methods available, problems still arise in the presence of 
electron rich aromatic rings, such as phenols and anilines. For this reason the generation of 
novel radiofluorination methods continues, including a spree of recent developments. Only a few 
notable and relevant examples will be described hereafter, while a detailed analysis of the 




The Gouverneur group at the University of Oxford published a study in 2014 showing that 
[
18
F]aryl fluorides can be formed under conditions that tolerate a vast array of functional 
groups.
484
 Starting from boronic esters, the copper complex [Cu(py)4]OTf2 is used to catalyse 
the desired radiofluorination within 20 minutes in DMF at 110°C. This reaction is particularly 
interesting as a wide selection of boronic esters is available commercially; the reaction is 
compatible to air and oxygen, and gives high specific activity products. However, its main 
limitation is the necessity of using conspicuous amounts of precursor. Moreover, once more 
primary amines and alcohols pose a problem to the radiochemical substitution, with yields 
dropping to 5-7% and recovering only when protecting groups are in place. 
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Another valuable contribution is the work done by the Årstad group at University College 
London on radiofluorination of sulfonium ions (Figure 54).
485
 Previous studies on sulfonium ions 
highlighted its potential as a precursor, without significantly managing to increase the appeal of 
the reaction due to feasibility issues.
486-488
 In this route, amines are tolerated, although the 
nucleophilicity of the 
18
F fluoride is susceptible to the presence of H-donors, leaving primary and 
secondary amine-functionalised aryls once more out of reach. The synthesis of the precursor 
requires an intermediate, poorly stable iodinium salt, which needs to be consumed rapidly for 
the formation of the much more stable sulfonium ion. 
 
Figure 54 Sulfonium ion fluorinations 
RCYs are moderate to high for a range of functional groups, and remarkably so for electron-rich 
aromatic rings.  
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Finally, a method to fluorinate aromatic rings relying on the use of nucleophilic fluoride coupled 
with metal catalysis has been developed. The latter offers enhanced rates of radiolabelling, as 
well as reactivity, selectivity and substrate diversity. The method is a palladium-catalysed 
aromatic fluorination developed by Hooker and Ritter (Figure 55A).
489
 This is effective in a 
variety of aromatic substrates, including electron rich rings. However, the catalyst requires an 
involved synthesis and it is air sensitive and unstable over time, thus requiring fresh preparation 
before each use. Additionally, difficulties in the translation of this method have been reported by 
the developers. These have prompted them to investigate a water-tolerant arylnickel complex as 
an alternative catalyst, which – in the presence of an oxidant and under mild conditions – is able 
to yield. C-
18




Figure 55 Metal-catalysed aromatic fluorinationIn particular, the use of the oxidant-compatible 
reagents [
18
F]TBAF and pyrodonium p-toluenesulfonate (PPTS) has opened up this method to 
large scale radiosyntheses and has demonstrated translational potential (Figure 55C).
491, 492
 The 
future also awaits the advent of synthetically simpler catalysts, such as Ag2NO3, which has been 
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very recently shown to be effective in deoxyradiofluorinations of phenols in the presence of the 




1.18.2 Nucleophilic aliphatic radiofluorinations 
Unlike aromatic substitutions, for aliphatic radiofluorinations and indirect aliphatic labelling, 
activating groups are not usually required, provided a good leaving group is present. 
Consequently, where multiple good leaving groups are present in a molecule, each may be 
susceptible to nucleophilic fluoride attack, thus requiring protection to direct the labelling. A 
classic example of aliphatic fluorination is [
18
F]FDG: the radioactive atom is introduced by 
substitution to the triflate activated 2-hydroxyl group. In order to drive selectivity, acyl protection 
and deprotection of the other hydroxyl groups is employed.
494
 
Short aliphatic structures however are particularly attractive from a radiosynthetic viewpoint as 
they allow the introduction of 
18
F into more complex molecules via indirect labelling. A common 
use is the labelling of a ditosyl, dibromo or diiodo aliphatic chain, where the first leaving group 
serves as an 
18
F attachment point, whereas the second provides a site of attachment to the 
nucleophilic part of a more complex structure.
495
 Of a similar nature is the use of monotosyl, 
bromo or iodo chains, functionalised with an azide group at the opposite end. These fragments 
are ideal for indirect 
18
F Huisgen 1,3-dipolar cycloaddition or “click” radiofluorination, a reaction 
widely exploited in this work. The radiochemical version of this reaction first appeared in the 
literature in 2006, as a quick and efficient method to tag peptides with fluorine radiolabels.
496
 
This work relied on the use of CuI catalysis, a base and a reducing agent (sodium ascorbate) to 
link [
18
F]fluoroalkynes (produced in 36-81% RCYs) to peptides. The final labelled peptides were 
obtained in 54-99% yields and high radiochemical purity (RCP) in 30 min. 
Since then, click radiochemistry became a very popular field, mostly for peptide and protein 
radiolabelling with either CuI, in situ reduced CuSO4 or Cu powder as source of copper for 
catalysis.
497, 498
 Moreover, strained cycloalkynes and norbonenes have been shown to have 
sufficient energetic affinity for tetrazines to undergo intermolecular cycloadditions without the 
need for copper catalysis.
499-501
 Worthy of special mention to exemplify the versatility of click 
reactions in radiochemistry are a set of high specific activity radiolabelled RGD peptides which 
target tumour integrin αvβ3 synthesised in 52% N.D.C. RCY with copper alkyne-azide 
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cycloadditions (CuAACs). In 2007, a robust method for the synthesis and cycloaddition of the 
fragment [
18
F]fluoroethyl azide to a range of small alkyne-functionalised molecules and a model 
peptide was devised.
410
 This was widely employed in the following years to radiolabel a wide 
variety of candidate PET tracers.
502-504
 Moreover, strain-promoted copper-free click chemistry 
was used to prepare a number of tumour targeting radiofluorinated bombesin probes.
505
 This 
demonstrated not only the ease with which click chemistry can be applied to radiochemistry, but 
also that it enables the facile introduction of a wide array of functional groups and to fine tune a 
compound’s hydrophilicity, both which need to be explored to ensure optimal target binding. 
Similarly, click chemistry can be applied to radiometal labelling via the introduction of a metal 










Zr and other metals,
506-509





  Finally, click chemistry has been shown to work directly on target (in vivo 
bioconjugation), whereby an azide tagged antibody can be engineered to reach a specific 





In recent years, several other reactions have been explored that enable the indirect aliphatic 
fluorination of a variety of organic molecules via the use of metal catalysts, ranging from the 
simple to the complex. Several interesting radiosynthetic advancements have been made in the 
area of metal-catalysed allylic fluorination reactions. An iridium
513, 514
 and a palladium catalytic 
system
515
 have both been shown to label linear, branched, aromatic, aliphatic and functionalised 
allyls with RCYs around 50%. Recently, a new method has become available to introduce chiral 
labels into aliphatic moieties. The Doyle group at Princeton University reacted racemic epoxides 
with chiral cobalt [
18
F]fluoride catalysts under mild conditions, achieving >85% ee with 
moderate-to-high RCY.
516
 Previously, enantiomeric labelling relied on the isolation of the 
desired enantiomer prior to the radiolabelling and radiolabelling from the corresponding cyclic 
sulfonates
517




Finally, the Groves lab at Harvard University recently introduced a manganese-catalysed 
method to introduce an 
18
F label upon disruption of a C-H bond.
519
 This method is air stable and 
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due to the relative chemical similarity between fluorine and hydrogen (with all the caveats 
discussed in chapter 2, section 1.7.2), it is a very promising method for high throughput 
productions of radiopharmaceuticals from cold pharmaceutical screening hits. The major issues 
with this method lie in the separation of the final product from the hydrogen-containing starting 







1.18.3 Radiosynthesis in this work 
The radiosynthetic reactions performed in this work are outlined in Figure 56. Please refer to 
this figure also as a legend for abbreviated compound names, whereas the complete IUPAC 
nomenclature of all compounds can be found in the experimental section of this chapter. 
 
  




1.18.4 Radiochemical nomenclature 
Often times, confusion arises as to the exact meaning of certain radiochemical terms due to the 
variety of terms employed by the scientific community for each parameter. To prevent such 
misunderstandings, Table 7 summarises the intended meaning of a set of sometimes 
ambiguous terms. 
Table 7 Radiochemical nomenclature and concepts employed within this chapter. 
 
Abbreviation Full term Description 
Hot Radioactive Radioactive compound. 
Cold Non-radioactive Non-radioactive compound. 
AUC Area under the curve 
Integration of the area delimited by a peak in an HPLC 




Percentage of radioactive product versus total 
radioactive starting material from start of synthesis, 




Percentage of radioactive product versus total 
radioactive starting material from start of synthesis, 




Analytical HPLC-derived percentage of the areas under 
the curve of the crude radioactive product versus the 
radioactive starting material indicated in each context. 
Sometimes it is referred to as “conversion” in the text. 
RCP Radiochemical purity 
Analytical HPLC-derived percentage of radioactive 
product area under the curve versus total area under 
the curve. 
QC run Quality control run 
Analytical HPLC of the product aimed at determining 
the final chemical and radiochemical purity of the 
radiotracer, its identity and its specific activity. 
SA Specific activity 
Tracer radioactivity per mole of compound as defined 
by the area under the curve of the carrier product in the 
UV chromatogram of a QC run. The area under the 
curve is converted in mass units by the use of a 
compound-specific calibration curve. 
EOB End of bombardment 
Time at which the cyclotron target bombardment is 
concluded and the resulting radioactivity is dispensed 
to a hot cell. 
SOS Start of synthesis 
Time at which the first radiochemical manipulation is 
performed. 
EOS End of synthesis 








Table 7 (continued) 











Radiochemical reaction competing with an analogous 
cold reaction due to the presence of an added cold 
radiosynthon-equivalent substance (in this context 
K
19
F instead of K
18
F). This practice enables the 
characterisation of products and byproducts by 
LC/MS. 
 
1.19 Materials and methods 
All materials and methods are described in chapter 3, with the following modifications. 
The HPLC and LC/MS apparatuses were equipped with a FC-3200 NaI/photomultiplier tube 
(PMT) LabLogic detector. Column parameters, mobile and stationary phase are specified in the 
text. Radioactive TLCs (ITLCs) were developed with the methods specified in the text and 
analysed on a Bioscan Flow-Count ITLC scanner equipped with a FC-3600 Plastic 
Scintillator/PMT LabLogic detection probe. Spectra were recorded and analysed with Laura 4 
(LabLogic). HPLC column specifications: Kinetex Phenomenex XB-C18 with guard, 4.6 x 150 
mm, 5 μm, 100 Å; Agilent Eclipse XDB C18, 9.4 x 250 mm, 5 μm, 100 Å. Solid phase extraction 
(SPE) cartridge specifications: Sep-Pak light lC18 Short SPE, 130 mg, 55-105 µm (cat. no. 
WAT023501, Waters), Sep-Pak tC18 Plus Long SPE Cartridge, 900 mg, 37-55 µm (cat. no. 
WAT036800, Waters), Sep-Pak Accell Plus QMA SPE Cartridge, 130 mg, 37-55 μm (cat. no. 
WAT023525, Waters), Strata-X-CW, 200 mg/3 mL, 33 μm (cat. no. 8B-S035-FBJ, 
Phenomenex), Oasis HLB Plus Short SPE Cartridge, 225 mg, 60 μm (cat. no. 186000132, 
Waters). 
All reactions were performed in 3 mL or 5 mL Wheaton V-vials, except for the microwave 
reactions, performed in microwaveable tubes and reactions >110°C were 16 x 125 mm 
borosilicate tubes with PTFE/silicone-lined screw caps (Sigma Aldrich). 
 
1.19.1 Chromatographic methods 
Throughout the project much time was devoted to the development of HPLC methods. A typical 
method development workflow is showed in Figure 57. On a given column, initial gradient 
scouting for organic molecules is performed with a programmed increase in organic solvent 
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content (%B) in water or buffer. If the peak(s) elute away from the solvent front, an isocratic 
method is run at the observed %B at which elution occurs. For peak(s) that elute with the 
solvent front, the initial %B is lowered while maintaining the chosen ramp, then the ramp 
steepness is decreased until the peak(s) are separated from each other/the solvent front. Peaks 
are then further resolved by, in order, lowering the %B, modifying the temperature, switching 
organic solvent or altering the flow rate. Moreover, for unresolved peak(s) or peak(s) with 
variable retention times, the isoelectric point is sought and the compound is buffered 
accordingly. In all instances, the pressure is maintained constant during injections. 
In this work, the use of acetonitrile was preferred to methanol due to the better solubility of the 
compound series in the former solvent and due to the possibility of evaporating it together with 
water by azeotropic distillation. Moreover, where applicable, SPE cartridge elution in methanol 
was found to be less effective than in acetonitrile. All HPLC methods developed are shown in 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.19.2 Radiotracer calibration curves 
Specific activities were determined via the use of compound-specific calibration curves. Defined 
concentrations of pure non-radioactive compounds were prepared and serially diluted. A 
minimum of 3 concentrations were analysed in duplicate by analytical HPLC methods B (EFA), 
D (AFA), E (OFA) and J (EFB). The best linear fit was then found with MS Office  Excel resulting 
in the calibration curves and respective equations shown in Figure 58. The latter were then 
utilised to derive the specific activity of each experimental run, given a specific injected volume 
in the HPLC. During the calibration curve data acquisition it was particular important to ensure 
that prior to each run the internal HPLC pressure was stable, that the columns were thoroughly 
clean and that the injected samples were thoroughly dissolved and at the correct dilution. 
Finally, it is useful to note that the UV activity of the carrier EFB in most experimental [
18
F]EFB 
runs was below the detection limit of 300 GBq/μmol. 
 
















through cyclotron-accelerated proton irradiation of enriched (95%) [
18
O]H2O. 150 MBq of 
aqueous [
18
F]fluoride were trapped in a Sep-Pak QMA cartridge pre-activated with  NaOH (5 mL 
1N), water (10 mL) and K2CO3 (5 mL 1N) followed by water (10 mL). The fluoride was released 
with Kryptofix 222 / potassium carbonate (30 mM:15 mM, 0.65 mL) dissolved in 85:15 
acetonitrile / water. The solution was dried three times at 90°C for 5 min in a Wheaton V-vial 
and under a flow of nitrogen. Tosylethyl azide (4.1 mg, 17 μmol) in acetonitrile (0.4 mL) was 
added to the dried fluoride and heated at 80°C for 15 min. Upon cooling of the reaction mixture 
to room temperature, propargyl precursor (20 μmol) in DMSO (0.3 mL), sodium ascorbate (19.8 
mg) in water (0.2 mL) and copper sulfate (7.5 mg) in PBS (0.2 mL, 0.1 M) were added in this 
order under a nitrogen atmosphere. Following heating for 20 min at 100-110°C (vide infra), the 
mixture was passed through a Whatman Spartan 13 mm 0.2 μm RC Minitip filter and injected 
onto a an HPLC apparatus for purification by semi-preparative methods B, D or E (Table 8). The 
acetonitrile/water product fraction was then dried for about 1 hour at 90-110°C under a stream 
of nitrogen, reformulated in the desired volume of PBS and sampled for QC analysis (analytical 












F]FEA, 5 mg QYL were added to the click reagents described in the general method and 
heated at 110°C for 20 min. The product was isolated in 160 min in >99% RCP, 4-26% D.C. 









F]FEA, 4 mg AYL were added to the click reagents described in the general method and 
heated at 100°C for 20 min. The product was isolated in 210 min in >99% RCP, 10-42% D.C. 









F]FEA, 4 mg OYL in 0.3 mL DMF were added to the click reagents described in the 
general method and heated at 100°C for 20 min. The product was isolated in 260 min in >99% 








F]Fluoride was produced, trapped, eluted and dried as per the general method described in 
section 1.20.1. Tosylethyl azide (2.1 mg, 8.5 μmol) in 0.4 mL acetonitrile was added to the dried 
fluoride and heated at 80°C for 15 min. The solution was then diluted in water to 1 mL and 
purified by semi-preparative HPLC method A. The fragment [
18
F]FEA was isolated in 30% 
acetonitrile in water (ca. 4 mL). The propargyl precursor QYL (4 μmol) in DMSO (0.3 mL) and a 
mixture of copper sulfate (4 μmol) in PBS (0.1 mL, 0.1 M), BPDS (2 μmol) in water (0.1 mL) and 
sodium ascorbate (15.2 μmol) in water (0.2 mL) were added under a nitrogen atmosphere. 
Following heating for 20 min at 100°C, the mixture was concentrated on a tC18 Sep-Pak 
cartridge and eluted in EtOH (300 μL). Dilution with water to 5 mL was followed by injection onto 
an HPLC apparatus for purification with semi-preparative HPLC method C (Table 8). The 
acetonitrile/water product fraction was then concentrated on a new tC18 Sep-Pak cartridge, 
eluted in EtOH and diluted in PBS or water prior to sampling for QC analysis (analytical 
methods B and C) resulting in >10 GBq/μmol specific activity. 
 




F]Fluoride was produced, trapped, eluted and dried as per the general method described in 
section 1.20.1. Tosylethyl azide (2.1 mg, 8.5 μmol) in acetonitrile (0.4 mL) was added to the 
dried fluoride and heated at 80°C for 15 min. The solution was then diluted in 10 mL water and 
passed sequentially through a light C18 Sep-Pak and an Oasis HLB cartridge. The cartridges 
were washed with water (20 mL) prior to elution of [
18
F]FEA by acetonitrile (0.9 mL) in a second 
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V-vial. To this were added the propargyl precursor QYL (4 μmol) in DMSO (0.3 mL) and a 
mixture of copper sulfate (30 μmol) in 0.1 M PBS (0.1 mL), BPDS (2 μmol) in water (0.1 mL) 
and sodium ascorbate (100 μmol) in water (0.2 mL) were added under a nitrogen atmosphere. 
Following heating for 20 min at 100°C, the mixture was diluted to 5 mL in water, passed through 
a Whatman Spartan 13 mm 0.2 μm RC Minitip filter and injected onto an HPLC apparatus for 
purification with semi-preparative method C (Table 8). The isolated product was concentrated 
on a tC18 Sep-Pak cartridge, eluted in EtOH and diluted in PBS or water prior to sampling for 




F]EFB) (boronic ester 
route) 
 




F]Fluoride was produced, trapped, eluted 
and dried as per the general method described in section 1.20.1. Upon cooling to 25-50°C it 
was aerated with >10 vial volumes of compressed air for 5-10 min. To the [
18
F]fluoride QPB (5-
40 μmol), Cu (OTf)2(py)4 (5-50 μmol) and pyridine (0-100 μmol) were added and dissolved in 
DMSO (0.3 mL) or DMF (0.3 mL). Heating at 110°C for 5-20 min was followed by quenching 
with water (0.2 mL) and analysis by analytical HPLC method G. The product was not isolated 






This method was previously described by Koslowsky et al.
521
 To dried [
18
F]fluoride (1-1.5 GBq), 
4-cyano-N,N,N-trimethylanilinium trifluoromethansulfonate (2 mg) in DMSO (0.3 mL) was added 
and reacted for 15 min at 110°C. Once the reaction was completed, the mixture was diluted with 
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water (30 mL) and passed through a Sep-Pak Plus C18 Waters SPE cartridge. The cartridge 
was washed with additional water (5 mL) before elution in THF (2 mL) in 40-60% D.C. RCY and 
>95% RCP. Radio-TLC (SiO2, petroleum ether/ethyl acetate (1:1), Rf 0.7). 
 






F]FBN in THF was transferred without further purification into a reaction vial containing 
NaBH4 (10 mg), Co(OAc)2 (5 mg). To this, water (1 mL) was added and the mixture was mixed 
and allowed to react at rt for 3 min.  Next, the mixture was diluted in 40 mL pH 6.2 phosphate 
buffer (6.7:1 NaH2PO4:Na2HPO4) so as to limit the organic solvent to 5%. The mixture was 
filtered (0.2 μm pore Whatman Spartan filters) and loaded on a Phenomenex Strata-X-CW SPE 
cartridge. Following an acetonitrile (5 mL) wash, a purple band formed in the cartridge and could 
be entirely eluted in the second of three aliquots of 5% TFA acetonitrile (0.6-0.7 mL each) in 45-
55% D.C. RCY (22-34% overall D.C. RCY) and >93% RCP. Radio-TLC (SiO2, nBuOH/HOAc–







0.4-0.7 mL of [
18
F]FBa in 5% TFA acetonitrile were neutralised with triethylamine (2 eq., 110-
112 μL) and added to of QSMe (11 μmol, 3.6 mg) in a sealed vessel. The reaction vessel was 
heated at 160°C for 15 min, cooled to 50°C and the solvent was concentrated at 50°C under a 
stream of nitrogen for 7-10 min. Next, the crude mixture was diluted in water (2 mL) ensuring 
<15% acetonitrile was present and injected in an HPLC semi-prep C18 column with method H 
129 
 
to provide isolation of the pure product in >99% purity and >300 GBq/μmol specific activity. The 
product was diluted to 30-50 mL in water and passed through a light C18 Sep-Pak cartridge for 
concentration in ethanol (200-500 μL). The resulting product was obtained in high purity and 
4.0% overall D.C. RCY in 3 h and 30 min from SOS. QC testing was performed with HPLC 
methods H and J (Table 8). 
 
1.21 Results and discussion 
1.21.1 Tosylethyl azide radiolabelling 
Initially following Galante’s procedure,
522
 2-tosylethyl azide in 0.4 mL acetonitrile was added to 
dried K222.K
18
F in a V-vial. Cooling the dried fluoride with an inert gas before exposing it to a 
tosylethyl azide/acetonitrile solution was found to be crucial to incorporate H
18
F. V-vials are 
particularly suitable for radiofluorinations as their shape maximises the recovery of the product. 
In this context, mixing is not particularly important as reagent convection governs the reactivity. 
A standard 5-95% acetonitrile analytical ramp was employed to analyse the reaction outcome 
(Figure 59 and analytical HPLC method A, Table 8), separating unreacted [
18
F]fluoride (solvent 
front, Rt = 2.5 min) from the product [
18
F]fluoroethyl azide (Rt = 7 min) and from an unknown 
byproduct, possibly bromoethyl fluoride (Rt = 9.4 min). The unreacted tosylethyl azide was then 
visible in the UV trace (about Rt = 10.2 min).  
 
Figure 59 Crude fluoroethyl azide (FEA) HPLC run with analytical method A 
 
Much effort was devoted to minimising the presence of cold byproducts in the final solution. 
While carrier fluoroethyl azide could not be readily detected due to absence of a UV 
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chromophore, the other cold impurities were hampering product formation and specific activity. 
This matter will be discussed in detail in section 1.21.3.  
  
1.21.2 Click radiolabelling: optimisation of the reaction conditions 
Reaction monitoring was performed with the methods described above. In order to quantify the 
yield improvements upon modification of the reaction conditions, the n.i. RCY of the 
intermediate [
18
F]fluoroethyl azide to [
18
F]XFA rather than that of [
18
F]fluoride to the product was 
considered. This allowed us to more closely analyse the effect of parameter optimisation on the 
product formation, regardless of the outcome of the first step of the radiolabelling.   
During the radiochemical optimisation phase, a typical analytical chromatogram of the crude 
resembled the curve displayed in Figure 60, where each [
18
F]XFA tracer displayed a slightly 
different retention time (Rt) between 8.30 min and 11 min. 
 




The non-isolated radiochemical yields (n.i. RCYs, reported in Table 9, Table 10 and Table 11) 






Several parameters were found to have little influence on the n.i. RCYs despite minor variations 
in the literature, i.e. it was equally suitable to employ copper sulfate in 0.008 mmol or 0.015 
mmol and sodium ascorbate in 4 or 5 eq. with respect to copper, without variations in yield. 
Instead, the proportion and volume of solvents affected the yields, as described by Zhou et al.
523
 
In this study it was found that increasing volumes of water or acetonitrile lowered the yields; 
however, the presence of excess DMF, reduced the detrimental effect of water. Generally 
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speaking, yields were more strongly correlated to the volume of the reaction or the 
concentration of the reagents than to the proportion of solvents (as long as 
MeCN<H2O<<DMF/DMSO). This can be explained by the second order kinetics with respect to 
the alkyne precursor and the availability of the copper catalyst in its +1 oxidation state in the 
reaction mixture. Consequently, in this work quantities of solvents were minimised, whilst 
ensuring appropriate solvation of the catalytic mixture and its interaction with the precursor. 
On the other hand, it is known that the copper-chelating bathophenanthroline disulfonic acid 
disodium (BPDS) ligand strongly enhances the rate of click reactions (Figure 61).
522
 BPDS 
poses some additional challenges with respect to the purification of the final product, particularly 




Figure 61 The bathophenanthroline disulfonic acid disodium salt ligand  
 
Furthermore, the order of addition of the reagents was significant: copper and the BPDS ligand 
were always pre-mixed in 0.05-0.1 M PBS before addition to the reaction pot.
522
 In the 
literature,
522
 around 1 eq. BPDS with respect to copper have been reported to increase click n.i. 
RCYs and reduce the time and temperature requirements. However, in our hands it was found 
that there were transfer and mixing issues in connection to BPDS due to formation of solid 
precipitate when mixed with copper, leading to loss of catalyst, difficulties in sampling the crude 
and overall apparent or actual decreases in conversion rates. In hindsight, BPDS in water could 
have been added directly to the reaction pot without prior mixing with copper, possibly improving 
the ease of transfer and mixing. Nonetheless, it was found that without BPDS, modifying other 
parameters such as outlined in Table 9 could lead to excellent conversion rates and improve the 
final product’s chemical purity. 
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Moreover, optimisation work involved modifications in the modality of sampling the reaction 
product. Where the crude product was a heterogeneous mixture with precipitates and its 
injection as such in an HPLC would have been problematic, several solutions were explored. 
Firstly, simple filtration; then filtration followed by dilution of 50 μL crude in 200 μL 50:50 
methanol/water; finally, dilution (which decreases organic solvent percentage and consequent 
lack of column retention) with no filtration followed by a short centrifugation to precipitate any 
suspended solid with sampling of 50uL of the supernatant. All methods were acceptable, but 
gave somewhat different n.i. RCY ratios for the same product. For consistency, all data 
presented exploited the last sampling method.  





F]EFA. Initially a protocol by Galante et al. was employed.
522
 This was 
demonstrated for 6-halopurine fluoroethyl-triazoles, but was described as being easily adaptable 
to the labelling of other triazole compounds. Nevertheless, despite mixing for 20 min in 
acetonitrile or 45 min in DMF (a better precursor solvent) no conversion was observed. Upon 
mixing in a microwave reactor at 300 W for 10 min at room temperature as suggested by 
several previous studies,
524-526
 some product was detected. It appeared clear that harsher 
conditions were necessary. Glaser
410
 and De Jesus
527
 reported employing heating at 80°C and 
variable amounts of starting materials. However, initially microwave heating was retained, as it 
had appeared beneficial in the previous iterations (Table 9, entry 3). When the reaction was 
performed with 10 μmol, 20 μmol or 30 μmol of alkyne starting material, a much higher 
conversion was observed. This was similar in all cases, but with an approximatively linear 
increase together with starting material concentration. An intermediate amount was adopted 
during further optimisations, seeking to balance the consumption of starting material and 
increased conversion. Next, the precursor solvent was changed to improve the solvation and 
boost the reactivity. Indeed, a slightly increased n.i. RCY (Table 9, entries 6-7) was observed. 
The reaction was then modified to exclude BPDS, which was found to cause mixing issues, as 
described above. This resulted in increased conversions, albeit very dependent on the fluoride 
batch. Furthermore, increasing the temperature to 110°C lead to more than doubling of the 
conversion rate, whereas a reaction temperature of 150°C had a detrimental effect. This effect 
was possibly due to the reaching of the boiling point of [
18
F]FEA (130°C). At this stage, the main 
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source of activity loss was found to be in the transfer from the V-vial used for fluoride drying to 
the microwave vial, suggesting as a possible optimisation avenue the modification of the 
microwave-assisted step. The abolition of microwave heating was found to affect positively the 
n.i. RCYs (cf. entry 7 and 11). The conversion rate was further improved by removal of BPDS 




F]EFA from the intermediate [
18







































































10 1 rt N MeCN Cu/BPDS/Na n/a 
1 
10 20 rt N MeCN Cu/BPDS/Na 0% 
2 
20 45 rt N DMF Cu/BPDS/Na 0% 
3 








7.5 15 80 N DMF Cu/Na n/a 
4 
10 20 80 Y DMF Cu/BPDS/Na 20.8% 
5 
20 20 80 Y DMF Cu/BPDS/Na 22.1% 
6 
30 20 80 Y DMF Cu/BPDS/Na 25.0% 
7 
20 20 80 Y DMSO Cu/BPDS/Na 23.6% 
8 
20 20 80 Y DMSO Cu/Na 37.0% ± 14.6% 
9 
20 20 110 Y DMSO Cu/Na 81.7% ± 26.0% 
10 
20 20 150 Y DMSO Cu/Na 15.8% ± 5.5% 
11 
20 20 80 N DMSO Cu/BPDS/Na 74.3% 
12 
20 20 80 N DMSO Cu/Na 77.7% ± 14.8% 
13 
20 20 110 N DMSO Cu/Na 91.8% ± 14.3% 
14 
20 20 100 N DMSO Cu/Na 99.5% ± 1.4% 
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F]EFA conversion n.i. RCY summary extract from Table 9 
 
A similar line of approach was also employed for all other radiotracers, with the benefit of the 
conclusions drawn in the analogous case of [
18
F]EFA. The reaction to synthesise [
18
F]AFA was 
attempted in the same conditions as entry 7 for [
18
F]EFA, achieving good n.i. RCY (Table 10). 
Similarly to [
18
F]EFA, the removal of BPDS increased the yields; instead, heating to 110°C 




F]AFA from the intermediate [
18




































































1 20 20 80 Y DMSO Cu/BPDS/Na 61.0% 
2 20 20 80 Y DMSO Cu/Na 79.6 ± 11.5% 
3 20 20 110 Y DMSO Cu/Na 56.9 ± 12.6% 
4 20 20 100 N DMSO Cu/Na 99.6 ± 1.3% 
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F]AFA conversion n.i. RCY summary extract from Table 10 
 
The radiosynthesis of [
18
F]OFA started with a 65% n.i. RCY with microwave irradiation. Reaction 
optimisation was attempted by microwave-assisted heating (Table 11, entries 1-3), resulting in 
an initial increase in conversion, followed by a drop at 140°C, consistent with the previous tracer 
optimisation observations. Microwave irradiation was then abolished, resulting in quantitative n.i. 




F]OFA conversion from the intermediate 
18



































































1 25 20 80 Y DMF Cu/Na 65.0% ± 31.9% 
2 25 20 110 Y DMF Cu/Na 79.3% ± 22.8% 
3 25 20 140 Y DMF Cu/Na 38.25% 
4 25 20 80 N DMF Cu/Na 61.4% ± 13.1% 
5 25 20 90 N DMF Cu/Na 100% 
6 20 20 110 N DMF Cu/Na 100% ± 0% 
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F]OFA conversion n.i. RCY summary extract from Table 11 
The identity of each radiotracer was confirmed by co-injection with the cold standard and/or 

















F]OFA co-injection with cold OFA, analytical HPLC method E 
 
1.21.3 Click radiolabelling: optimisation of the purification procedure 
Following successful conversion of the precursors to the desired products, the specific activity 
required optimisation. The specific activity (SA) is by definition: 
SA (GBq/μmol) = activity (GBq) / mass (μmol) 
Thus, given the unfeasibility of increasing the activity beyond the low GBq level in a research 
environment, the focus was shifted to carrier mass reduction. The strategy was threefold: 
reduction of the mass of precursor employed, optimisation of the reaction conditions so as to 







































efforts to comply with the first 2 points of this strategy were described above, this section details 
the optimisation of the product isolation and the analysis of the purified radiotracers. 
For the most part, tracer isolation was performed by semi-preparative HPLC. Iterative HPLC 
method modifications and testing, resulted in the optimal methods described in Table 8. We 
then focused on improving the isolated radiochemical yield through the iterations described in 
section 1.21.2 and consistently reaching an overall 10-42% D.C. RCY for [
18
F]AFA, 4-26% D.C. 
RCY for [
18
F]EFA, 5-9% D.C. RCY for [
18
F]OFA and >99% RCP for all tracers. For the 
determination of the final RCP and SAs, HPLC-isolated tracers were dried by azeotropic 
evaporation under a flow of nitrogen and re-dissolved in the desired volume of PBS. A 50 μL 
aliquot was then sampled by analytical HPLC, allowing the determination of the desired 
parameters upon comparison with a standard mass-curve. The specific activities obtained 
ranged between 0.5-61 GBq/μmol for [
18
F]AFA, 0.1-14 GBq/μmol for [
18
F]EFA and 0.3-2 
GBq/μmol for [
18
F]OFA. This was due mostly to the insufficiently clear UV baseline and some 
variability in retention times, leading to difficulties in unmistakenly identifying the carrier peak in 
all instances. 
To further improve the specific activity, two issues were acted upon: the poor chemical purity of 
the intermediate radiolabelled fragment [
18
F]FEA and the suboptimal isolation of the final 
product [
18
F]XFA. Concerning the former, it has been established that tosylethyl azide, 
azidoethanol and the elimination byproduct vinyl azide are all present at completion of the 
tosylethyl azide labelling, reacting with the substrate to form cold byproducts.
351, 410, 528
 Three 







 and solid phase extraction.
528
 The first is effective at isolating [
18
F]FEA in 
50% D.C. RCY and medium specific activities by distillation with MeCN at 130°C. The second 
method works at a temperature of 90°C, which is lower than the boiling point of vinyl azide and 
thus prevents its co-distillation giving >80% yields and high specific activities. The authors also 
claim that it resolves the issue of backflow of distilled product which can often lead to lower 
yields or extra distillation time. In this context, the procedure was attempted albeit resulting in 
extensive backflow of the product and overall poor yields. Instead, unpublished research in our 
department showed that optimal separations could be obtained by HPLC method D (Table 8) 
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with less development work required (Figure 68). However, the radiolabelled fragment was 
isolated in about 4 mL 30% acetonitrile, leading to different requirements for the click reaction. 
 
Figure 68 Pure [
18
F]FEA after purification by semi-preparative HPLC method A 
 
This was utilised as an opportunity to further improve the reaction conditions. 2 μmol (0.5 eq.) of 
diluted BPDS could be reintroduced without making the - now diluted - mixture as dense as 
previously observed, thus decreasing the reaction times to 5 min and removing the need for 
heating. Also, lower reagent masses were employed, reducing the precursor to 4 μmol (1 eq.), 1 
eq. copper sulfate, 3.8 eq. sodium ascorbate and 2.1 eq. tosylethyl azide. In order to further 
remove UV-active contaminants, the product was trapped on a tC18 cartridge and eluted in 300 
μL EtOH, then readjusted for HPLC injection to a suitable percentage in water. Taken together, 
this improved considerably the analytical HPLC UV baseline, giving carrier signal under our 
detection limit (calculated as approximately 5 nmol for EFA).  Despite a significant byproduct 
could be observed, it could be successfully separated from the desired product by isocratic 
elution.  
A further attractive alternative from the point of view of radiosynthetic automation and reduction 
of the overall time of tracer production was found in Zhou’s cartridge-based click radiochemistry 
purification method developed at Washington University.
528
 This improved procedure involved 
trapping of the unreacted precursor and impurities in the solvent front in a light C18 Sep-Pak 
cartridge, followed by trapping of the [
18
F]fluoroethyl azide fragment in an Oasis HLB cartridge 
with removal of waste reagents such as the K222 cryptand and carbonate. Following elution in 
0.9 mL MeCN from the Oasis HLB cartridge, the clean [
18





































a new vial with the click reagents and the radiotracer precursor QYL with heating. Following 
HPLC purification, the mixture could then be diluted in water and concentrated on a tC18 Sep-
Pak cartridge. Quality control was performed by HPLC method C (Table 8) yielding >99.9% 
pure [
18
F]EFA in 1.2 mL ethanol and a very clear UV baseline indicative of a high specific 
activity final product (>10 GBq/μmol) (Figure 70). 
 
 
Figure 69 Pure [
18





F]EFA QC at end of synthesis with analytical HPLC method C 
1.21.4 Attempted radiosynthesis of [
18
F]EFB via a boronic ester radiofluorination 
The boronic ester nucleophilic substitution reaction was explored as an attempt to directly 
radiofluorinate compound QPB (Figure 56 for structure). The resulting product [
18
F]EFB 
presents a fluorine atom para to a methylguanidine group. The aromatic ring in this compound is 
electron rich, which is a known challenge in nucleophilic radiofluorinations. The boronic ester 
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fluorination attempted is that reported by Tredwell and co-workers.
484
 Whilst realising this 
method was unlikely to produce high RCYs, it was decided to explore this radiosynthetic 
strategy with some slight modifications aimed at reducing the basicity of the guanidine amine 
and facilitating the fluoride attack, as suggested by work carried out by the Aigbirhio group at 
the University of Cambridge.
531, 532
. 
Table 12 below shows the various conditions attempted. Initially, the strength of the protocol 
was tested by replicating the bisphenyl boronic ester labelling described in the literature.
484
 In 
our hands, this was found to be lower yielding despite multiple iterations, possibly due to 
differences in n.i. RCY calculation methods. Moreover, the yield was found to strongly vary 
depending on the concentration of precursor. This represents a major drawback of the 
published method, as it demands copious amounts of precursor. The method was then applied 
to the boronic ester precursor QPB at various precursor and catalyst concentrations, as well as 
in the presence or absence of air or the use of caesium as counter ion. Although some trace 


































60 5.3 110 20 Y DMF K2CO3 74 
Bisphenyl 
replicate 1 





10 5 110 20 Y DMF K2CO3 0 
1 
10 5 110 20 Y DMSO K2CO3 2.0 
2 
10 5 110 20 N DMSO K2CO3 2.9 
3 
10 20 110 20 Y DMSO K2CO3 2.3 
4 
10 20 110 20 N DMSO K2CO3 7.3 
5 
40 5 110 20 Y DMSO K2CO3 2.8 
6 
30 5 110 20 N DMSO K2CO3 5.3 
7 
30 20 110 20 N DMSO K2CO3 7.7 
8 




10 7 110 20 Y DMSO Cs2CO3 0 
10 
10 5 110 5-20 Y DMSO 
3 x K2CO3 0 
11 
10 50 110 5-20 Y DMSO 
K2CO3 0 
12 
10 50 110 5-20 Y DMSO 3 x K2CO3 1.4 
13 
20 50 110 5-20 Y DMSO 3 x K2CO3 0.9 
14 
10 50 + 100 
pyridine 
110 5-20 Y DMSO 3 x K2CO3 2.3 
15 
10 50 110 5-20 Y DMSO 
3 x Cs2CO3 1.4 
 
Further iterations were inspired by the work of Scott and co-workers at the University of 
Michigan in relation to their work on GSK3 radiotracer development.
532
 They observed some 
higher degree of radiolabelling upon addition of excess amounts of scavenging base. In their 
rationale, higher equivalents of copper catalysis should have sufficed to drive fluoride 
substitution. However, the presence of an N-carbamothioylimidamide had to be counteracted by 
a competing excess of free base, such as dimethylaminopyridine (DMAP) or pyridine. Thus, a 
number of reactions in line with this rationale were attempted, while also altering the 





































Figure 72 QPB - [
18
F]EFB conversion n.i. RCY summary extract from Table 12 
 
Next, we attempted the preparation of a Boc-protected version of the precursor QPB to obviate 
the electron donating complications posed by the unprotected guanidine. Consequently, the 
labelling procedure would now necessitate a second acidic deprotection step. Unfortunately, the 
preparation of this compound was not immediately straightforward and could only afford a 
mixture of mono-Boc protected QPB (see chapter 3), leading us to set aside this labelling 
method altogether to concentrate on the more promising approach described in the following 
section. The difficulty in Boc-acylating this class of compounds is not new and it is known that, 









F]EFB radiosynthesis via [
18
F]Fluorobenzyl amine 
This procedure relied on the synthetic route described by the Wuest group at the University of 











The procedure for the manual synthesis of [
18
F]FBa was applied with only minor alterations to 
the literature method.
521
 Radiofluorination of the quaternary ammonium salts to [
18
F]FBN was 
attempted under different conditions with the aim of improving the average n.i. RCYs to 80-85% 
as described by Turkman et al. (Table 13).
535
 In order to ensure an efficient radiolabelling 
(Figure 74, entry 5), it was of paramount importance to produce the trimethylammonium triflate 
salt in the highest possible purity via double recrystallization in methanol. 
Table 13 [
18
F]FBN synthetic attempts 
Entry Scale (SM μmol) Time (min) Temperature (°C) n.i. RCY (%) 
1 3.2 15 95 63.0 (n=8) 
2 3.2 20-25 95 65.2 (n=3) 
3 3.2 15 110  42.9 (n=2) 
4 6.4 15 95 68.0 (n=2) 
5 6.4 15 110 75.9 (n=4) 
6 6.4 20 110 66.9 (n=2) 
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Figure 74 TBACN - [
18
F]FBN conversion n.i. RCY summary extract from Table 13 
 
The isolation of the radiolabelled compound from the unreacted fluoride and precursor 
compound was carried out in a tC18 Sep-Pak cartridge. Being the radiolabelled [
18
F]FBN the 
only non-ionic radioactive product, this easily resulted in near-quantitative retention in the 
cartridge and elution in 2 mL THF. The highest recovery rates of about 80% were in particular 
achieved when loading the crude mix as a <2% DMSO solution in water.  
Next, the nitro reduction by cobalt-assisted sodium borohydride hydrogenation could be 
performed quantitatively. Curiously, the reaction was shown to produce higher yields in the 
presence of water.
521
 The authors reason that the limited yields in organic solvents could be due 
to a detrimental accumulation of cobalt borite on the vial walls, leading to unavailability of the 
metal centre for catalysis coupled with absorption and sequestration of significant amounts of 
product. In the presence of water instead, this byproduct precipitates without the tendency to 
stick. These observations appear to be further supported by the mechanistic observations made 
in the 80s by Osby and co-workers at Cornell University.
536
 Through observing that the reaction 
proceeds in the presence of CoCl2 but not Co2B alone, that the reaction proceeds independent 
of precursor concentration and is first order borohydride-dependant, they concluded that the 
nitrile precursor must first undergo activation by the cobalt boride via nitrogen-boride 
coordination, followed by rate-determining borohydride addition from undissolved, 




Figure 75 Possible mechanism of nitrile reduction  
  
In our hands, the nitrile reduction proceeded on average at 67.1% n.i. RCY after 1.5 min (n=3), 
90.1% after 3 min (n=7) and 82.5% after 5 min (n=14) at room temperature as assessed by 
ITLC. Purification of the resulting crude mixture was carried out in three distinct ways. In our 
hands, the literature-suggested Waters C18 plus Sep-Pak solid phase extraction in basic media 
resulted in unreliable <50% product recoveries. Replacement with a polymeric yet still 
hydrophobic Phenomenex Strata-X SPE cartridge led to slightly improved 50-60% product 
recoveries. However, the purity of the resulting [
18
F]FBa was a matter of concern, as this 
method failed to remove unreduced fluorobenzonitrile and only part of the [
18
F]FBa could be 
retained. Thus, further optimisation was carried out by introducing a Phenomenex Strata-X-CW 
weak cation exchange cartridge purification step. After preconditioning the cartridge with 
phosphate buffer at pH 6.2, the crude product was loaded in 5:95 THF / pH 6.2 phosphate 
buffer (as suggested by the FBa titration curve shown in Figure 76) was loaded and trapped on 
the cartridge by cation exchange. Acetonitrile washes removed the unreacted, non-cationic 
unreacted starting material, allowing for the recovery of 50-60% of a highly pure, distinctively 
violet band of [
18
F]FBa in <750 μL acidic acetonitrile. Admittedly, this method is still suboptimal 
due to the substantial loss of product in the loading and elution steps and could possibly be 









F]FBa was obtained in high purity as indicated by ITLC (Rf 0.4, lit.
521
 0.4) and 
HPLC (Figure 77). 
 
Figure 77 Co-injection of [
18
F]FBa with cold FBa standard with analytical HPLC method H 
 
Next, we neutralised the 10-40 μL TFA present in the [
18
F]FBa acetonitrile solution with two to 
four times as many equivalents of triethylamine, as indicated in Table 14 and Figure 78. When 
required for mass spectrometric identification of the product, the mixture was mixed at this point 
with 1-2 eq. cold fluorobenzyl amine carrier before mixing with QSMe and heating (refer to 
Figure 73 above for the reaction scheme). 
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0.7 1 140 35 53.0 (n=2) 


























F]EFB conversion n.i. RCY summary extract from Table 14 
 
The conversion to the product was calculated based on integration of the area under the peak 
with analytical HPLC method H. However, in a successive optimisation step it was found that 
this method was not suitable for the separation of the desired substance from an unwanted 
byproduct (Figure 79). Therefore further reaction optimisations were performed using analytical 
HPLC method J. Table 15 and Figure 80 show the further optimisations which could be carried 




Figure 79 Analytical HPLC elutions of crude EFB with method H and method J  
 
 



















































































































































MeCN + 5% 
TFA 
0.5-0.7 1 120 15 41.4 (n=2) 7.0 (n=2) 13.7 (n=2) 
2 
11 2 
MeCN + 5% 
TFA 
0.5-0.7 1 125 15 39.0 (n=2) 15.3 (n=2) 19.6 (n=2) 
3 
11 2 
MeCN + 5% 
TFA 
0.5-0.7 1 130 15 43.5 (n=2) 10.1 (n=2) 41.4 (n=2) 
4 
11 2 
MeCN + 5% 
TFA 
0.5-0.7 1 140 15 35.9 (n=2) 6.2 (n=2) 47.6 (n=2) 
5 
11 3 
MeCN + 5% 
TFA 
0.5-0.7 1 140 15 32.7 (n=1) 3.7 (n=1) 37.5 (n=1) 
6 
11 2 
MeCN + 5% 
TFA 
0.5-0.7 1 150 15 41.1 (n=3) 7.7 (n=3) 38.4 (n=3) 
7 
11 2 
MeCN + 5% 
TFA 




































F]EFB conversion n.i. RCY summary extract from Table 15 
 
Next, the product was isolated by semi-preparative HPLC with method H and concentrated on a 
C18 light Sep-Pak cartridge in <360 μL ethanol. The purity, identification and specific activity of 
the product could be calculated from the final QC performed with analytical HPLC method J. 
Purity was consistently >99% (Figure 81) and the product co-eluted with its cold counterpart 
upon co-injection (Figure 82c), although a second UV peak representative on an impurity could 
be observed.  
 
Figure 81 QC run with analytical HPLC method J  
 
In order to further confirm the identity of the radioactive peak, the cold standard co-injected 

















































































Figure 82 Identification of product with and without cold product co-injection with analytical HPLC 
method J 
The 58 sec elution difference between runs could be accounted for by the variations in retention 
inherent to the instrumentation setup. Upon merging the two UV traces (Figure 82b) 
proportionally to the radioactive tracer retention difference (chromatogram not shown), the cold 
radiotracer eluted at 20 min, before the radioactive peak at 20.8 min (Figure 82.2), as expected 
from the order and distance between the UV and the radioactivity detectors in our HPLC setup. 





m/u, which could not be further identified. Instead, the fraction corresponding to the hot peak 
and before the impurity at 21 min, resulted in an ionised mass (M+H)
+ 
of 320 m/u, as desired. 
Finally, the product was isolated by semi-preparative method H, which enabled the separation 
of two further peaks, both seemingly corresponding to the desired product by mass detection 
but likely to be two different, non-interchangeable conformations (Figure 83). Nevertheless, the 
major peak at 51 min was fully isolable and separable from both the minor peak at 53 min and 
the strong UV impurity at 54 min, resulting in >300 GBq/μmol specific activity. 
 





The work presented in this chapter describes the radiosynthesis and purification of four novel 
18
F tracers.  Three of them (the [
18
F]XFA series) were developed via indirect copper alkyne 
azide cycloaddition radiolabelling. Extensive optimisation was performed to maximise reaction 
yields and reduce the carrier mass. The product conversion optimisation concentrated on the 
alteration of the reaction parameters, on the introduction of the rate-accelerating ligand BPDS 
and on the use of microwave heating. The latter optimisation focused on improving upon the 
analytical and semi-preparative HPLC methods and on the superior purification of the synthon 
[
18
F]fluoroethyl azide. This work resulted in the production of [
18
F]EFA in 4-26% RCY, >99% 
RCP and >10 GBq/μmol, of [
18
F]AFA in 10-42% RCY, >99% RCP and 0.5-61 GBq/μmol and of 
[
18





F]EFB was initially attempted via boronic ester radiofluorination. Despite 
multiple optimisations, this resulted in overall unsatisfactory radiochemical yields. Therefore, an 
attractive alternative was found in a 3-step indirect radiofluorination strategy incorporating the 
synthon [
18
F]fluorobenzyl amine. Upon several optimisation steps, including alteration of the 
reaction conditions and elaboration of a new solid-phase-extraction-assisted purification 
strategy, the reaction could afford the desired product in >99% RCP, >300 GBq/μmol and with a 





















Cell binding assays 
1.23 Introduction 
The affinity and selectivity of the radioligands for P2X7 was established with the use of two 
different assays. Radioligand binding assays evaluated the tracers’ affinity in a cell line where 
P2X7 expression can be altered upon pre-treatment with different substances and competition 
assays were employed to indicate the degree of target selectivity. Secondly, non-radioactive 
calcium influx assays were used to quantify the functional effect of P2X7 antagonists on the ion 
transporter role of the receptor. The latter assay was used to indicate the affinity of the tracers in 
the context of this experimental setup for easy comparison with antagonists described 
elsewhere in the literature. 
 
1.23.1 BV-2 microglia as cell model for the radioligand binding assays 
The BV-2 immortalised microglia mouse cell line commonly employed in our division and 
elsewhere in the context of neuroinflammation studies
537, 538
 was chosen as a model for the 
radioligand binding assays. An important feature of microglia is their innate ability to differentiate 
their response to external and environmental stimuli. Typically, these brain immune cells reside 
in a surveiling state, known as M0, where they present ramifications used for surveillance for 
pathogens and injury. When certain stimuli are sensed, microglia can change their phenotype 
(a.k.a. polarise) to a pro- or anti-inflammatory amoeboid-looking activated state,
539
 known 
respectively as M1 and M2 (Figure 84).
540
 This change involves the expression of inflammatory 
receptors and the release of a range of cytokines, inflammatory mediators and growth 
factors.
541
. Of particular interest for this project are the LPS and IL-4 stimuli, treatments of 
choice to induce the alteration of the P2X7 receptor expression and of the microglial phenotype 
towards M1 and M2, respectively.  
 
Despite the widespread historical distinction between M1 and M2 microglia, it is important to 
note that this classification comes with its limitations in that microglia are better known to exhibit 
a wide spectrum of markers uniquely expressed depending on the exact environmental and 
pathophysiological conditions.
542
 This is particularly true in vivo.
543
 However, the M1-M2 




Figure 84 Functional differentiation of microglia in response to neuronal injury  
  
1.23.2 Transfected P2X7 cells for calcium influx functional assays 
Calcium influx functional assays rely on the intracellular detection of calcium by a fluorescent 
dye pre-incubated with an agonist responsible for the ionic flux. The cell membrane-permeable 
dye needs to be primed by esterase enzymes to its active, negatively charged form before being 
trapped intracellularly.  Upon receptor-mediated intracytoplasmic flux, the calcium is detected by 
the active dye, which fluoresces (Figure 85).
544
 Practically speaking, the value of interest is the 
difference between the baseline calcium flow in the presence of an agonist (ATP or BzATP) and 




Figure 85 Fluorescence-mediated calcium detection 
The typical ATP-mediated Ca
2+
 flow response is a sharp peak followed by a sustained plateau 
phase (Figure 86).
545
 Omission or sequestration of extracellular Ca
2+
 has been shown to 
uniquely affect the plateau signal. Thus, the latter represents calcium response through 









 The latter, in turn, are regulated by 





Figure 86 Typical ATP-mediated [Ca
2+













The P2X7-selective antagonist oxATP irreversibly reduces the plateau phase, suggesting a 
dominant role of P2X7 in calcium influxes.
545
 This is further supported by the fact that BzATP, a 
potent P2X7 agonist, evokes a much higher signal than aspecific P2 agonist ATP.
214
 In this 
work, pEC50 values for BzATP in adherent HEK293 cells were taken from Hibell et al.
549
 and 
calculated with respect to the Yo-Pro dye uptake response (Table 16). The values remain 
unvaried with increasing lengths of agonist exposure times.
550
 
Table 16 BzATP agonist pEC50 values for a range of P2X7 receptor isoforms
549
 
Agonist hP2X7 rP2X7 mP2X7 
100 μM BzATP 6.8±0.14 6.3±0.13 - 




The materials used in this work were purchased as indicated hereafter. Buffers: Dulbecco’s 
phosphate buffered saline (DPBS, Sigma), heat inactivated foetal bovine serum (FBS, Sigma), 
RPMI 1640 (Gibco), DMEM-F12 (Sigma-Aldrich), PBS tablets pH 7.4 (Applichem Lifescience). 
Antibiotics: Gentamicin (Sigma), Penicillin (Invitrogen, Italy), Streptomicin (Invitrogen, Italy). Cell 
harvesting: Trypsin-EDTA solution (Sigma), RIPA lysis buffer system (Santa Cruz 
biotechnology). Transfection reagents: pcDNA3 plasmid (Invitrogen), G418 sulfate (Geneticin). 
Cell viability: MTT (3-(4,5-Dimethylthiazol-2-yl-)-2,5-diphenyl-2H-tetrazolium bromide, Sigma), 
trypan blue (Sigma). Cell treatments: recombinant Mouse Interleukin-4 (IL-4, Source 
BioScience), lipopolysaccharide from E.coli (L2880 LPS, Sigma). RT-PCR: RNeasy mini kit 
(Qiagen, Courtaboeuf, France), iScript™ cDNA synthesis kit (Bio-Rad, Marnes-la-Coquette, 
France), SYBR Green Supermix (Bio-Rad). Pre-staining treatments: protease free BSA (Acros 
Organics), Triton X-100 (Yorlab), paraformaldehyde (PFA, Sigma), fluorescein isothiocyanate 
(FITC) anti-mouse CD16/CD32 2.4G2 Fc receptor block (Insight biotechnology). Antibodies: 
extracellular domain-targeting P2X7 antibody (Dr Gary Buell, Ares-Serono, Geneva, 
Switzerland), APR-004 P2X7 rabbit polyclonal antibody (targeting the C-terminal intracellular 
576-595 epitope of P2X7, Alomone labs, Jerusalem, Israel), AHP2024 C-terminal AIF-1 goat 
polyclonal antibody (Abd Serotec now Bio-Rad, UK), DAPI (Prolong Gold antifade reagent by 
Life technologies, USA and DAKO DAPI), Alexa Fluor 488 and Alexa Fluor 594 conjugated goat 
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anti-rabbit secondary antibodies (Invitrogen or Insight biotechnology). Assays: Fura-2/AM 
(Molecular Probes, Inc., Eugene, OR, USA), 2′(3′)-O-(4-Benzoylbenzoyl)adenosine 5′-
triphosphate triethylammonium salt (BzATP, Sigma), Brilliant blue G (BBG, Acros Organics). 
 
1.24.1 Buffers 
Table 17 Buffers used in this work. 
Application Buffer 
Radiotracer solutions for in vitro DPBS 
Radioligand assay washes DPBS 
Cell harvesting in radioligand assays RIPA 
BV-2 cell cultures RPMI, 10% FBS, 25 mg/mL gentamycin 
BV-2 plating for experiments RPMI, 5% FBS, 25 mg/mL gentamycin 
HEK293 and B16 cell cultures 
DMEM-F12, 10% FBS, 100 U/mL penicillin, 100 
mg/mL streptomycin 
Transfected HEK293 and B16 cell cultures 
DMEM-F12, 10% FBS, 100 U/mL penicillin, 100 




-containing (1 mM) saline solution (150 
mM NaCl, 5 mM KCl, 1 mM MgCl, 5.5. mM 
glucose, 20 mM Hepes, pH 7.4) 
 
1.25 Methodology 
1.25.1 Radioligand cell binding assays 
BV-2 microglia cell culture 
Immortalised BV-2 microglia were donated by Professor R. Donato (University of Perugia, 
Perugia, Italy); they were generated by infecting primary mouse microglia cultures with a v-raf/v-
myc oncogene-carrying retrovirus (J2).
551
  BV-2 were cultured in RPMI media containing 25 
mg/mL gentamycin, supplemented with 10% foetal bovine serum (FBS) for expansion, and 5% 
FBS when plated for experiments. Pilot experiments to determine the correct cell density to 
prevent overcrowding and standardise treatments across plate types had previously been 
performed. All cells were from between passage number 39 and 45. On experiment days, the 
microglia were polarised by treatment with PBS (1µl/mL), LPS at 1µg/mL or IL-4 at 20ng/mL for 




Cell viability: mitochondrial activity MTT assay and trypan blue assay 
The viability of microglia was quantified using MTT or trypan blue assays. In the former, the 
tetrazolium dye MTT is bio-reduced in the mitochondria of viable cells to purple formazan, 
detectable by spectrophotometry. Following PBS, LPS or IL-4 treatment, cells were exposed to 
a final concentration of 250 µg/mL MTT for 30 min. Formazan, which is insoluble in cell culture 
medium was then dissolved in 0.1% DMSO and the absorbance was measured at 490 nm with 
a spectrophotometer. 
The second assay relies on the ability of the trypan blue dye to stain only necrotic and apoptotic 
cells, as it is otherwise unable to cross cell membranes and bind to intracellular proteins. Upon 
staining, the cells were manually counted and their viability was recorded as a percentage. 
Protein assay 
Alongside ensuring consistent cell viability, uniform cell numbers for tracer screening were 
guaranteed by quantifying the protein content in the final radioligand binding assay step. The 
samples were analysed by spectrophotometry and protein content was automatically calculated 
with reference to the absorption at 280 nm. 
 
RT-PCR 
Total RNA from microglial cell cultures was extracted with the RNeasy mini kit according to the 
manufacturer’s instructions. RNA quality and concentration were assessed by 
spectrophotometry with the Nanodrop™ apparatus (Thermoscientific, Wilmington, DE, USA). 
Total RNA (1-2 µg) was subjected to reverse transcription using the iScript™ cDNA synthesis 
kit. RT-PCR was performed in duplicate for each sample using SYBR Green Supermix for 40 
cycles with a 2-step program (5 seconds of denaturation at 96°C and 10 seconds of annealing 
at 60°C). Amplification specificity was assessed with a melting curve analysis. Primers were 
designed using Primer3. The relative expression of P2RX7, the gene of interest (GOI), was 
determined relative to the reference gene of the glyceraldehyde 3-phosphate dehydrogenase 




Radioligand binding assay protocol 
Radiotracers were synthesised and purified as outlined in chapter 4. Radiotracer solutions were 
formulated in PBS with and without the presence of BBG block and self-block. BV-2 cells plated 
in the cluster plates listed in Table 18  and treated as outlined previously (top of section 1.25.1) 
were washed once with PBS and incubated with the radiotracer solutions in triplicate or 
sextuplicate. Cells were then cooled to 4°C for 1 h, similarly to the tissue incubations described 
in chapter 6. Thereafter, unbound radiotracer fractions were collected together with 2 x PBS 
washes. Cells were treated with RIPA for 5 min, scraped and collected together with 2 x PBS 
washes. From the combined bound fractions, 20 μL of re-suspended cells were collected for 
protein assays. The bound and unbound fractions from the cell-containing wells and the control 
empty wells were then analysed by gamma counting with 120 s counting time, background 
correction, 
18
F half-life correction, and ensuring that dead time and counting error were <10%. 
The bound and unbound fraction values for each sample were then summed and normalised to 
the mean radioactive dose. Results were expressed as normalised bound fractions over the 
total radioactive dose. 
















24-wells 50-100 0.1 0.4 0.2 
12-wells 100-200 0.4-0.5 0.8 0.4 
6-wells 1,000 1 1 0.5 
 
1.25.2 Immunostaining 
Immunocytochemical (ICC) staining 
Cells were plated in chamber slides and grown to confluency in 200 μL gentamicin-RPMI with 
5% FBS. After rinsing with 1 x 250 μL PBS, cells were exposed to 4% PFA for 10 min at room 
temperature. After rinsing with 3 x 250 μL PBS, blocking and permeabilisation was performed 
with 2% BSA, 5% FBS and 0.1% Triton X for 60 min at room temperature. The block mixture 
was then tipped off and primary antibodies diluted to the correct concentration (as detailed in 
Table 19) were applied overnight at 4°C. Following rinsing with 3 x 250 μL PBS, the secondary 
antibodies were applied for 2 h at room temperature in darkness. After rinsing with 3 x 250 μL 
162 
 
PBS, the chambers were removed and DAPI mounting medium was applied. Visualisation of the 
immunostaining was performed after 30 min with an EVOS digital fluorescence microscope. 
Control wells containing PBS instead of primary and/or secondary antibody solutions were 
implemented.  






AIF1 1:1000 1:250 
P2X7 1:400 1:250 
 
Immuno-flow cytometry (IFC) 
6 M cells from each treatment type were plated and grown to confluency in gentamicin-RPMI 
with 5% FBS. Each well was then washed with PBS, trypsinised and diluted with gentamicin-
RPMI and 5% FBS in 15 mL Falcon tubes. Triplicate fractions of each sample were centrifuged 
for pelleting at 423 g for 6 min after each stage of the protocol. After washing with 2 mL PBS, 
the cells were blocked with FITC Fc receptor blocking solution for 30 min on ice. Without prior 
washes, the cells were then incubated for 1 h at 37°C on an Innova40 incubator shaker (New 
Brunswick Scientific) at 100 rpm with 1 mL primary P2X7 APR-004 antibodies at the 
concentrations indicated in Table 19 with or without control antigens at 1:1 w/w with respect to 
the antibody. After washing with 2 mL PBS, the cells were incubated in darkness with 1 mL 
secondary antibodies at the concentration indicated in Table 19 for 1 h at 37°C with 100 rpm 
shaking. After a 2 mL PBS wash, the cells were pelleted, resuspended in 100 μL PBS and 
analysed by flow cytometry with a BD FACSCalibur with the settings indicated in Table 20 and 
the CellQuant and Flowing softwares. 








FSC E00 1.50 Lin 
SSC 380 1.00 Lin 




1.25.3 Functional assays  
The materials and methods employed in this section are described in Cabrini et al.
30
 The assays 
were kindly performed by Dr. Simonetta Falzoni in the Di Virgilio laboratory, University of 
Ferrara, Italy. 
Cell cultures and transfections 
HEK293 and B16 cells were cultured in DMEM-F12. The media was complemented with 10% 
heat-inactivated foetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin. 
HEK293 cells were transfected with the calcium phosphate method as described in Rizzuto et 
al.
552
 and Morelli et al.
553
 All cDNAs were in pcDNA3 plasmid. Stably P2X7 transfected, single 
cell-derived clones were obtained by limiting dilutions. Transfected cells were then kept under 
selection in the presence of 0.2mg/ml G418 sulfate. Instead, B16 cells natively expressed the 
mouse P2X7 receptor. Surface expression of P2X7 was performed by indirect 
immunofluorescence and flow cytometry with a P2X7 mouse monoclonal antibody directed 
against the extracellular domain of the human P2X7 receptor. 
 
Measurement of cytosolic Ca
2+
 
Experiments were performed in a Ca
2+
-containing (1 mM) saline solution (150 mM NaCl, 5 mM 
KCl, 1 mM MgCl, 5.5 mM glucose, 20 mM Hepes, pH 7.4) at 37°C. Cytosolic free Ca
2+
 
measurements were performed in a thermostat-controlled and magnetically stirred PerkinElmer 
fluorimeter with the fluorescent indicator Fura-2/AM, as described previously (Section 1.23.2).
554
 
Briefly, cells were loaded with 1 μM Fura-2/AM for 30 min in the presence of 250 μM 
sulfinpyrazone to reduce excretion of intracellular Fura-2. Cells were then rinsed and re-
suspended in saline solution at a final concentration of 500,000/ml.
59
 Excitation ratio and 
emission wavelengths were 340/380 and 505 nm, respectively. The calcium ionophore 
ionomycin (1 μM) was added at the end of each time course as an internal assay control. 




]i) flux variation from baseline while 
in the presence of 100% activating BzATP (100 μM for hP2X7 and rP2X7, 200 μM for mP2X7). 
Inhibition was measured on both peak and plateau phases. The final value was chosen as the 




1.25.4 Statistical analysis 
Data are expressed as means ± SEM from three independent replicates unless otherwise 
indicated. Statistical analysis was performed with GraphPad Prism 5.0 (San Diego, USA) as a 
one-way ANOVA with a multiple comparisons Bonferroni post-test unless otherwise specified in 
the figure captions. Protein assays were analysed with a one-sample t-test against the mean as 
hypothetical value. Different symbols were used to indicate significant difference towards 
different controls (* towards empty well, 
$
 towards PBS-treated cells, 
£
 towards LPS-treated 
cells, unless otherwise indicated). In all cases, one symbol indicates P<0.01; two symbols 




1.26.1 PCR primer validation 
The suitability of polarised BV-2 cells for P2X7 antagonist evaluation was initially established by 
RT-PCR. Two primers unique to the P2X7 sequence were tested. Melting curve analysis 
showed that exons 2-3 and exon 11 both gave suitable amplification at several dilutions (1:10 – 
1:6250 with 5 x increments in-between) after 40 cycles in contrast to an unselective primer. 
Instead, the amplification with lowest dilution (1:2) stalled and was thus avoided. The 
amplification elicited per cycle was visualised as the difference between the bound fluorescent 
SYBR Green dye value and the background value (ΔRn), normalised to the signal of the passive 
reference dye.  
 
1.26.2 BV-2 treatments elicit alternative P2X7 mRNA expression 
Semi-quantitative P2X7 mRNA expression in treated against untreated BV-2 microglia at 
various time points and concentrations was found with exons-2-3-initiated RT-PCR. PBS, LPS 
and IL-4 treatments, known to induce M0, M1 and M2 microglial profiles, respectively,
541
 













































































































































Figure 87 P2X7 mRNA expression in M0, M1 and M2a BV-2 cells as assessed by RT-PCR analysis 
The P2X7 receptor resulted significantly downregulated with increasing concentrations of LPS 
already at 12 h, while it was only mildly downregulated with IL-4. Moreover, the expression 
difference between 1 μg LPS and 20 ng IL-4 increased proportionally with concentration already 
at 12 h. These treatments were thus employed throughout this work together with 12 h PBS in 
equal volumes to the other treatments (significance of P<0.01 with respect to LPS, but non-
significant with respect to IL-4). 
 
1.26.3 BV-2 P2X7 receptor expression 
Receptor surface expression was evaluated visually with immunostaining. Visual inspection 
revealed P2X7 expression specific to the outer cell membranes and processes in PBS, IL-4 and 
LPS-treated cells. Low non-specific binding of the receptor was observed. Figure 88 also shows 





Figure 88 Immunocytochemical staining of BV-2 cells 
 
1.26.4 Radiotracer binding correlation to P2X7 genetic expression in BV-2 cells 
 [
18
F]AFA (0.65 nM at 1.17 GBq/μmol), [
18
F]EFA (3.3 nM at 0.1 GBq/μmol),  [
18
F]OFA (7.55 nM 
of at 0.08 GBq/μmol) and [
18
F]EFB (11 nM at >300 GBq/μmol) were incubated for 1 h at 4°C in 





F]EFA reflected the P2X7 mRNA expression with respect to the three BV-2 treatments. With 
[
18
F]AFA, LPS showed a statistically significant 96% decrease in binding with respect to PBS, 
and a significant 97% decrease with respect to IL-4. No significance was reached in the 143% 
increase in binding in IL-4 with respect to PBS. Instead, LPS decreased [
18
F]EFA binding by 
69% with respect to PBS. 
However, all tracers’ cell binding did not result significantly higher than that by the empty wells. 
In all experiments, no significant change in MTT output from control (PBS) conditions was found 
and trypan blue assays indicated >99% cell viability. Consistent protein concentrations in each 






































































































































































































































































F]EFA ,  [
18
F]OFA  and  [
18
F]EFB  in differentially polarised BV-2 





















































































Figure 89 (continued) 
 
1.26.5 Exploration of the causes of high well binding 
The steady state conditions of the assays were challenged by varying the concentration (75 pM 
- 7.5nM) and time of incubation (1 h – 4 h) of [
18
F]AFA (1.1 GBq/μmol) (Figure 90). The 
























































































F]AFA kinetic binding in BV-2 cells and related protein assay ( 
   
The tracer cell binding did not significantly change between 1 h and 4 h of incubation and 
decreased with increasing concentrations. Also, significantly higher binding was observed in 
unseeded wells, suggesting a lack of involvement of kinetic and saturation binding in the 
observed effect. Moreover, at low [
18
F]AFA concentrations the cells appear to be significantly 
169 
 
inhibiting the binding to the well. Protein assays showed consistent cells numbers in each 
fraction. 
 
Secondly, the ability of the well material to bind the tracers was investigated. The experiment 
was conducted with [
18





plastic and glass wells (Figure 91). No significant variation was observed between well types or 
the radiochemical species. Also, the binding was generally very low compared to the total dose 
applied (Figure 91). This experiment indicated no special affinity of our radiotracer for the plastic 





































































 binding in plastic and glass wells ( 
  
Next, direct receptor blockade was attempted with the use of P2X7-selective antagonist Brilliant 
Blue G (BBG) and the cold standard of AFA (self-block, SB) at a range of concentrations. 
 [
18
F]AFA (0.2 nM, 1.13 GBq/μmol for BBG and 0.9 nM at 0.55 GBq/μmol for SB) was incubated 
with 0 M to 1 mM BBG in 10
3 
increments and with 0 M to 100 μM SB with 3 x increments. Both 
in the presence of either SB or BBG (Figure 92) no significant variation in binding was observed. 
These results corroborated the hypothesis that the binding observed was either unspecific to 





























































































































































































F]AFA binding with and without block in BV-2 cells 
1.26.6 Quantitative BV-2 P2X7 receptor expression 
In order to elucidate whether the receptor expression levels were sufficiently high for radiotracer 
detection, flow cytometric analysis of P2X7 in polarised BV-2 cells was performed. This showed 
low significance between the fluorescence signal in treated cells and that arising because of 
non-specific binding (secondary antibody only and control peptide co-incubated cells), while 
antibody-free cells displayed a significantly lower signal (Figure 93). Given the narrow difference 
between specific and non-specific fluorescence signal (Figure 94), the low receptor expression 


























































Figure 93 Variation in fluorescence intensity in alternatively treated cells and controls 
 
Figure 94 Overlay histogram of all cell populations as analysed by flow cytometry 
 
1.26.7 Calcium influx functional assays 
Dose-inhibition curves for the 4 tracers were measured against the established P2X7 blockers 
A-740003 and BBG, both with nM affinity for the radiotracer.
214
  
All compounds were evaluated over a range of concentrations between 0.01-25 μM. Data were 
plotted as the variation from the baseline [Ca
2+
]i flux. The data were then logarythmically 
transformed and fitted to a four parameters variable slope before IC50 values were extracted and 
converted to Ki measures via the Cheng-Prusoff equation. Figure 95 and Table 21 show, 











































































































































































































































































































































































































































































































Figure 95 Calcium influx assays in the presence of P2X7 selective control blocks A-740003 and 
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 5.59 8.25 
 
No data are presented for AFA, EFA and OFA as the compounds did not induce functional 
inhibiton in this model. Also, no data were collected for BBG in hP2X7-H293 cells as the 
compound is poorly selective towards the human strain of the receptor. EFB exhibited a low 





The work presented in this chapter aimed at exploring the degree of affinity and selectivity of the 
compound series developed. These results come with limitations which prevent us from fully 
establishing the extent of P2X7 targeting. This section intends to explore the latter and present 




1.27.1 P2X7 expression in polarised microglia 
P2X7 expression in BV-2 cells subject to alternative treatments was evaluated by mRNA RT-
PCR with reference to GAPDH, a universally abundant, stably and constitutively expressed 
housekeeping gene involved in eukaryotic cell glycolysis.
557
 The choice of GAPDH as the 
reference gene does not come without limitations. In particular, the gene can on occasion 
undergo upregulation by LPS, making it problematic as a control.
558
 Despite this, there are no 
reports of its upregulation in BV-2 cells, where it is widely employed as a housekeeping gene.
541
  
The RT-PCR revealed a statistically significant downregulation of the receptor mRNA after LPS 
treatment with respect to PBS treatment; whereas lower (albeit not statistically significant) 
expression was observed in 1 μg LPS compared to 20 ng IL-4 treatment at 12 h (Figure 87). 
Instead, the expression levels did not significantly differ between treatments and from the 
background signal, suggesting that protein expression is generally low in this cell model. 
Internalisation can be excluded as a cause of low surface receptor presentation as 
immunocytochemistry localised the receptor uniquely on cell membranes. On the other hand, 
ligand binding, especially in an agonist capacity, was not ICC-tested. This might have induced 
receptor internalisation, as sometimes observed for P2X7 in the presence of ATP.
559
 
The mRNA expression levels suggest that P2X7 is characteristic of a resting (M0) and 
neuroprotective (M2) microglial phenotype. This matches previous observations in dynamically-
activated mouse peritoneal macrophage P2X7 mRNA.
560
 Conversely, in human peripheral blood 
mononuclear cells and monocytes P2X7 mRNA was shown to become mildly upregulated in the 
presence of IL-4 (x1.2), whereas a stronger increase in expression was seen after LPS 
treatment (x2.0).
561
  This was not the case in BV-2 and N9 LPS-treated microglia
562, 563
 as well 
as in a further study on alternatively polarised mouse macrophages, where no P2X7 mRNA 
variations were found.
564
 Furthermore, western blot analysis of BV-2 and N9 microglia P2X7 
receptor expression demonstrated that P2X7 protein expression was downregulated upon  
stimulation by M1-inducing LPS.
563
 This was in contrast with the finding of this work that the 
latter is unaffected by polarising treatments at a protein expression level (Figure 93, section 
1.26.6). Taken together, these results suggest that P2X7 regulation differs between cell types 
and depends strongly on the experimental conditions. 
175 
 
On a different note, in vivo P2X7 expression was not explored in this work, hence defining 
whether P2X7 is more characteristic of an M1 or and M2 phenotype in vivo is not possible. 
However, an overall tendency towards upregulation in response to any (pro or anti-
inflammatory) stimulus seems to dominate the literature, while its expression in M0 polarised 




1.27.2 Radioligand binding assays 
The radioligand binding assays in alternatively treated BV-2 cells resulted in a surprisingly high 
binding in the empty wells, which was unexpected particularly since immunocytochemical 
staining clearly indicated P2X7 expression on the outer cell membranes (Figure 88).  This 
binding pattern did not appear to be caused by oversaturation of the target, as demonstrated by 
the persistence of this effect even at picomolar concentrations of [
18
F]AFA (Figure 90), albeit 
future studies will need to explore the binding at further concentrations and with the remaining 
radiotracers. Moreover, empty well binding was not imputable to the well material, nor it differed 
from that of unfunctionalised [
18
F]fluoride, as demonstrated by the constant binding observed in 
different well materials and with different radioactive molecules (Figure 91). Additionally, 
independent from the empty well binding, after 1 h of incubation steady state appeared to have 
been reached, as demonstrated by the lack of significant binding variation after 4 h (Figure 90). 
Yet, receptor blockade indicated a lack of P2X7-selective binding for [
18
F]AFA (Figure 92), while 









F]EFB (Figure 89). These trends remained poorly significant in light of the high 
well binding, which suggested either lack of specific binding to P2X7, high non-specific binding 
or too low receptor expression for radiotracer binding detection, calling for further investigations. 




 so as to 
fully elucidate the extent of P2X7 cell expression. Also, the use of P2X7-transfected cells such 





1.27.3 Calcium influx assays 
Receptor-transfected cells are ideal to maximise calcium fluxes and facilitate their detection.
567
 
In this work, human (hP2X7) and rat (rP2X7) P2X7 HEK293 cells were employed, while for the 
mouse receptor (mP2X7), natively high P2X7-expressing B16 cells were more readily available. 
Cell transfection has the effect of rendering the signal from all other calcium pathways 
negligible. Thus, IC50 values arising from plateau or peak readings (as discussed in section 
1.23.2) were substantially indistinguishable. Further complications however arose from the use 
of different cell lines and transfected receptors. The assay was performed in both human and 
rodent cells lines. The human and rat receptor cavities present similar topologies and 
physicochemical properties, where the most significant difference is a phenylalanine residue 
(Phe288) in the rat receptor in place of a tyrosine (Tyr288) in the human isoform.
394
 Despite 
functional behaviour similarities to the rat receptor, the human recombinant P2X7 displays a 
distinct pharmacological profile with respect to agonist and antagonist sensitivity.
568
 In fact, in 
order to induce maximal calcium influx, hP2X7-HEK293 cells require lower agonist 
concentrations than mP2X7-B16 cells. Additionally, the chosen P2X7 agonist BzATP is much 
more potent than the endogenous ligand ATP.
214
 
Furthermore, IC50 values are not fully comparable between different cell lines as they measure 
the effectiveness of an inhibitor towards the blockade of a specific biological function in a 
precise cellular environment. Also, they can considerably be affected by the composition of the 
buffer, the temperature of the assay and the concentration of the agonist. Ideally, the 
experiments should have been designed in such a way as to explore the effect of these 
variables on the inhibition effect.
549
 Nevertheless, it is possible via the Cheng-Prusoff equation 
to derive the inhibition constant (Ki), an absolute measure of inhibitor affinity to the receptor.
569
 It 
must be noted that also this measure can fluctuate to some extent according to the binding 














where [EC50] represents the concentration of agonist required for the receptor to be 50% 
effective, and [A] is the concentration of agonist employed in the IC50 measurement. The 
equation can only be applied in this form to competitive antagonists,
571
 such as A-804598, the 
parent scaffold to this work’s radiotracer library.
229
 Besides, A-804598 might also be interacting 
with an allosteric pocket, as on one occasion even the application of a high mM concentration of 
BzATP was unable to fully reverse its inhibitory activity.
67
 Additionally, the fact that the structural 
modifications introduced upon the parent scaffold do not modify the ligand binding modality is 
an assumption, the breach of which renders the use of this equation inappropriate.  
 
In our hands, the calcium assays showed no specificity of the three XFA compounds for the 
target. Instead, EFB showed 0.850 nM, 36.1 nM and 547 nM Ki in human, rat and mouse P2X7 
receptors, respectively, when considering the peak or plateau dataset displaying the best fit to a 
four parameters variable slope. As indicated by the R
2
 values in Table 21, these were not 
optimal for all datasets, showing the need for further replicates and for higher antagonist 
concentrations. Additionally, control P2X7 antagonists A-740003 and BBG failed to match 
literature affinities. For instance, according to Able et al.
67
, the compound A-740003 would have 
an rP2X7 pKi of 7.57±0.04 M, while in our hands it resulted in 8.06 M affinity. This warrants 
further work into this assay, with the primary aim of revalidating the protocol with the known 
inhibitors and a secondary aim of repeating the work on all the novel molecules. 
  
1.28 Conclusions 
In this chapter, two in vitro assays for the determination of the tracer library target affinity were 
reported. A radioligand binding assay was based on alternatively polarised BV-2 microglia. 
However, the results were corrupted by the low signal-to-noise level as indicated by the high 
well binding across the entire tracer library. Still, RT-PCR indicated that P2X7 is genetically 
under-regulated in LPS-treated M1 microglia and upregulated in IL-4-treated (M2) when 
compared to PBS-treated (M0) cells, whereas ICC staining indicated unique expression on 
outer cell membranes and processes. However, IFC indicated a lack of distinction between 
expression levels resulting from alternative BV-2 polarisation, suggesting post-translational 
receptor regulation or surface expression variations induced by ligand-binding. 
178 
 
Furthermore, a preliminary calcium influx functional assay was performed on hP2X7-HEK293, 
rP2X7-HEK293 and mP2X7-B16 cells. Here, compound EFB resulted potent against P2X7, with 
Ki affinities of 0.850 nM, 36.1 nM and 547 nM for human, rat and mouse P2X7 receptors, while 
no XFA receptor reached <0.1 mM selectivity for P2X7. Nevertheless, this assay did not display 
optimal curve fitting in all cases, which demands further replicates and the use of higher 
antagonist concentrations. Additionally, control P2X7 antagonists failed to match literature 
affinities, indicating a need for further validation of the assay protocol. Despite the lack of 
conclusive quantitative data, given that EFB showed some extent of functional affinity for P2X7, 
it was selected as a candidate for in vivo evaluation, whereas the binding of the [
18
F]XFA 
















Tissue binding assays  
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Tissue binding assays 
1.29 Introduction 
Tissue autoradiography relies on the phenomenon of luminescence, as displayed by phosphors 
applied on a screen. Exposure to radioactivity excites individual electrons within the phosphor, 
which then slowly relax down to their ground state upon photon emission. The latter is captured 
with high precision by a Phosphorimager, enabling resolutions up to 10
-4
 m (thus higher than in 
PET) and proving an excellent technique to understand in detail which regions a tracer binds 
to.
572
 The results can be quantified by calculating the digital light units (DLU) emitted within 
user-defined regions of interest (ROIs). This value can be directly correlated to the 




Tissue autoradiography can be performed in two contexts: ex vivo and in vitro. Ex vivo involves 
culling the animal after it has been injected with the radiotracer and following an amount of time 
necessary for the radiotracer to distribute to the target organs. This can be useful to understand 
and quantify precisely the whole-body distribution and tissue accumulation of tracers. For CNS-
targeting compounds, it is often employed to assess the extent of blood-brain barrier (BBB) 
permeability. In vitro autoradiography is performed entirely on culled animals. It is still useful to 
assess the specificity and kinetics of binding of a compound, in particular regardless of its 
biodistribution and metabolic profile but still in a native setting. Moreover, it can be employed to 
evaluate tissue receptor expression. In this work, to provide a rough evaluation of the brain 
distribution and target selectivity of the [
18
F]XFA radiotracers, regardless of their ability to 
penetrate the BBB, in vitro autoradiography was the technique of choice. 
 
1.29.1 Introduction to brain injury models and polarised microglia 
Immature hypoxic ischemic (HI) mice were employed as a model for assessing the tracer 
uptake in an inflamed tissue. This model is characterised by an ischemic event induced by 
unilateral carotid artery cauterisation. This in itself does not induce injury, as perfusion is 
maintained through collateral circulation. However, on subsequent exposure to hypoxia, a 






This is an acute model of neuroinflammation. Within minutes from the generation of the infarct, 
oxygen/glucose deprivation causes neuronal death and an immediate microglial response 
(Figure 96).
575
 Then, after a period of latency in which microglia and macrophages infiltrate the 
ischemic areas to combat the expanding encelopathy, a delayed secondary neuronal death 
phase occurs. In the core of the infarct, pan-necrosis ensues. Necrotic tissue is characterised by 
the presence of amoeboid-like microglia, whereas in the proximity of living neurons, active yet 
ramified glia have been observed.
576
 These gradually become predominantly and ubiquitously 
activated and acquire a round morphology. Microglia initially respond to the insult by assuming 
an M2, neuroprotective phenotype. However, ischemic neurons then prime microglial 
polarisation towards an M1, neurotoxic phenotype.  In the cortical zones around the ischemic 
infarct (penumbra), an early recruitment of activated microglia and infiltrated macrophages was 
found to rescue brain tissue from the expanding neuronal necrosis.
577
 In the external perimeter 
of the lesion, microglia display a phagocytotic behaviour and this was also corroborated in 
temporarily macrophage-depleted rodents.
578, 579
 Moreover, a stronger neuroinflammatory 
response to HI is present in postnatal day 9 compared to postnatal day 30, suggesting a higher 
suitability of the more immature model for the purposes of this study.
580
 Further details on the 





Figure 96 Representative schematic of the microglial response to a hypoxic ischemic infarct over 
time in rodent tissues 
 
 
In the unfolding of these events, P2X7 expression is temporarily upregulated in the periphery of 
the insult. This is particularly characteristic to microglia until day 4 post-ischemia, closely 
resembling the M2 microglial expression pattern. Thereafter, the expression returns to basal 
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These patterns are observed selectively in the ipsilateral region (Figure 97).
584
  However, on 
one occasion widespread P2X7 and activated microglia tissue distribution, including the 
contralateral side, was shown at 24 h post-ischemia by IHC.
565
 Also, on other cell types, such as 
on oligodendrocyte precursor cells and on radial glial cone cells, a decrease in P2X7 expression 





The work presented in this chapter aimed at: 
 Developing an in vitro autoradiography assay with wild type rat brain tissue 
slices. 
 Exploring the tracer binding in the native inflamed tissue setting of the hypoxic 
ischemic mouse, resulting in a preliminary assessment of the tracer binding 
profiles. 
To this aim, the regions of interests for the analysis of the radiotracer binding in HI tissues were:  
 A hotspot region focused on the binding in the subcortical, infarcted lesion. 
 A penumbra region in the cortical, peri-infarct region.  
 A whole-hemisphere region for full comparison between the damaged and the 
control, intact brain. 
 
Figure 97 Hypoxic ischemic mouse tissue regions of interest of radiotracer binding 
 
1.30 Methodology 
1.30.1 Animal provenance and tissue preparation 
BALB/C mice pups were raised in-house at St Thomas’ Hospital after mating between wild-type 








left carotid artery cauterisation. The animals were then awaken and placed in a hypoxic 
chamber (8% oxygen) for 3.5 hours.
587
 One day later, the mice were sacrificed by an authorised 
Schedule 1 procedure. The brains were removed, submerged in a 20% sucrose solution for 20 
min and snap-frozen in liquid nitrogen before storage at -80°C. The frozen cortical (hypoxic 
ischaemic mouse) 20 μm brain sections were then cut with a Maskold 5030 microtome using an 
optimal cutting temperature (OCT) embedding medium to mount the tissue on the sample 
holder. The slices were then thaw-mounted onto microscope slides which were then stored at -
20°C until the time of assay. Instead, wild-type male Sprague-Dawley rats weighing 300 g were 
bought from Charles River Laboratories International, Inc. and were directly culled without prior 
procedures. Following dissection, their brains were cut into sagittal slices. The animals were 
housed under pathogen-free conditions in a temperature- and humidity-controlled environment 
and given access to food and water ad libitum. All experimental procedures were performed 
after over a week of acclimatisation in the new environment and in accordance with the Animals 
(Scientific Procedures) Act 1986, Amendment Regulations 2012 and approved by the local 
ethics committee. Project licence: Licence holder – Prof Reza Razavi, PPL 70/8230 and Dr 
Diana Cash, PPL 70/8480. Personal Licence: Licence holder: Enrico Fantoni, PIL 70/3001. All 
experiments were carried out in the Rayne Institute, St. Thomas’ Hospital, King’s College 
London between 2015 and 2016. 
 
1.30.2 Tracer tissue binding assays and autoradiography 
Radiotracers were synthesised and purified as outlined in the experimental section. Radiotracer 
solutions at 0.1-5 nM were formulated in PBS with and without the presence of 10 μM Brilliant 
Blue B (BBG), 10 μM ATP or 10 μM self-block. Tissue slides were allowed to slowly thaw to 
room temperature prior to washing in cold PBS.  The slides were then completely submerged in 
15 mL of buffered radiotracer (20 mM PBS/0.1% BSA, pH 7.4 at 4°C) and incubated for 1 h at 
4°C as determined from time course and saturation experiments. The slides were then 
submerged for 2 x 1 min in cold 20 mM PBS and 1 x 1 min in cold distilled water. Following 
drying in a cool airstream, the slides were exposed overnight at room temperature together with 
3 standards of different concentrations to 
18
F-sensitive phosphor screens (Amersham, UK) in X-
ray cassettes. Phosphor screens were then imaged using a GE Healthcare Typhoon or a 
184 
 
Version 5.0 Perkin Elmer OptiQuant. Regions of interest were defined with Image J (Version 
1.48, open source software).  
 
1.30.3 Statistical analysis 
All data were background corrected and expressed as mean ± SEM from three independent 
replicates unless otherwise indicated. Statistical analysis was performed with GraphPad Prism 
5.0 (San Diego, USA) as a two-way ANOVA with Bonferroni post-test unless otherwise specified 
in the figure captions. *: P<0.01; **: P<0.005; ***: P<0.001 with respect to the contralateral (CL) 






: P<0.001 with respect to the ipsilateral 




1.31.1 Method development in wild type rat brain  
All incubated tracers were >95% pure with variable specific activity and concentration, both 
because of the inherent variability of the tracer production at this stage of the project.  
Incubation of 0.1 nM of 60 GBq/μmol [
18
F]AFA with sagittal wild type rat cortical brain slices 








The method was further explored with wash lengthening to 2 min, giving widespread non-
specific binding, while Trizma or PBS buffering did not impact the tracer binding. The study was 
repeated in rat mid-brain slices and 10.6 GBq/μmol [
18
F]AFA at 0.2 nM, in the presence and 
absence of 1 mM P2X7-selective block BBG over 2 - 180 min. After 1 h, 2 h or 3 h incubation, 
similarly heterogeneous binding was observed in the unblocked slices. Instead, receptor 
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blockade resulted in increased binding in selected brain regions identified by comparison with 








1.31.2 Hypoxic ischemic mouse tissue binding of [
18
F]XFA tracers 
The conditions employed in wild type rat brains were integrally translated to immature hypoxic 






F]OFA binding.  
Incubation of 11.7 GBq/μmol [
18
F]AFA at 0.2 nM resulted in a marked increase in binding in all 
regions compared to the respective control regions in the non-ischemic hemisphere. 
Conversely, the lesion site displayed uneven binding across replicates, resulting in a lack of 
significance with respect to the control hemisphere (Figure 100). Binding in the hypoxic 
hemisphere did not decrease significantly with BBG blockade in any of the ROIs, whereas an 
increased binding was observable in the infarct region. Instead, significant inhibition of binding 
was observable in the presence of self-blockade. In line with the previous findings, no decrease 









Next, incubation of 5.4 GBq/μmol [
18
F]EFA at 0.2 nM showed increased, but not significant 
binding in the damaged whole hemisphere and peri-infarct regions compared to the 
contralateral side, and significant decrease in binding with BBG blockade.  
 






Instead, in the infarct region no variation of binding as found with BBG blockade. Unfortunately, 
the images were not as clear as in the other incubation studies, resulting in a lower incidence of 
statistically significant binding compared to [
18
F]AFA. 
Finally, incubation of 0.73 GBq/μmol [
18
F]OFA at 0.2 nM gave a marked binding increase in the 
damaged hemisphere, particularly in the lesion site. However, statistically significant increase in 
binding was observed upon blocking in the infarct and whole hemisphere regions, indicative of 
extensive non-specific binding. 
 







1.32.1 Wild type rat brain tissue autoradiography 





H]JNJ-54232334, respectively, showed discordant binding profiles. The 
former displayed heterogeneous binding, with hot spots in the colliculus, hypothalamus, 
olfactory nucleus and thalamus.
67
 However, in a later study with P2X7 receptor blockade, 
hippocampal and cortical binding was attributed to non-specific binding.
231
 Instead, 





 Somewhat in accordance to the latter study, in this work a relatively 
homogeneous binding was seen with [
18
F]AFA, while patches of increased binding were found 
in the caudate putamen and orbital cortex. With BBG blockade the binding appeared increased, 
particularly in the thalamus, hypothalamus, anterior commissure and olfactory nucleus but not 
the colliculus. This effect was surprising, as BBG is a well-established selective blocker with 10-
12 nM affinity for P2X7.
215
 
A possible direct BBG-AFA interaction was investigated by HPLC. However, no reduction in 
AFA and BBG signature peak intensities and no appearance of new peaks after 1 h of co-
incubation at 25°C were found, indicating a lack of direct interaction between the two 
compounds in isolation. This did not exclude positive allosteric binding to P2X7, as suggested 




 However, the latter is usually 
concentration-dependent, while in the case under discussion tracer binding was consistently 
higher over a range of concentrations of BBG and of the tracer. Conversely, the lack of known 
tracer affinity leaves the possibility of an alternative P2 receptor selectivity for AFA, in which 
case the observed BBG-induced patterns might have been a consequence of reduced non-
specific binding to P2X7 while increasing the specific binding for the unknown target. Further 
experiments are required to clarify this effect. In particular, it appears necessary to analyse the 
receptor expression upon BBG exposure, to study the allosteric modulation potential of AFA and 
to investigate the tracer binding upon receptor blockade by an alternative antagonist. 
 
1.32.2 Hypoxic ischemic mouse brain tissue autoradiography 
In the hypoxic ischemic mouse model at 24 hours post-ischemia, binding was expected in the 
peri-infarctic region, where the P2X7 and M2 microglial expression levels are highest. In line 
with the expectations, [
18
F]AFA displayed peri-infarct binding and low non-specific binding. 
[
18
F]EFA presented high non-specific binding, possibly due to recognition of the quinoline 
moiety by proteins other than the target. Finally, [
18
F]OFA showed poor correlation with P2X7 
expression in the periphery of the infarct, while instead high peri-necrotic binding was observed. 
However this could be an artefact arising from the tissue lesion. The loss of target selectivity 
could be imputable to the decrease in SAR or to the increased H-bonding ability of [
18
F]OFA 





Further complications arose with the presence of blockers. Self-blocking, but not P2X7-selective 
BBG blocking reduced the binding of [
18
F]AFA, suggesting selective binding to a target other 
than P2X7. [
18
F]EFA binding was reduced by BBG, suggesting P2X7 selectivity, albeit in the 
presence of high non-specific binding, as previously discussed. Finally, [
18
F]OFA binding was 
increased by BBG, suggesting an allosteric modulation effect, similarly to that of [
18
F]AFA. 
This mixture of responses points to a variety of tracer binding modes which is in need of further 
scrutiny. Yet this study provided a useful starting point for further explorations. Further work 
should also aim to clarify the P2X7 expression levels in the ischemic tissue as well as the 
contralateral side by immunohistochemical staining. It must however be noted that there is 
uncertainty regarding the exact M1/M2 phenotype within and surrounding the infarct over time, 
as highlighted by the discrepant observations reported in the literature.
589, 590
 This might well be 
because of the difficulty in studying in a living model such a mutable condition as is 





In conclusion, in wild type rat brains a fairly homogeneous binding was observed for [
18
F]AFA. 
This was heterogeneously increased in the presence of BBG blockade, suggesting allosteric 
modulation, binding to a different target or other effects which merit further inspection. In the 
immature HI mouse brain, [
18





F]EFA displayed, respectively, low target affinity and 
high non-specific-binding. Thus, [
18
F]AFA appeared as the most promising tracer in this series, 

















In vivo tracer evaluation  
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In vivo tracer evaluation 
1.34 Introduction 
This chapter focuses on the preliminary in vivo evaluation of tracer [
18
F]EFB, the most promising 
candidate out of the tracer series developed. 
 
1.34.1 In vivo pharmacokinetic considerations 
While the pharmacokinetic parameters described in section 2.1.1 (chapter 2) provide a good 
description of the receptor-ligand interaction, the in vivo picture is complicated by the increasing 
complexity of the system. Preclinically, the tracer undergoes absorption (except when injections 
are intravenous), distribution, metabolism and excretion (ADME); the nonspecific binding is 
affected by the presence of biomolecules in plasma and non-target tissues, metabolites can 
form and the studies are not necessarily being conducted under true equilibrium conditions as 
free and bound ligand concentrations change over time.
592
  
A frequently used model to interpret and quantify in vivo tracer distribution is the two tissue-
compartment model. Compared to the model adopted for in vitro tracer quantitation (chapter 2) 
in the two-tissue model (Figure 103), the plasma is treated as a separate compartment from the 
tissue of interest. The latter is divided into a free + non-specific binding compartment and a 
specific binding compartment. This model can be exploited to calculate the binding potential 
given that the free tracer in arterial plasma is assumed equal to the free tracer within the target 
tissue at equilibrium, which is a reasonable assumption for drugs that passively diffuse across 
tissue barriers.
333
 However, it is not always practical to sample the tracer in arterial plasma over 
time due to logistic difficulties. Hence, often the binding potential is more conveniently 
calculated from the specific to non-displaceable tissue tracer ratio at a unique equilibrium time 
point (the time point of maximal specific binding, calculated with respect to a reference 
background region). The binding potential calculated from this method is called “non-
displaceable binding potential” (BPND) and is treated as an estimate of the true BP, as the non-
displaceable tracer in the tissue actually represents only a fraction of the true free plasma 







Figure 103 Two-tissue compartment model   
 
 
Another difference in vivo is the presence of endogenous ligands that might lower the total 
number of binding sites available. Thus, instead of BMAX, one should refer to the total receptor 
concentration as a combination of available (BAVAIL) and unavailable (BUNAVAIL) binding sites.
592
 
Furthermore, the concept of volume of distribution (VD) has been adopted from clinical 
pharmacology. In the context of in vivo imaging, the volume of distribution (VT) is defined as the 
ratio of the concentration of radiotracer in plasma (in kBq/mL) to that within a target organ 
volume (in kBq/cm
3
), expressed in mL/cm
3
. In other terms, it represents the volume of plasma 
that would be required to account for the radioligand in the target organ volume. VT is the sum of 
free tracer volume of distribution (VF), that of the specifically bound tracer (VS) and that of the 
non-specifically bound tracer (VNS).
594
 
Additionally, in vivo it is necessary to take into account not only the concentration of tracer, but 
also its specific activity, as low specific activity can now lead to saturation of the target sites, 
with consequent non-specific binding increase and alteration of the signal readout. The 
challenge that the radiochemist faces here is that unless the specific activity is high, the overall 
mass of tracer becomes significant and could saturate the target. In a study carried out by 
Hume et al.,
595
 when maximal receptor occupancy for an in vivo imaging experiment is 
constrained to 1%, a variable specific activity/radioactivity ratio threshold was estimated 
depending on the tracer binding affinity (Figure 104). For example, to image dopamine D2 
receptors in rat brains with a tracer such as 
3
H-raclopride (Bmax = 0.0235 pmol/mg; Kd = 1 nM)
596
 
at 50 GBq/umol, a limit of 2.5 MBq of activity are injectable in a rat (Figure 104b) if the 






Figure 104 In vivo limits of radioactivity  as a function of specific activity   
 
1.34.2 An LPS rodent model for P2X7 tracer validation 
In order to perform in vivo evaluation of [
18
F]EFB, we employed a simple inflammatory rodent 
model consisting of a wild type rat with an intraperitoneal lipopolysaccharide (LPS) challenge. 
Intraperitoneal injections of the bacterial endotoxin LPS are known to induce even at low 
dosage a lasting neuroinflammatory response.
597
 On a symptomatic level, in rodents it leads to 
a sickness behaviour, mild loss of appetite, depressive-like symptoms, moderate piloerection, 
social withdrawal and a hunched back.
598
 At a biochemical level, LPS was found to raise the 
levels of most inflammatory markers in the blood, including TNF-α, NF-κβ and IL-1β.
599
 Brain 
cortex expression of IL-1β, IL-6, toll like receptors (TLRs) and glial fibrillary acidic protein 
(GFAP) are upregulated within 4 h, suggesting that glial activation and cortical inflammation 
quickly follow systemic inflammatory episodes,
600, 601
 often outlasting them.
602
 
Upon reaching the CNS, LPS is known to loosen the BBB and affect some of its normal 
functions, enabling the spread of inflammation into the brain through endothelial cell-mediated 
microglial activation and via brain infiltration of blood-based inflammatory cells.
603, 604
 The 
specific routes by which LPS might cause brain inflammation have not been fully clarified. 
However, BBB leakage is known not to occur until an LPS concentration threshold of 3 mg/kg 
has been reached,
605




To determine the time point of maximal inflammation, the dose of LPS administered was found 
to be important. It can range between 0.002-10 mg/kg, causing microglia to become activated 
after 3 hours, reaching full activation between 8h and 2 days post-injection. However, several 
studies used a regular injection regimen to maintain a constant level of inflammation, as detailed 
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in a systematic review by Hoogland et al.
607
 Also, several reported that systemic LPS-induced 




Despite the certain inflammatory consequences of LPS administration, it is important to note 
that there is yet only one study showing direct evidence of LPS inducing P2X7-overexpression 
in rodent models. This is an immunohistochemical study by Choi et al. where 24 h post-injection 
with 0.5 mg/kg LPS rats displayed moderate P2X7 overexpression, whereas this became strong 
with a 5 mg/kg dose.
610
 Moreover, three studies carried out in P2X7
-/- 
rodent models provide 
indirect evidence of P2X7 by reporting downregulation of pathways downstream of the receptor, 
as measured by IL-1β secretion (ELISA, PCR)
90, 99
 or pleasure feeling (sucrose preference).
159
 
Additionally, P2X7 is known to be tightly correlated with LPS and with inflammation, as 
discussed in chapter 1. P2X7 is also known to mediate LPS downstream inflammatory 
signalling
115, 611-613





The work presented in this chapter aimed to characterise in vivo [
18
F]EFB. In particular, we 
sought to determine: 
 The in vivo distribution and kinetic profile of the tracer 
 The extent by which it is able to cross the BBB 
 How well it is cleared from the body and by which routes 




1.35.1 Animals  
Female BALB/C mice from Harlan UK Ltd. underwent imaging at 10-12 weeks of age. 
Alternatively, male Sprague-Dawley rats of 240-270 g were bought from Charles River 
Laboratories International, Inc. and used within 90 days. The animals were housed under 
pathogen-free conditions in a temperature- and humidity-controlled environment and given 
access to food and water ad libitum. All experimental procedures were performed after over a 
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week of acclimatisation in the new environment and in accordance with the Animals (Scientific 
Procedures) Act 1986, Amendment Regulations 2012 and approved by the local ethics 
committee. Project licence: Licence holder – Prof Reza Razavi, PPL 70/8230 and Dr Diana 
Cash, PPL 70/8480. Personal Licence: Licence holder: Enrico Fantoni, PIL 70/3001. All 
experiments were carried out in the Rayne Institute, St. Thomas’ Hospital, King’s College 
London between 2015 and 2016. 
 
1.35.2 Treatment regimen 
300-9000 GBq/μmol, 0.2-5 MBq [
18
F]EFB were administered to control mice without any further 
pre-treatment. Rats were pre-treated with an intraperitoneal injection of 0.5 mg/kg at 0.5 mg/mL 
LPS (Lipopolysaccharides from Escherichia coli 0111:B4 L2630, Sigma Aldrich) or with 1 mL/kg 
sterile saline solution 24 hours prior to scanning.  
 
1.35.3 Radiotracer administration for scanning 
Dynamic PET imaging of all mice, 3 LPS and 3 control rats was performed under isoflurane 
anaesthesia. The oxygen was kept at 1 L/min flow rate with isoflurane levels of 5% for induction 
and termination, while maintenance was carried out with a 1 L/min oxygen flow and an 
isoflurane rate of 1.5-3% with constant breathing and temperature monitoring. The saline-
dissolved reformulated radiotracer was injected in 0.2-5 MBq and high specific activity via tail 
vein injection (mice) or cannulation (rats) and followed by 0.02-0.05 mL (mice) or 0.1-0.2 mL 
saline flush (rats).  
 
1.35.4 PET/CT acquisition and quantitative image analysis 
PET/CT scans were acquired via the Nuclide software with a Mediso NanoPET/CT scanner with 
lithium yttrium orthosilicate: cerium (LYSO:Ce) crystals of size 1.12 mm x 1.12 mm x 13 mm, 
within the energy window of 400-600 keV, coincidence detection ratio 1-5 and voxel resolution 




 CT scanning was performed immediately before or after the PET 
scans with X-ray energy of 45 KVp, 360 projections and 0.25 x 0.25 x 0.21 mm
3
 voxel size. The 
datasets were resolved by dynamic fine reconstructions using the single-slice rebinning, ordered 
subset expectation minimisation (SSRB-OSEM 3D) algorhythm with coincidence detection ratio 
196 
 
1-5 (1-3 in mice) and decay correction to the time of injection. Additionally, attenuation and 
scatter corrections were carried out. Binning was performed in incremental time units of 1 to 60 
min size (mice, 5 x 1 min, then 1 x 10 min, 1 x 15 min, 1 x 30 min, 1 x 60 min) or 5 to 30 min 
size (rats, 3 x 5 min, then 1 x 15 min, 1 x 30 min). All reconstructed datasets were analysed with 
VivoQuant 1.21 (InviCRO, LLC, Boston, USA), which enables PET/CT co-registration, 
alignment, image pre-processing to determine the concentration or MBq of uptake by tissue, the 
demarcation of regions of interest (ROIs) and colour scaling. ROI activity quantification was then 
corrected for background noise and binding was expressed as %ID/g, as calculated with 
reference to the injected activity dose at the time of injection and the ROI size in mm
3
. Mouse 
brain binding was blood-volume-corrected. The latter is an experimentally calculated theoretical 
adjustment where blood represents 5.8% of the total brain volume and it only partially reflects 
the true blood-independent brain binding.
616
 Binding was also expressed as organ-to-plasma 
ratio, both background corrected and where the plasma ROI was drawn on the coronary artery. 
All data are presented as mean ± SEM unless otherwise stated. 
 
1.35.5 Biodistributions 
Immediately after imaging, the animals were culled by terminal anaesthesia and cervical 
dislocation. The animals were dissected and organs and body fluids were collected for gamma 
counting (LKB Wallac 1282) and weighed. A counts-to-Becquerel standard curve was made for 
18
F so as to enable conversion between the two units. The radiotracer binding in each organ 
was expressed as %ID/g, where %ID was the percent ratio of the measured organ radioactivity 
to the total administered dose. The latter was defined as the MBq injected to the animals, decay 
corrected to the start of counting. The resultant biodistribution data were used to validate the 
PET scan quantification methodology as well as to assess the routes of elimination of the tracer. 
 
1.35.6 Statistical analysis 
Data are expres
615
sed as means ± SEM from three independent replicates unless otherwise 
indicated. Statistical analysis of the %ID/g variation in the PET scans and biodistributions was 
performed with GraphPad Prism 5.0 (San Diego, USA) as a parametric two-way ANOVA test 
197 
 
with Bonferroni post-test, unless otherwise specified in the figure captions. * indicates P<0.01; 




1.36.1 Model validation 
An LPS injection regimen is known to increase IL-1β at 24 hours post-injection and to induce a 
5-10% weight loss by 24 hours. In our hands, the LPS-treated rats also showed significant 
weight loss after 24 hours, indicative of effectiveness of the treatment. This was accompanied 






































Figure 106 Number of hippocampal microglia dose response to increasing concentrations of LPS 
at 24 h post-injection  
  
1.36.2 In vivo distribution and kinetic profile of [
18
F]EFB 
In order to determine the distribution profile of [
18
F]EFB, whole-body wild type mouse imaging 
was performed (Figure 110, representative scan at the 7.5 min time point). The graphs in Figure 
107 show that in all mouse CNS regions tracer uptake is maximal at 3±0.5 min post tracer 
administration, suggesting rapid BBB penetration. The tracers then washed off from the CNS, 
reaching baseline values after 2 hours. Note that CNS clearance was confounded by fast tracer 
excretion from the blood, which contributed to CNS concentrations remaining about an order of 
magnitude lower than in blood (Figure 107). 
Figure 108 depicts the organ-to-blood partition over time. This draws the attention on the fact 
that the partition appears to slightly increase over time, suggesting a different rate of excretion 


































































































































































































Figure 107 Whole-body BALB/C WT mouse longitudinal tracer uptake between 0 and 90 min 
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Figure 108 Longitudinal CNS-region-to-blood ratios of [
18
F]EFB from 0 to 90 min post tracer 
administration 
 
Blood and heart followed a similar exponential clearance, possibly due to the difficulty in 
sampling the heart ROI with exclusion of blood. Liver and kidney uptake was particularly 
elevated at the early time points, indicating fast metabolism and excretion of the tracer. 
Excretion appeared to be only partially intestinal while the large majority of tracer was removed 
via the urine and to the bladder. This was further confirmed in the biodistribution studies (Figure 
109). Here, only marginal yet significant uptake was found in the CNS at the earlier time point. 
Finally, bone uptake was marginal and readily decreased over time, suggesting a lack of 
























































































































































































Figure 109 Biodistribution of [
18






Figure 110 Representative female WT BALB/C mouse PET/CT scan of [
18
F]EFB at 7.5 min 
1.36.3 [
18
F]EFB correlation to inflammation 
Evaluation of [
18
F]EFB as an inflammation-dependent tracer was performed by comparison of 
wild type and 0.5 mg/kg LPS-pre-treated Sprague-Dawley rats via quantitative PET imaging and 
biodistribution analysis. However, the scanning of rats could not be performed as a whole-body 
acquisition, as the field of view of the scanner was restricted to the upper body (Figure 113). 
Rat longitudinal uptake profiles (Figure 111) revealed a slower wash out in all organs compared 
to mouse, characteristic of the reduced metabolic rate. In fact, the blood concentration remained 
relatively stable around 0.1 %ID/g. The CNS uptake stayed between 0.05-0.1 %ID/g for the 
spinal cord, while it reached a maximum of 0.02-0.07 %ID/g in the whole brain, the olfactory 
bulb, the cerebellum and the basal ganglia. These percentages correlate very well with the 
terminal biodistribution (Figure 112), demonstrating that the methodology adopted for PET 
quantification was reliable. Moreover, the significant mean binding found in the spinal cord of 
203 
 
the LPS injected rats was consistent with the P2X7 expression hotspot in spinal cord grey 
matter found by Able et al.
67
 
Additionally, LPS-treated rats demonstrated a statistically significant mean increase in tracer 
binding compared to untreated rats. This could reflect increased P2X7 expression which, even 
with moderate BBB permeability, could be captured by the tracer. 
Brain









































































































































Figure 111 In vivo uptake of [
18
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Figure 112 Biodistribution of [
18
F]EFB at 90 min post-injection in LPS and saline injected rats  
 
Furthermore, organ-to-blood partition plots (Figure 114) lost statistical significance between 




Figure 113 Representative male Sprague-Dawley rats PET/CT scans of [
18
F]EFB at 22.5 min
Brain

































































































































































































Figure 114 In vivo longitudinal organ-to-blood ratios of [
18
F]EFB in 24 h post-LPS and 1 h post-BBG 
injections and control rats  
1.37 Discussion 
In this chapter it’s been shown that [
18
F]EFB exhibits some but not all of the desired features for 





F]EFB was quickly absorbed and distributed in both animals and excreted predominantly via 
the urinary route. In mice this was visible by comparison of the early time points, where tracer 
uptake was mostly in the circulation, with the later time points, where the tracer was transferred 
to the urine and bladder.  In rats, this was less evident due to the imaging being limited to the 
upper body, yet it could be understood from the biodistribution, where high first pass elimination 
appeared likely. The transient high uptake in the mouse liver suggested some degree of 
metabolism of the tracer, meaning that EFB could also be have been broken down to a more 
hydrophilic form which then would undergo urinary excretion. This tracer excretion profile is 
desirable in that it allows fast removal of the radioactivity, minimising the exposure to harmful 
radiation. Conversely, it reduces the longitudinal bioavailability of the radiotracer, limiting the 
amount able to cross the BBB. 
The mean longitudinal binding of [
18
F]EFB was significantly higher in LPS compared to 
untreated rats. Thus, the tracer appeared promising in recognising inflammation in the CNS. 
However, individual time points failed to reach a significant difference, suggesting that 
increasing replication would be necessary. This was also linked to the limited sensitivity 
achievable with the low radioactivity levels at which the scans had to be performed given the 
limitations inherent to the lengthy radiosynthesis of [
18
F]EFB (at times 0.2-0.5 MBq at start of 
scan). Nevertheless, the low radioactivity matched with the specific activity >300 GBq/μmol, far 
exceeding the required approximately >40 GBq/μmol for in vivo receptor imaging,
619
 meant that 
less non-specific binding could be expected as a consequence of the lower receptor 
occupancy.
595
 On the other hand, the lack of statistical significance in individual time points 
following radiotracer administration might be a result of high binding variation within the ROIs, 
possibly because of heterogeneous receptor upregulation within the tissues. Besides, 
significance might only be achievable at the later time points, as steady state conditions take 
over. Finally, the lack of a full validation of the tracer’s receptor-specificity gave an extra degree 
of uncertainty when attempting a complete interpretation of this dataset. Thus, further work to 
clearly validate the target(s) of this tracer and to enable its quantitative pharmacokinetic and 
bioavailability profiling is required. 
In the rat, the CNS showed limited and stable binding at 0.02-0.1 %ID/g at all time points. 
Several factors might have influenced this. The tracer might have limited BBB permeability, or 
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be subject to brain efflux via trans-barrier pumps, such as the P-glycoprotein (P-gp). Tracer 
metabolism might be so fast as to prevent all but marginal absorption of the original compound 





brain retention highlights that there is scope for further exploration of the 
cyanoguanidine scaffold. In particular, radiometabolite analysis could reveal important 
information regarding in vivo molecular alterations. A future structural modification strategy 
should take the latter into account as well as including further LogP reductions in adherence 
with the modified Lipinski rule-of-5 to improve on the compound’s solubility. 
Moreover, there are inherent limitations to the chosen experimental animal model. Firstly, P2X7 
upregulation has not been verified for the CNS or the rest of the body. This affects the ability to 
predict where to expect increased binding, despite the LPS insult is known to elicit inflammation 
systemically and centrally. Since P2X7 is much more highly expressed in the CNS than 
peripherally, it is reasonable to expect a much higher accuracy of detection of its upregulation in 
the CNS, while peripherally the overexpression might go unnoticed. Secondly, the model lacks 
an internal reference region against which to compare the increased binding. This is particularly 
due to the ubiquitous expression of the receptor. Further work would need to be oriented at 
immunohistologically staining control and inflamed tissues with a P2X7 antibody and correlating 
these with tracer binding by autoradiography. Additionally, the animal model would need to be 
further characterised in terms of its relative P2X7 receptor abundance by PCR or western 
blotting. Metabolite analysis and kinetic modelling could provide further insights into the 
pharmacokinetic factors responsible for the observed binding trends. 
 
1.38 Conclusions 
This work served as a preliminary study to assess the distribution and pharmacokinetics of 
[
18
F]EFB in an in vivo model of inflammation. The tracer showed a promising distribution and 
excretion profile and the potential to distinguish inflamed from healthy CNS tissues. However, 
the lack of an individual time point at which the tracer could distinguish P2X7 expression 
variations points primarily towards the need for further characterisation of the tracer for its 
selectivity against P2X7, as well as the need for further replication with higher radioactivity 
levels for enhanced PET scan sensitivity. Secondly, the low overall CNS binding of the tracer 
208 
 
highlights that the LPS model and control are insufficiently characterised and might not differ 
enough in P2X7 expression for tracer binding differences to be noticeable. 
Future work should thus be oriented towards resolving these critical questions, as well as 





















The development of a novel PET tracer targeting P2X7 has the potential to offer both new 
insight into the role of this receptor in health and disease, as well as to provide an alternative 
tool to image neuroinflammation. Only rarely PET tracers are developed to assist drug 
discovery. Yet important financial and scientific gains can arise from them and lead to profitable 
non-invasive diagnostics.  
In this work, four new 
18
F tracers based on the A-804598 molecular structure and targeting 
P2X7 have been described. In order to incorporate the 
18
F label while lowering the parent 
scaffold’s LogP for enhanced BBB permeability, three tracers (collectively referred to as 
[
18
F]XFA) were designed to feature a cyclotriazole ring with a pendant 
18
F label. The [
18
F]XFA 
tracers presented different aryl functionalities: a hydrophobic quinoline, a less bulky phenyl ring 
and a hydrophilic phenol. A fourth compound ([
18
F]EFB) closely resembling the parent scaffold, 
was directly radiofluorinated on a mildly electron-rich phenyl ring.  
All compounds were docked by molecular modelling to the P2X7 receptor’s binding pocket and 
their affinity was assessed quantitatively, delivering promising SAR predictions. Moreover, a set 
of physicochemical properties were investigated computationally, suggesting a suitable 
biological profile for the library of tracers. 
The synthesis of the tracer precursors and reference standards was carried out successfully via 
the development of a novel route comprising in particular a step-wise trisubstituted guanidine 
synthesis and a copper alkyne azide cycloaddition. The overall yields were moderate, 
particularly due to the limited purification process success in the final synthetic steps.  




F]XFA was carried out with copper alkyne azide cycloadditions. [
18
F]EFB 
was indirectly labelled by nucleophilic substitution followed by a two-step functional 
interconversion process. The resulting tracers were produced as outlined in Table 22 and their 
identity confirmed by HPLC analysis. The long synthetic times were partly due to the multiple 
steps involved in the radiolabelling procedures and the extensive purification processes. For 
[
18




Table 22 Radiosynthetic parameters for the library of tracers developed 
Tracer RCP D.C. RCY Synthesis time (min) SA (GBq/μmol) 
[
18
F]EFA >99% 4-26% 160 >10  
[
18
F]AFA >99% 10-42% 210 0.5-61 
[
18
F]OFA >99% 5-9% 260 5-9 
[
18
F]EFB >99% 3-5% 210 >300 
 
However, further work remains necessary to translate these developments to the other 
compounds of the series. Byproduct formation and the presence of an alcohol group in [
18
F]OFA 
caused the yields to remain moderate. Full characterisation of the byproducts could provide 
useful avenues for the further improvement of the radiolabelling processes. While the specific 
activity of [
18




F]EFA are within an 
acceptable range, whereas that of [
18
F]EFB is excellent. 
 
Evaluation of the tracers was performed with a range of biological techniques with the triple aim 
of providing multiple quantitative and qualitative evaluation platforms with different complexities 
for the P2X7 tracers, to explore the value of each model and to establish benchmark methods 
for validating future tracers. 
In cellulo, all compounds were assessed by radioligand binding and calcium influx functional 
assays.  The former was ineffective at elucidating the affinity of the tracers due to low signal-to-
noise ratio, probably imputable to low receptor expression. However, this work serves as a 
starting point and inspiration for the future validation of tracers aiming to visualise microglial 
polarisation states. The calcium influx assay showed selectivity of [
18
F]EFB but not of the 
[
18
F]XFA series for the target. The former has been found to have a Ki of 0.85 nM, 36.1 nM and 
547 nM at human, rat and mouse P2X7 receptors, respectively, while in all other instances the 
affinity is >0.1 mM.  
In vitro tissue autoradiography was used to provide a preliminary binding profile of the [
18
F]XFA 
series in the native inflamed tissue setting of the hypoxic ischemic mouse. [
18
F]AFA stood out as 
the tracer displaying the least non-specific binding and which best correlated with the expected 
P2X7 distribution in tissues. However, the atypical response to receptor blockade rendered the 
212 
 
tracer affinity to P2X7 complex to interpret, prompting further studies. [
18
F]EFA presented high 
non-specific binding accompanied by a suitable P2X7-blockade-induced binding reduction. 
Finally, [
18
F]OFA correlated poorly with the expected P2X7 expression profile and did not 
appear specific for P2X7. All in all, these results pointed to some advantages in the use of the 
immature HI mouse model as a native tissue platform to assess P2X7 tracers. Future work will 
be focused on the P2X7 immunohistochemical staining of the tissues for full corroboration of the 
results. In both in vitro assays, receptor blockade by BBG repeatedly resulted in abnormal 
[
18
F]XFA binding patterns. Potentially, this points to a positive allosteric effect and calls for 
further elucidations. 
In vivo wild type mouse and LPS rat PET scanning, coupled with ex vivo biodistribution served 
to assess the potential of [
18
F]EFB as PET tracer. The tracer was able to distinguish inflamed 
from healthy CNS tissues. Its distribution and pharmacokinetic profile appeared promising as 
indicated by the good rate of excretion accompanied by some degree of retention in the target 
organs. However, the overall rat CNS binding was 0.02-0.1 %ID/g, fairly low for CNS imaging, 
while the peripheral binding would be in a much more suitable range to progress this molecule. 
Whether the limited CNS binding was due to low receptor expression levels of P2X7 in the 
chosen rodent model or whether the transport across the BBB was restricted remains to be 
clarified.  
Besides the need for further characterisation of the tracer with respect to its P2X7 selectivity 
and metabolite formation, this compound provided new and important information regarding the 
amenability of diaryl-cyanoguanidine scaffolds for in vivo P2X7 imaging. The limited BBB-
permeability of [
18





well as the apparent lack of target affinity of the [
18
F]XFA tracers, rather than being suggestive 
of a bio-incompatibility of the cyanoguanidine scaffolds, point to the need of carefully altering 
their physicochemical properties to achieve permeability with retention of the target affinity. This 
was previously achieved, among others, by the Hooker group at Harvard University.
339
 A 
possible next step in this direction could be a radiofluorinated or radiocarbonated version, 
respectively of the amide-functionalised compounds p-EFC and EFC2 (as discussed in chapter 
2), Both in fact displayed higher hydrophilicity than [
18
F]EFB whilst modifying more moderately 
than [
18
F]EFA the parent molecular structure. Moreover, further tracer improvements could 
213 
 
benefit from additional in silico and in vitro predictions, thus enabling more rapid trial-and-error 
than traditional radiotracer development methods allow. Among them, LC/MS/MS showed 
potential as a method to instruct structural modifications to apply to poorly BBB-penetrant 
tracers,
620
 while additional computational estimates could be carried out.
373
 However, it is 
common for these tests to inaccurately predict tracer binding,
621
 as was partly the case in this 
study. This was certainly partially imputable to gaps in knowledge of the full P2X7 receptor 3D 
structure, which await advancements in the field of X-ray crystallography. While computational 
tools remain a useful aid in the initial scaffold selection, as a series of compounds are 
radiolabelled and tested in vivo, insightful trends can arise that can guide future success.  
 
On top of achieving the characterisation of four new radiotracers, this project was novel in many 
other aspects. Firstly, in that it added to the scientific field new and improved synthetic organic 
methods for the production of novel organic molecules. It also provided further applications for 
the incorporation of radioactive fluorine using current radiochemical techniques, building upon 
the existing knowledge surrounding “click” radiofluorinations, boronic ester aromatic 
fluorinations and multi-step fluorinations with the fluorobenzyl amine synthon. Moreover, it 
opened new avenues for the study of P2X7 ligands with the exploration of a range of biological 
assays and models, emphasising the strengths and limitations of each.  
To image P2X7 means to enable the detection of the onset and progression of numerous 
important diseases presenting an inflammatory component. Research into novel radiotracers is 
especially important in this historical period, characterised by a shift towards preventative 
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The true delight is in the finding out rather than in the knowing. 
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